<!DOCTYPE html>
<html lang='en'>

<head>
<meta charset="utf-8">
<title>Divalproex - FDA prescribing information, side effects and uses</title>
<meta name="viewport" content="width=device-width, initial-scale=1">
<meta name="description" content="Divalproex official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.">
<meta name="referrer" content="origin-when-cross-origin">
<link rel='canonical' href='https://www.drugs.com/pro/divalproex.html'>
<link rel='search' type='application/opensearchdescription+xml' href='/opensearch.xml' title='Drugs.com'>
<!-- Facebook Open Graph Summary -->
<meta property="fb:app_id" content="1470988726468809">
<meta property="article:author" content="https://www.facebook.com/Drugscom">
<meta property="article:publisher" content="https://www.facebook.com/Drugscom">
<meta property="og:title" content="Divalproex - FDA prescribing information, side effects and uses">
<meta property="og:image" content="https://www.drugs.com/img/social/ddc-opengraph-logomark.png">
<meta property="og:site_name" content="Drugs.com">
<meta property="og:locale" content="en_US">
<meta property="og:type" content="article">
<meta property='og:description' content="Divalproex official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.">
<meta property='og:url' content="https://www.drugs.com/pro/divalproex.html">
<!-- Twitter Summary Card -->
<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@drugscom">
<meta name="twitter:title" content="Divalproex - FDA prescribing information, side effects and uses">
<meta name="twitter:image" content="https://www.drugs.com/img/social/ddc-opengraph-logomark.png">
<meta name='twitter:description' content="Divalproex official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.">
<!-- Favicons -->
<link rel='manifest' href='/manifest.json'>
<link rel='icon' type='image/png' sizes='32x32' href='/img/logo/favicon/ddc-icon-32x32.png'>
<link rel='icon' type='image/png' sizes='16x16' href='/img/logo/favicon/ddc-icon-16x16.png'>
<link rel='apple-touch-icon' sizes='180x180' href='/img/logo/favicon/apple-touch-icon-180x180.png'>
<meta name='theme-color' content='#259cd8'>
<!-- CSS -->
<style>body{margin:0;padding:0;}img{max-width:100%;height:auto;}.contentBox{overflow-wrap:break-word;word-wrap:break-word;}</style>
<link rel='stylesheet' href='/bundle/css/ddc-pack-site.min.fde32fb9.css'>
<link rel='stylesheet' href='/bundle/css/component/component.nav-toc.min.e724a1c8.css'>
<link rel='stylesheet' href='/bundle/css/section/ddc-section-pro.min.5fb861d5.css'>
<link rel='stylesheet' href='/bundle/css/ddc-print.min.e6665d40.css' media='print'>
<!-- Schema -->
<script type='application/ld+json'>[{"@context":"http://schema.org/","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Professionals","item":{"@type":"MedicalWebPage","@id":"https://www.drugs.com/professionals.html"}},{"@type":"ListItem","position":2,"name":"FDA PI","item":{"@type":"MedicalWebPage","@id":"https://www.drugs.com/pro/"}},{"@type":"ListItem","position":3,"name":"Divalproex","item":{"@type":"MedicalWebPage","@id":"https://www.drugs.com/pro/divalproex.html#"}}]},{"@context":"http://schema.org/","@type":"MedicalWebPage","@id":"https://www.drugs.com/pro/divalproex.html","url":"https://www.drugs.com/pro/divalproex.html","audience":{"@context":"https://schema.org","@type":"medicalAudience","audienceType":["Patient","Clinician","MedicalResearcher"]},"publisher":{"@context":"http://schema.org/","@type":"Organization","@id":"https://www.drugs.com/#organization","name":"Drugs.com","url":"https://www.drugs.com","logo":{"@context":"http://schema.org","@type":"ImageObject","url":"https://www.drugs.com/img/logo/schema/drugscom-logo-600x60.png","width":600,"height":60}},"image":{"@type":"ImageObject","contentUrl":"https://www.drugs.com/images/pills/nlm/002450180.jpg","url":"https://www.drugs.com/images/pills/nlm/002450180.jpg","caption":"Divalproex sodium 125 mg"},"about":{"@type":"Drug","@id":"https://www.drugs.com/pro/divalproex.html#divalproex sodium","name":"divalproex sodium","nonProprietaryName":"divalproex sodium","prescriptionStatus":"http://schema.org/PrescriptionOnly","image":{"@type":"ImageObject","contentUrl":"https://www.drugs.com/images/pills/nlm/002450180.jpg","url":"https://www.drugs.com/images/pills/nlm/002450180.jpg","caption":"Divalproex sodium 125 mg"}},"reviewedBy":{"@context":"http://schema.org/","@type":"Organization","@id":"https://www.drugs.com/#organization","name":"Drugs.com","url":"https://www.drugs.com","logo":{"@context":"http://schema.org","@type":"ImageObject","url":"https://www.drugs.com/img/logo/schema/drugscom-logo-600x60.png","width":600,"height":60}},"lastReviewed":"2020-12-01 00:00:00","name":"Divalproex","description":"Divalproex official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology."},{"@context":"https://schema.org","@graph":[{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Overview","url":"https://www.drugs.com/mtm/divalproex-sodium.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Side Effects","url":"https://www.drugs.com/sfx/divalproex-sodium-side-effects.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Dosage","url":"https://www.drugs.com/dosage/divalproex-sodium.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Professional","url":"https://www.drugs.com/pro/divalproex.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Tips","url":"https://www.drugs.com/tips/divalproex-sodium-patient-tips"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Interactions","url":"https://www.drugs.com/drug-interactions/divalproex-sodium.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Pregnancy Warnings","url":"https://www.drugs.com/pregnancy/divalproex-sodium.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Breastfeeding Warnings","url":"https://www.drugs.com/breastfeeding/divalproex.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"User Reviews","url":"https://www.drugs.com/comments/divalproex-sodium/"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Drug Images","url":"https://www.drugs.com/divalproex-sodium-images.html"}]}]</script>
</head>

<body class='page-section-pro page-doctype-content page-pro-divalproex-html'>


<a class='ddc-skiplink-content' href='#content'>Skip to Content</a>


<header id="header">
	<div class="top-container">

		<div class="header-wrap container">
			<div class="header">

				<div class="brand">
					<a href="//www.drugs.com/">
						<img class='logo' src='/img/logo/drugscom-logo.svg' alt="Drugs.com" width='280' height='58' data-ga-category="Top Nav" data-ga-action="Logo">
					</a>
				</div>
				<form method='get' action='/search.php' class='search-main'>
					<div class="input-group-attached">
						<label class="ddc-form-label-placeholder" for="livesearch-main">Search Drugs.com</label>
						<input type="text" id="livesearch-main" name="searchterm" data-required="1" data-value="divalproex sodium" class="livesearch webkit-speech" placeholder="Search" value="" maxlength="70" />

						<div class="search-filter">
							<div class="nav-facade-active header-select-wrapper">
								<span class="search-filter__label" data-value="search-alias=aps">
									<span data-search-select-value>All</span>
									<svg class='ddc-icon ddc-icon-down' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z' /></svg>								</span>
								<label>
									<span class="ddc-sr-only">Select the section you want to search in</span>
									<select name="sources[]" class="search-filter__select" data-search-select>
<option value=''>All</option>
<option value='consumer'>Consumer</option>
<option value='professional'>Professional</option>
<option value='drugimages'>Pill ID</option>
<option value='interactions'>Interactions</option>
<option value='news'>News</option>
<option value='fdaalerts'>FDA Alerts</option>
<option value='newdrugapprovals'>Approvals</option>
<option value='newdrugapplications'>Pipeline</option>
<option value='clinicaltrials'>Clinical Trials</option>
<option value='cg'>Care Notes</option>
<option value='natural'>Natural Products</option>
									</select>
								</label>
							</div>

						</div>

						<a href="#" class='search-close' role='button'>
							<span class="ddc-sr-only">Close</span>
							<span class='search-close-icon'>
								<svg class='ddc-icon ddc-icon-close' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M17 5.94L18.06 7l-5 5 5 5L17 18.06l-5-5-5 5L5.94 17l5-5-5-5L7 5.94l5 5 5-5z' /></svg>							</span>
						</a>

						<button class='ddc-btn'>
							<span class='ddc-sr-only'>Search</span>
							<svg class='ddc-icon ddc-icon-search' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M10 2a8 8 0 016.32 12.9l5.6 5.6-1.42 1.41-5.6-5.59A8 8 0 1110 2zm0 2a6 6 0 100 12 6 6 0 000-12z' /></svg>						</button>
					</div>

					<div class="ddc-link-no-visited search-browse">
						Browse all medications:
						<span class="alpha-list">
<a href='/alpha/a.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='a'>a</a>
<a href='/alpha/b.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='b'>b</a>
<a href='/alpha/c.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='c'>c</a>
<a href='/alpha/d.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='d'>d</a>
<a href='/alpha/e.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='e'>e</a>
<a href='/alpha/f.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='f'>f</a>
<a href='/alpha/g.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='g'>g</a>
<a href='/alpha/h.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='h'>h</a>
<a href='/alpha/i.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='i'>i</a>
<a href='/alpha/j.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='j'>j</a>
<a href='/alpha/k.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='k'>k</a>
<a href='/alpha/l.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='l'>l</a>
<a href='/alpha/m.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='m'>m</a>
<a href='/alpha/n.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='n'>n</a>
<a href='/alpha/o.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='o'>o</a>
<a href='/alpha/p.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='p'>p</a>
<a href='/alpha/q.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='q'>q</a>
<a href='/alpha/r.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='r'>r</a>
<a href='/alpha/s.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='s'>s</a>
<a href='/alpha/t.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='t'>t</a>
<a href='/alpha/u.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='u'>u</a>
<a href='/alpha/v.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='v'>v</a>
<a href='/alpha/w.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='w'>w</a>
<a href='/alpha/x.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='x'>x</a>
<a href='/alpha/y.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='y'>y</a>
<a href='/alpha/z.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='z'>z</a>
<a href='/alpha/0-9.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='0-9'>0-9</a>
						</span>
						<div class="search-browse-options">
							<a href="/search_advanced.html" data-ga-category="Top Nav" data-ga-action="Advanced Search">Advanced Search</a>
						</div>
					</div>
				</form>
				<nav class='ddc-nav-account'>
					<a class='ddc-btn ddc-btn-empty ddc-btn-sm ddc-btn-register' rel='nofollow' href='/account/register/'>Register</a>
					<a class='ddc-btn ddc-btn-secondary ddc-btn-sm' rel='nofollow' href='/account/login/'>Sign In</a>
				</nav>
				<div class='nav-block'>
					<a href='#' data-nav-toggle data-ga-category="Top Nav" data-ga-action="Hamburger" role='button'>
						<span class='ddc-sr-only'>Main navigation</span>
						<svg class='ddc-icon ddc-icon-menu' width='28' height='28' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M21 17v2H3v-2h18zm0-6v2H3v-2h18zm0-6v2H3V5h18z' /></svg>						<svg class='ddc-icon ddc-icon-close' width='32' height='32' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M17 5.94L18.06 7l-5 5 5 5L17 18.06l-5-5-5 5L5.94 17l5-5-5-5L7 5.94l5 5 5-5z' /></svg>					</a>
				</div>

			</div>
		</div>
	</div>


<nav class='ddc-nav'>
		<ul>
					<li class='ddc-nav-item'>
				<a href='/account/' rel='nofollow'>Account</a>
				<ul>
					<li><a href='/account/login/' rel='nofollow'>Sign In</a></li>
					<li><a href='/account/register/' rel='nofollow'>Register</a></li>
				</ul>
			</li>
					<li class='ddc-nav-item'><a href='/drug_information.html'>Drugs A-Z</a></li>
		<li class='ddc-nav-item'><a href='/pill_identification.html'>Pill Identifier</a></li>
		<li class='ddc-nav-item'><a href='/drug_interactions.html'>Interactions Checker</a></li>
		<li class='ddc-nav-item'><a href='/news.html'>News &amp; Alerts</a></li>
		<li class='ddc-nav-item'><a href='/professionals.html'>Pro Edition</a></li>
		<li class='ddc-nav-item'><a href='/sitemap.html'>More<span class='ddc-sr-only'> Resources</span></a></li>
	</ul>
</nav>

</header>


<div class='topbanner-wrap'>
<div id='drugs-drugs-1' class='display-ad display-ad-728x90'>
<script>
var ehs_ad_called = ++ehs_ad_called || 1;
</script>
</div>
<script src='//ads.ehealthcaresolutions.com/a/?adid=drugs-drugs-1&slotid=1&url=www.drugs.com%2Fpro%2Fdivalproex.html&size=728x90&vpos=t&hpos=l&site=ehs.pro.drugs.drugs&drg=divalproex_sodium&drc=fatty_acid_derivative_anticonvulsants&dra=1' defer></script>
	<button class='ddc-topbanner-close' data-toggle-class='.topbanner-wrap'>
		<span class='ddc-sr-only'>Close</span>
		<svg class='ddc-icon ddc-icon-close' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M17 5.94L18.06 7l-5 5 5 5L17 18.06l-5-5-5 5L5.94 17l5-5-5-5L7 5.94l5 5 5-5z' /></svg>	</button>
</div>

<main id='container' class='container'>

<div id='contentWrap' class='ddc-clear-both'>

<div id='content' class='content'>
<div class='contentHead'>
<nav class='ddc-breadcrumb' aria-label='breadcrumb'>
<ol class='ddc-breadcrumb-3'>
<li class='ddc-breadcrumb-item'><a href='/professionals.html'>Professionals</a></li>
<li class='ddc-breadcrumb-item'><a href='/pro/'>FDA PI</a></li>
<li class='ddc-breadcrumb-item active' aria-current='page'><span>Divalproex</span></li>
</ol>
</nav>
<div class='page-icons page-icons-header'>
<a href='#print' role='button' data-action='print' data-ga-category='social' data-ga-action='DDC' data-ga-label='Print Top'>
<svg class='ddc-icon ddc-icon-print' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M17.75 3.25v4h4v10.5h-4v3H6.25v-3h-4V7.25h4v-4h11.5zm-1.5 9.5h-8.5v6.5h8.5v-6.5zm4-4H3.75v7.5h2.5v-5h11.5v5h2.5v-7.5zm-4-4h-8.5v2.5h8.5v-2.5z' /></svg> Print
</a>
<a href='#save' role='button' data-action='share-mednotes' data-ga-category='social' data-ga-action='DDC' data-ga-label='Save Drug Top'>
<svg class='ddc-icon ddc-icon-save' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M19 15v2.75h2.75v1.5H19V22h-1.5v-2.75h-2.75v-1.5h2.75V15H19zM18 2.25c.9182 0 1.6712.7071 1.7442 1.6065L19.75 4v9h-1.5V4a.2501.2501 0 00-.1927-.2434L18 3.75H6a.2501.2501 0 00-.2434.1927L5.75 4v15.25h7v1.5H5a.7502.7502 0 01-.7432-.6482L4.25 20V4c0-.9182.7071-1.6712 1.6065-1.7442L6 2.25h12zM12.75 13.5V15H8v-1.5h4.75zm3.25-3V12H8v-1.5h8zm0-3V9H8V7.5h8z' /></svg> Save
</a>
</div>
</div>
<!-- google_ad_section_start -->

<div class="contentBox">
<div class='pronounce-title'><h1>Divalproex</h1><audio id='pronounce-audio' preload='none'>
  <source src='https://www.drugs.com/audio/mp3/918-0.mp3' type='audio/mpeg'>
  <source src='https://www.drugs.com/audio/wav/918-0.wav' type='audio/wav'>
</audio>
<a id='pronunciation' class='pronounce-icon' href='#pronunciation' title="Listen to audio pronunciation" onclick="document.getElementById('pronounce-audio').play();return false;"><svg class='ddc-icon ddc-icon-pronunciation' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M10.73 3.81a1.75 1.75 0 013.02 1.2v13.97a1.75 1.75 0 01-3.02 1.2l-4.2-4.43H3.24v-7.5h3.27zm1.39.99a.25.25 0 00-.3.04l-4.07 4.3v5.72l4.07 4.3c.03.03.07.05.11.06l.07.01c.14 0 .25-.1.25-.25V5.02a.25.25 0 00-.08-.18zm5.7 1.52A6.24 6.24 0 0121.25 12a6.24 6.24 0 01-3.43 5.68.75.75 0 11-.64-1.36A4.74 4.74 0 0019.75 12c0-1.9-1.03-3.59-2.57-4.32a.75.75 0 11.64-1.36zm-1.48 3c.87.45 1.41 1.51 1.41 2.68 0 1.17-.54 2.23-1.41 2.67a.75.75 0 01-.76-1.29l.08-.05c.32-.16.59-.69.59-1.33 0-.59-.23-1.08-.5-1.28l-.09-.05a.75.75 0 11.68-1.34zm-10.09.43h-1.5v4.5h1.5v-4.5z' /></svg></a></div>
<p class='drug-subtitle'><b>Generic name:</b> Divalproex sodium<br />
<b>Dosage form:</b> tablet, extended release<br><b>Drug class:</b> <a href='/drug-class/fatty-acid-derivative-anticonvulsants.html'>Fatty acid derivative anticonvulsants</a></p>
	<p class='ddc-reviewed-by'><span><a href='/support/editorial_policy.html#editorial-staff'>Medically reviewed</a> by Drugs.com. Last updated on Dec 1, 2020.</span></p>
<ul class='nav-tabs nav-tabs-collapse nav-tabs-pill'>
<li><a class='nav-item' href='/mtm/divalproex-sodium.html' data-ga-category='In Page Nav' data-ga-action='Top Tab' data-ga-label='Overview'>Overview</a></li>
<li><a class='nav-item' href='/sfx/divalproex-sodium-side-effects.html' data-ga-category='In Page Nav' data-ga-action='Top Tab' data-ga-label='Side Effects'>Side Effects</a></li>
<li><a class='nav-item' href='/dosage/divalproex-sodium.html' data-action='drug-dosage-disambiguation' data-ddc_id='918' data-brand_id='0' data-ga-category='In Page Nav' data-ga-action='Top Tab' data-ga-label='Dosage'>Dosage</a></li>
<li><b class='nav-item here'>Professional</b></li>
<li><a class='nav-item' href='/tips/divalproex-sodium-patient-tips' data-ga-category='In Page Nav' data-ga-action='Top Tab' data-ga-label='Patient Tip'>Tips</a></li>
<li><a class='nav-item' href='/drug-interactions/divalproex-sodium.html' data-ga-category='In Page Nav' data-ga-action='Top Tab' data-ga-label='Interactions'>Interactions</a></li>
	<li class='nav-more'>
		<a class='nav-item' href='#moreResources' rel='nofollow'>More<svg class='ddc-icon ddc-icon-down' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z' /></svg></a>
	</li>
	</ul>





<!-- start intra-page-menu -->
<div id='articleTableOfContents' class='ddc-toc'><h5 class='ddc-toc-heading'>On This Page</h5><div class='ddc-toc-content'><ul>
<li><a href="#s-34066-1">Boxed Warning</a></li>
<li><a href="#s-34067-9">Indications and Usage</a></li>
<li><a href="#s-34068-7">Dosage and Administration</a></li>
<li><a href="#s-43678-2">Dosage Forms and Strengths</a></li>
<li><a href="#s-34070-3">Contraindications</a></li>
<li><a href="#s-43685-7">Warnings and Precautions</a></li>
<li><a href="#s-34084-4">Adverse Reactions/Side Effects</a></li>
<li class='ddc-toggle-hidden'><a href="#s-34073-7">Drug Interactions</a></li>
<li class='ddc-toggle-hidden'><a href="#s-43684-0">Use In Specific Populations</a></li>
<li class='ddc-toggle-hidden'><a href="#s-34088-5">Overdosage</a></li>
<li class='ddc-toggle-hidden'><a href="#s-34089-3">Description</a></li>
<li class='ddc-toggle-hidden'><a href="#s-34090-1">Clinical Pharmacology</a></li>
<li class='ddc-toggle-hidden'><a href="#s-43680-8">Nonclinical Toxicology</a></li>
<li class='ddc-toggle-hidden'><a href="#s-34092-7">Clinical Studies</a></li>
<li class='ddc-toggle-hidden'><a href="#s-34093-5">References</a></li>
<li class='ddc-toggle-hidden'><a href="#s-34069-5">How Supplied/Storage and Handling</a></li>
<li class='ddc-toggle-hidden'><a href="#s-34076-0">Patient Counseling Information</a></li>
<li class='ddc-toggle-hidden'><a href="#s-42231-1">Medication Guide</a></li>
</ul></div><div class='ddc-toc-footer toggle-view-all' data-toggle-class='.ddc-toc'><a class='toggle-btn' href='#' role='button'>Expand <span class='icon icon-arrow-down'></span></a></div></div>
<!-- end intra-page-menu -->

<div class="blackboxWarning"><a id="ID19"></a><a id="section-!"></a><a id="s-34066-1"></a>
<span class="Bold"><span class="following_xmChange">WARNING: LIFE THREATENING ADVERSE REACTIONS</span></span>
<a id="ID20"></a><a id="section-!.1"></a>
<p class="First"><a id="ID21"></a><span class="Bold">Hepatotoxicity</span></p>
<p><span class="Bold"><span class="Italics">General Population:</span> Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months <span class="Italics">[see Warnings and Precautions (<a href="#ID66">5.1</a>)]</span>.</span></p>
<p><span class="Bold">Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. When Divalproex sodium extended-release tablets are used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.</span></p>
<p><span class="Bold"><span class="Italics">Patients with Mitochondrial Disease:</span> There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA Polymerase &gamma; (POLG) gene (e.g. Alpers Huttenlocher Syndrome). Divalproex sodium extended-release tablets are contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder <span class="Italics">[see Contraindications (<a href="#ID60">4</a>)]</span>. In patients over two years of age who are clinically suspected of having a hereditary mitochondrial disease, Divalproex sodium extended-release tablets should only be used after other anticonvulsants have failed. This older group of patients should be closely monitored during treatment with Divalproex sodium extended-release tablets for the development of acute liver injury with regular clinical assessments and serum liver testing. POLG mutation screening should be performed in accordance with current clinical practice <span class="Italics">[see Warnings and Precautions (<a href="#ID66">5.1</a>)]</span>.</span></p>
<p><span class="Bold">Fetal Risk</span></p>
<p><span class="Bold">Valproate can cause major congenital malformations, particularly neural tube defects (e.g., spina bifida). In addition, valproate can cause decreased IQ scores and neurodevelopmental disorders following in utero exposure.</span></p>
<p><span class="Bold">Valproate is therefore contraindicated for prophylaxis of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception <span class="Italics">[</span></span><span class="Bold"><span class="Italics">see Contraindications</span></span> <span class="Bold"><span class="Italics">(<a href="#ID60">4</a>)]</span></span><span class="Bold">.</span> <span class="Bold">Valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.</span></p>
<p><span class="Bold">Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.</span> <span class="Bold">In such situations, effective contraception should be used</span> <span class="Bold"><span class="Italics">[see</span></span> <span class="Bold"><span class="Italics">Warnings and Precautions (<a href="#ID68">5.2</a>, <a href="#ID70">5.3</a>, <a href="#ID72">5.4</a>)]</span></span><span class="Bold">.</span></p>
<p><span class="Bold">A Medication Guide describing the risks of valproate is available for patients <span class="Italics">[see Patient Counseling Information (<a href="#ID199">17</a>)]</span>.</span></p>
<p><span class="Bold">Pancreatitis</span></p>
<p><span class="Bold">Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to death. Cases have been reported shortly after initial use as well as after several years of use. Patients and guardians should be warned that abdominal pain, nausea, vomiting and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated <span class="Italics">[see Warnings and Precautions (<a href="#ID74">5.5</a>)]</span>.</span></p>

</div>
<a id="ID26"></a><a id="s-34067-9"></a>
<a id='indications'></a><h2>Indications and Usage for Divalproex</h2>
<a id="ID27"></a>
<h3>Mania</h3>
<p class="First"><a id="ID28"></a>Divalproex sodium extended-release tablets are valproate and are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. A mixed episode is characterized by the criteria for a manic episode in conjunction with those for a major depressive episode (depressed mood, loss of interest or pleasure in nearly all activities).</p>
<p>The efficacy of Divalproex sodium extended-release tablets are based in part on studies of Divalproex sodium delayed-release tablets in this indication, and was confirmed in a 3-week trial with patients meeting DSM-IV TR criteria for bipolar I disorder, manic or mixed type, who were hospitalized for acute mania <span class="Italics">[see Clinical Studies (<a href="#ID178">14.1</a>)]</span>.</p>
<p>The effectiveness of valproate for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. Therefore, healthcare providers who elect to use Divalproex sodium extended-release tablets for extended periods should continually reevaluate the long-term risk-benefits of the drug for the individual patient.</p>

<a id="ID29"></a>
<h3>Epilepsy</h3>
<p class="First"><a id="ID30"></a>Divalproex sodium extended-release tablets are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with complex partial seizures that occur either in isolation or in association with other types of seizures. Divalproex sodium extended-release tablets are also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures in adults and children 10 years of age or older, and adjunctively in adults and children 10 years of age or older with multiple seizure types that include absence seizures.</p>
<p>Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present.</p>

<a id="ID31"></a>
<h3>Migraine</h3>
<p class="First"><a id="ID32"></a>Divalproex sodium extended-release tablets are indicated for prophylaxis of migraine headaches. There is no evidence that Divalproex sodium extended-release tablets are useful in the acute treatment of migraine headaches.</p>

<a id="ID33"></a>
<h3>Important Limitations</h3>
<p class="First"><a id="ID34"></a>Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable <span class="Italics">[see Warnings and Precautions (<a href="#ID68">5.2</a>, <a href="#ID70">5.3</a>, <a href="#ID72">5.4</a>)</span>, <span class="Italics">Use in Specific Populations (<a href="#ID141">8.1</a>), and Patient Counseling Information (17)]</span>.</p>
<p>For prophylaxis of migraine headaches, Divalproex sodium extended-release tablet is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception <span class="Italics">[see Contraindications (<a href="#ID60">4</a>)]</span>.</p>


<a id="ID38"></a><a id="s-34068-7"></a>
<h2>Divalproex Dosage and Administration</h2>
<a id="ID39"></a>
<p class="First"><a id="ID40"></a>Divalproex sodium extended-release tablet is an extended-release product intended for once-a-day oral administration. Divalproex sodium extended-release tablets should be swallowed whole and should not be crushed or chewed.</p>

<a id="ID41"></a>
<h3>Mania</h3>
<p class="First"><a id="ID42"></a>Divalproex sodium extended-release tablets are administered orally. The recommended initial dose is 25 mg/kg/day given once daily. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose which produces the desired clinical effect or the desired range of plasma concentrations. In a placebo-controlled clinical trial of acute mania or mixed type, patients were dosed to a clinical response with a trough plasma concentration between 85 and 125 mcg/mL. The maximum recommended dosage is 60 mg/kg/day.</p>
<p>There is no body of evidence available from controlled trials to guide a clinician in the longer term management of a patient who improves during Divalproex sodium extended-release tablet treatment of an acute manic episode. While it is generally agreed that pharmacological treatment beyond an acute response in mania is desirable, both for maintenance of the initial response and for prevention of new manic episodes, there are no data to support the benefits of Divalproex sodium extended-release tablets in such longer-term treatment (i.e., beyond 3 weeks).</p>

<a id="ID43"></a>
<h3>Epilepsy</h3>
<p class="First"><a id="ID44"></a>Divalproex sodium extended-release tablets are administered orally, and must be swallowed whole. As Divalproex sodium extended-release tablets dosage is titrated upward, concentrations of clonazepam, diazepam, ethosuximide, lamotrigine, tolbutamide, phenobarbital, carbamazepine, and/or phenytoin may be affected <span class="Italics">[see Drug Interactions (<a href="#ID134">7.2</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Complex Partial Seizures</span></span></p>
<p>For adults and children 10 years of age or older.</p>
<p><span class="Bold"><span class="Italics">Monotherapy (Initial Therapy):</span></span></p>
<p>Divalproex sodium extended-release tablets have not been systematically studied as initial therapy. Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made.</p>
<p>The probability of thrombocytopenia increases significantly at total trough valproate plasma concentrations above 110 mcg/mL in females and 135 mcg/mL in males. The benefit of improved seizure control with higher doses should be weighed against the possibility of a greater incidence of adverse reactions.</p>
<p><span class="Bold"><span class="Italics">Conversion to Monotherapy:</span></span></p>
<p>Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made.</p>
<p>Concomitant antiepilepsy drug (AED) dosage can ordinarily be reduced by approximately 25% every 2 weeks. This reduction may be started at initiation of Divalproex sodium extended-release tablets therapy, or delayed by 1 to 2 weeks if there is a concern that seizures are likely to occur with a reduction. The speed and duration of withdrawal of the concomitant AED can be highly variable, and patients should be monitored closely during this period for increased seizure frequency.</p>
<p><span class="Bold"><span class="Italics">Adjunctive Therapy:</span></span></p>
<p>Divalproex sodium extended-release tablets may be added to the patient's regimen at a dosage of 10 to 15 mg/kg/day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made.</p>
<p>In a study of adjunctive therapy for complex partial seizures in which patients were receiving either carbamazepine or phenytoin in addition to valproate, no adjustment of carbamazepine or phenytoin dosage was needed <span class="Italics">[see Clinical Studies (<a href="#ID180">14.2</a>)]</span>. However, since valproate may interact with these or other concurrently administered AEDs as well as other drugs, periodic plasma concentration determinations of concomitant AEDs are recommended during the early course of therapy <span class="Italics">[see Drug Interactions (<a href="#ID131">7</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Simple and Complex Absence Seizures</span></span></p>
<p>The recommended initial dose is 15 mg/kg/day, increasing at one week intervals by 5 to 10 mg/kg/day until seizures are controlled or side effects preclude further increases. The maximum recommended dosage is 60 mg/kg/day.</p>
<p>A good correlation has not been established between daily dose, serum concentrations, and therapeutic effect. However, therapeutic valproate serum concentration for most patients with absence seizures is considered to range from 50 to 100 mcg/mL. Some patients may be controlled with lower or higher serum concentrations <span class="Italics">[see Clinical Pharmacology (<a href="#ID170">12.3</a>)]</span>.</p>
<p>As Divalproex sodium extended-release tablets dosage is titrated upward, blood concentrations of phenobarbital and/or phenytoin may be affected <span class="Italics">[see Drug Interactions (<a href="#ID134">7.2</a>)]</span>.</p>
<p>Antiepilepsy drugs should not be abruptly discontinued in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life.</p>

<a id="ID45"></a>
<h3>Migraine</h3>
<p class="First"><a id="ID46"></a>Divalproex sodium extended-release tablets are indicated for prophylaxis of migraine headaches in adults.</p>
<p>The recommended starting dose is 500 mg once daily for 1 week, thereafter increasing to 1,000 mg once daily. Although doses other than 1,000 mg once daily of Divalproex sodium extended-release tablets have not been evaluated in patients with migraine, the effective dose range of Divalproex sodium delayed-release tablets in these patients is 500 to 1,000 mg/day. As with other valproate products, doses of Divalproex sodium extended-release tablets should be individualized and dose adjustment may be necessary. If a patient requires smaller dose adjustments than that available with Divalproex sodium extended-release tablets, Divalproex sodium delayed-release tablets should be used instead.</p>

<a id="ID47"></a>
<h3>Conversion from Divalproex Sodium Delayed-Release Tablets to Divalproex Sodium Extended-Release Tablets</h3>
<p class="First"><a id="ID48"></a>In adult patients and pediatric patients 10 years of age or older with epilepsy previously receiving Divalproex sodium delayed-release tablets, Divalproex sodium extended-release tablets should be administered once-daily using a dose 8 to 20% higher than the total daily dose of Divalproex sodium delayed-release tablets (Table 1). For patients whose Divalproex sodium delayed-release tablets total daily dose cannot be directly converted to Divalproex sodium extended-release tablets, consideration may be given at the clinician's discretion to increase the patient's Divalproex sodium delayed-release tablets total daily dose to the next higher dosage before converting to the appropriate total daily dose of Divalproex sodium extended-release tablets.</p>
<a id="ID49"></a>
<div class='responsive-table-wrap'><table class="Noautorules" style="width: 100%; ">
<caption>Table 1. Dose Conversion</caption>
<col style="width: 50%; " />
<col style="width: 49%; " />
<tfoot>
<tr>
<td colspan="2" style="text-align: left; ">
<dl class="Footnote">
<dt><a href="#footnote-reference-1" id="footnote-1">*</a></dt>
<dd>These total daily doses of Divalproex sodium delayed-release tablets cannot be directly converted to an 8 to 20% higher total daily dose of Divalproex sodium extended-release tablets because the required dosing strengths of Divalproex sodium extended-release tablets are not available. Consideration may be given at the clinician's discretion to increase the patient's Divalproex sodium delayed-release tablets total daily dose to the next higher dosage before converting to the appropriate total daily dose of Divalproex sodium extended-release tablets.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Divalproex Sodium Delayed-Release Tablets</span><br /></td>
<td class="Botrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Divalproex Sodium Extended-Release Tablets</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: center; "><span class="Bold">Total</span> <span class="Bold">Daily Dose (mg)</span><br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; "><span class="Bold">(mg)</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">500<a href="#footnote-1" class="Sup" id="footnote-reference-1">*</a> to 625<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">750<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">750<a href="#footnote-1" class="Sup">*</a> to 875<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1,000<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">1,000<a href="#footnote-1" class="Sup">*</a> to 1,125<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1,250<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">1,250 to 1,375<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1,500<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">1,500 to 1,625<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1,750<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">1,750<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">2,000<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">1,875 to 2,000<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">2,250<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">2,125 to 2,250<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">2,500<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">2,375<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">2,750<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">2,500 to 2,750<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">3,000<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">2,875<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">3,250<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">3,000 to 3,125<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">3,500<br /></td>
</tr>
</tbody>
</table></div>
<p><a id="ID50"></a>There is insufficient data to allow a conversion factor recommendation for patients with Divalproex sodium delayed-release tablets doses above 3,125 mg/day. Plasma valproate C<span class="Sub">min</span> concentrations for Divalproex sodium extended-release tablets on average are equivalent to Divalproex sodium delayed-release tablets, but may vary across patients after conversion. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL) <span class="Italics">[see Clinical Pharmacology (<a href="#ID168">12.2</a>)]</span>.</p>

<a id="ID51"></a>
<h3>General Dosing Advice</h3>
<p class="First"><a id="ID52"></a><span class="Bold"><span class="Italics">Dosing in Elderly Patients</span></span></p>
<p>Due to a decrease in unbound clearance of valproate and possibly a greater sensitivity to somnolence in the elderly, the starting dose should be reduced in these patients. Starting doses in the elderly lower than 250 mg can only be achieved by the use of Divalproex sodium delayed-release tablets. Dosage should be increased more slowly and with regular monitoring for fluid and nutritional intake, dehydration, somnolence, and other adverse reactions. Dose reductions or discontinuation of valproate should be considered in patients with decreased food or fluid intake and in patients with excessive somnolence. The ultimate therapeutic dose should be achieved on the basis of both tolerability and clinical response <span class="Italics">[see Warnings and Precautions (<a href="#ID94">5.14</a>), Use in Specific Populations (<a href="#ID151">8.5</a>), and Clinical Pharmacology (<a href="#ID170">12.3</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Dose-Related Adverse Reactions</span></span></p>
<p>The frequency of adverse effects (particularly elevated liver enzymes and thrombocytopenia) may be dose-related. The probability of thrombocytopenia appears to increase significantly at total valproate concentrations of &ge; 110 mcg/mL (females) or &ge; 135 mcg/mL (males) <span class="Italics">[see Warnings and Precautions (<a href="#ID82">5.8</a>)]</span>. The benefit of improved therapeutic effect with higher doses should be weighed against the possibility of a greater incidence of adverse reactions.</p>
<p><span class="Bold"><span class="Italics">G. I. Irritation</span></span></p>
<p>Patients who experience G.I. irritation may benefit from administration of the drug with food or by slowly building up the dose from an initial low level.</p>
<p><span class="Bold"><span class="Italics">Compliance</span></span></p>
<p>Patients should be informed to take Divalproex sodium extended-release tablets every day as prescribed. If a dose is missed it should be taken as soon as possible, unless it is almost time for the next dose. If a dose is skipped, the patient should not double the next dose.</p>

<a id="ID249"></a>
<h3>Dosing in Patients Taking Rufinamide</h3>
<p class="First"><a id="ID250"></a>Patients stabilized on rufinamide before being prescribed valproate should begin valproate therapy at a low dose, and titrate to a clinically effective dose <span class="Italics">[see Drug Interactions</span> <span class="Italics">(<a href="#ID134">7.2</a>)</span><span class="Italics">]</span>.</p>


<a id="ID55"></a><a id="s-43678-2"></a>
<h2>Dosage Forms and Strengths</h2>
<a id="ID56"></a>
<p class="First"><a id="ID57"></a>Divalproex sodium extended-release tablets USP, 250 mg are available as white, oval shaped, film coated tablets, imprinted "L088" on one side and plain on the other side. Each extended-release tablet contains Divalproex sodium equivalent to 250 mg of valproic acid.</p>
<p>Divalproex sodium extended-release tablets USP, 500 mg are available as grey colored, oval shaped, film coated tablets, imprinted "L089" on one side and plain on the other side. Each extended-release tablet contains Divalproex sodium equivalent to 500 mg of valproic acid.</p>


<a id="ID60"></a><a id="s-34070-3"></a>
<h2>Contraindications</h2>
<a id="ID61"></a>
<ul class="Disc">
<li>  Divalproex sodium extended-release tablets should not be administered to patients with hepatic disease or significant hepatic dysfunction <span class="Italics">[see Warnings and Precautions (<a href="#ID66">5.1</a>)].</span></li>
<li>  Divalproex sodium extended-release tablets are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase &gamma; (POLG; e.g, Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder <span class="Italics">[see Warnings and Precautions (<a href="#ID66">5.1</a>)]</span> .</li>
<li>  Divalproex sodium extended-release tablets are contraindicated in patients with known hypersensitivity to the drug <span class="Italics">[see Warnings and Precautions (<a href="#ID90">5.12</a>)].</span></li>
<li>  Divalproex sodium extended-release tablets are contraindicated in patients with known urea cycle disorders <span class="Italics">[see Warnings and Precautions (<a href="#ID76">5.6</a>)].</span></li>
<li>  For use in prophylaxis of migraine headaches: Divalproex sodium extended-release tablet is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception <span class="Italics">[see Warnings and Precautions (<a href="#ID68">5.2</a>, <a href="#ID70">5.3</a>, <a href="#ID72">5.4</a>) and Use in Specific Populations (<a href="#ID141">8.1</a>)]</span> .</li>
</ul>


<a id="ID65"></a><a id="s-43685-7"></a>
<h2>Warnings and Precautions</h2>
<a id="ID66"></a>
<h3>Hepatotoxicity</h3>
<p class="First"><a id="ID67"></a><span class="Bold"><span class="Italics">General Information on Hepatotoxicity</span></span></p>
<p>Hepatic failure resulting in fatalities has occurred in patients receiving valproate. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur.</p>
<p>Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months of valproate therapy. However, healthcare providers should not rely totally on serum biochemistry since these tests may not be abnormal in all instances, but should also consider the results of careful interim medical history and physical examination.</p>
<p>Caution should be observed when administering valproate products to patients with a prior history of hepatic disease. Patients on multiple anticonvulsants, children, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease may be at particular risk. See below, "Patients with Known or Suspected Mitochondrial Disease."</p>
<p>Experience has indicated that children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those with the aforementioned conditions. When Divalproex sodium extended-release tablets are used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. In progressively older patient groups experience in epilepsy has indicated that the incidence of fatal hepatotoxicity decreases considerably.</p>
<p><span class="Bold"><span class="Italics">Patients with Known or Suspected Mitochondrial Disease</span></span></p>
<p>Divalproex sodium extended-release tablets are contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder <span class="Italics">[see Contraindications (<a href="#ID60">4</a>)]</span>. Valproate-induced acute liver failure and liver-related deaths have been reported in patients with hereditary neurometabolic syndromes caused by mutations in the gene for mitochondrial DNA polymerase &gamma; (POLG) (e.g., Alpers- Huttenlocher Syndrome) at a higher rate than those without these syndromes. Most of the reported cases of liver failure in patients with these syndromes have been identified in children and adolescents.</p>
<p>POLG-related disorders should be suspected in patients with a family history or suggestive symptoms of a POLG-related disorder, including but not limited to unexplained encephalopathy, refractory epilepsy (focal, myoclonic), status epilepticus at presentation, developmental delays, psychomotor regression, axonal sensorimotor neuropathy, myopathy cerebellar ataxia, ophthalmoplegia, or complicated migraine with occipital aura. POLG mutation testing should be performed in accordance with current clinical practice for the diagnostic evaluation of such disorders. The A467T and W748S mutations are present in approximately 2/3 of patients with autosomal recessive POLG-related disorders.</p>
<p>In patients over two years of age who are clinically suspected of having a hereditary mitochondrial disease, Divalproex sodium extended-release tablets should only be used after other anticonvulsants have failed. This older group of patients should be closely monitored during treatment with Divalproex sodium extended-release tablets for the development of acute liver injury with regular clinical assessments and serum liver test monitoring.</p>
<p>The drug should be discontinued immediately in the presence of significant hepatic dysfunction, suspected or apparent. In some cases, hepatic dysfunction has progressed in spite of discontinuation of drug <span class="Italics">[see <a href="#ID19">Boxed Warning</a> and Contraindications (<a href="#ID60">4</a>)]</span>.</p>

<a id="ID68"></a>
<h3>Structural Birth Defects</h3>
<p class="First"><a id="ID69"></a>Valproate can cause fetal harm when administered to a pregnant woman. Pregnancy registry data show that maternal valproate use can cause neural tube defects and other structural abnormalities (e.g., craniofacial defects, cardiovascular malformations, hypospadias, limb malformations). The rate of congenital malformations among babies born to mothers using valproate is about four times higher than the rate among babies born to epileptic mothers using other anti-seizure monotherapies. Evidence suggests that folic acid supplementation prior to conception and during the first trimester of pregnancy decreases the risk for congenital neural tube defects in the general population <span class="Italics">[see Use in Specific Populations (<a href="#ID141">8.1</a>)]</span>.</p>

<a id="ID70"></a>
<h3>Decreased IQ Following in utero Exposure</h3>
<p class="First"><a id="ID71"></a>Valproate can cause decreased IQ scores following <span class="Italics">in utero</span> exposure. Published epidemiological studies have indicated that children exposed to valproate <span class="Italics">in utero</span> have lower cognitive test scores than children exposed <span class="Italics">in utero</span> to either another antiepileptic drug or to no antiepileptic drugs. The largest of these studies<span class="Sup">1</span> is a prospective cohort study conducted in the United States and United Kingdom that found that children with prenatal exposure to valproate (n=62) had lower IQ scores at age 6 (97 [95% C.I. 94 to 101]) than children with prenatal exposure to the other antiepileptic drug monotherapy treatments evaluated: lamotrigine (108 [95% C.I. 105 to 110]), carbamazepine (105 [95% C.I. 102 to 108]), and phenytoin (108 [95% C.I. 104 to 112]). It is not known when during pregnancy cognitive effects in valproate-exposed children occur. Because the women in this study were exposed to antiepileptic drugs throughout pregnancy, whether the risk for decreased IQ was related to a particular time period during pregnancy could not be assessed.</p>
<p>Although all of the available studies have methodological limitations, the weight of the evidence supports the conclusion that valproate exposure <span class="Italics">in utero</span> can cause decreased IQ in children.</p>
<p>In animal studies, offspring with prenatal exposure to valproate had malformations similar to those seen in humans and demonstrated neurobehavioral deficits <span class="Italics">[see Use in Specific Populations (<a href="#ID141">8.1</a>)]</span>.</p>

<a id="ID72"></a>
<h3>Use in Women of Childbearing Potential</h3>
<p class="First"><a id="ID73"></a>Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, and major congenital malformations (including neural tube defects), which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. This is especially important when valproate use is considered for a condition not usually associated with permanent injury or death such as prophylaxis of migraine headaches <span class="Italics">[</span>see <span class="Italics">Contraindications (4)]</span>. Women should use effective contraception while using valproate.</p>
<p>Women of childbearing potential should be counseled regularly regarding the relative risks and benefits of valproate use during pregnancy. This is especially important for women planning a pregnancy and for girls at the onset of puberty; alternative therapeutic options should be considered for these patients <span class="Italics">[see <a href="#ID19">Boxed Warning</a> and Use in Specific Populations (<a href="#ID141">8.1</a>)]</span>.</p>
<p>To prevent major seizures, valproate should not be discontinued abruptly, as this can precipitate status epilepticus with resulting maternal and fetal hypoxia and threat to life.</p>
<p>Evidence suggests that folic acid supplementation prior to conception and during the first trimester of pregnancy decreases the risk for congenital neural tube defects in the general population. It is not known whether the risk of neural tube defects or decreased IQ in the offspring of women receiving valproate is reduced by folic acid supplementation. Dietary folic acid supplementation both prior to conception and during pregnancy should be routinely recommended for patients using valproate.</p>

<a id="ID74"></a>
<h3>Pancreatitis</h3>
<p class="First"><a id="ID75"></a>Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with rapid progression from initial symptoms to death. Some cases have occurred shortly after initial use as well as after several years of use. The rate based upon the reported cases exceeds that expected in the general population and there have been cases in which pancreatitis recurred after rechallenge with valproate. In clinical trials, there were 2 cases of pancreatitis without alternative etiology in 2,416 patients, representing 1,044 patient-years experience. Patients and guardians should be warned that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, Divalproex sodium extended-release tablets should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated <span class="Italics">[see <a href="#ID19">Boxed Warning</a>]</span>.</p>

<a id="ID76"></a>
<h3>Urea Cycle Disorders</h3>
<p class="First"><a id="ID77"></a>Divalproex sodium extended-release tablets are contraindicated in patients with known urea cycle disorders (UCD). Hyperammonemic encephalopathy, sometimes fatal, has been reported following initiation of valproate therapy in patients with urea cycle disorders, a group of uncommon genetic abnormalities, particularly ornithine transcarbamylase deficiency. Prior to the initiation of Divalproex sodium extended-release tablets therapy, evaluation for UCD should be considered in the following patients: 1) those with a history of unexplained encephalopathy or coma, encephalopathy associated with a protein load, pregnancy-related or postpartum encephalopathy, unexplained mental retardation, or history of elevated plasma ammonia or glutamine; 2) those with cyclical vomiting and lethargy, episodic extreme irritability, ataxia, low BUN, or protein avoidance; 3) those with a family history of UCD or a family history of unexplained infant deaths (particularly males); 4) those with other signs or symptoms of UCD. Patients who develop symptoms of unexplained hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment (including discontinuation of valproate therapy) and be evaluated for underlying urea cycle disorders <span class="Italics">[see Contraindications (<a href="#ID60">4</a>) and Warnings and Precautions (<a href="#ID86">5.10</a>)]</span>.</p>

<a id="ID78"></a>
<h3>Suicidal Behavior and Ideation</h3>
<p class="First"><a id="ID79"></a>Antiepileptic drugs (AEDs), including Divalproex sodium extended-release tablets, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</p>
<p>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.</p>
<p>The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</p>
<p>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.</p>
<p>Table 2 shows absolute and relative risk by indication for all evaluated AEDs.</p>
<a id="ID80"></a>
<div class='responsive-table-wrap'><table class="Noautorules" style="width: 625px; ">
<caption>Table 2. Risk by Indication for Antiepileptic Drugs in the Pooled Analysis</caption>
<col style="width: 84px; " />
<col style="width: 103px; " />
<col style="width: 103px; " />
<col style="width: 191px; " />
<col style="width: 144px; " />
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Indication</span><br /></td>
<td class="Botrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Placebo</span> <span class="Bold">Patients</span> <span class="Bold">with Events Per 1,000 Patients</span><br /></td>
<td class="Botrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Drug</span> <span class="Bold">Patients with Events Per 1,000 Patients</span><br /></td>
<td class="Botrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Relative Risk: Incidence</span> <span class="Bold">of Events in Drug Patients/Incidence in Placebo Patients</span><br /></td>
<td class="Botrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Risk</span> <span class="Bold">Difference: Additional Drug Patients with Events Per 1,000 Patients</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Epilepsy<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1.0<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">3.4<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">3.5<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">2.4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Psychiatric<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">5.7<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">8.5<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1.5<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">2.9<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Other<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1.0<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1.8<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1.9<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">0.9<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Total<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">2.4<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">4.3<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1.8<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1.9<br /></td>
</tr>
</tbody>
</table></div>
<p><a id="ID81"></a>The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.</p>
<p>Anyone considering prescribing Divalproex sodium extended-release tablets or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</p>

<a id="ID82"></a>
<h3>Bleeding and Other Hematopoietic Disorders</h3>
<p class="First"><a id="ID83"></a>Valproate is associated with dose-related thrombocytopenia. In a clinical trial of valproate as monotherapy in patients with epilepsy, 34/126 patients (27%) receiving approximately 50 mg/kg/day on average, had at least one value of platelets &le; 75 x 10<span class="Sup">9</span>/L. Approximately half of these patients had treatment discontinued, with return of platelet counts to normal. In the remaining patients, platelet counts normalized with continued treatment. In this study, the probability of thrombocytopenia appeared to increase significantly at total valproate concentrations of &ge; 110 mcg/mL (females) or &ge; 135 mcg/mL (males). The therapeutic benefit which may accompany the higher doses should therefore be weighed against the possibility of a greater incidence of adverse effects. Valproate use has also been associated with decreases in other cell lines and myelodysplasia.</p>
<p>Because of reports of cytopenias, inhibition of the secondary phase of platelet aggregation, and abnormal coagulation parameters, (e.g., low fibrinogen, coagulation factor deficiencies, acquired von Willebrand's disease), measurements of complete blood counts and coagulation tests are recommended before initiating therapy and at periodic intervals. It is recommended that patients receiving Divalproex sodium extended-release tablets be monitored for blood counts and coagulation parameters prior to planned surgery and during pregnancy <span class="Italics">[see Use in Specific Populations (<a href="#ID141">8.1</a>)]</span>. Evidence of hemorrhage, bruising, or a disorder of hemostasis/coagulation is an indication for reduction of the dosage or withdrawal of therapy.</p>

<a id="ID84"></a>
<h3>Hyperammonemia</h3>
<p class="First"><a id="ID85"></a>Hyperammonemia has been reported in association with valproate therapy and may be present despite normal liver function tests. In patients who develop unexplained lethargy and vomiting or changes in mental status, hyperammonemic encephalopathy should be considered and an ammonia level should be measured. Hyperammonemia should also be considered in patients who present with hypothermia <span class="Italics">[see Warnings and Precautions (<a href="#ID88">5.11</a>)]</span>. If ammonia is increased, valproate therapy should be discontinued. Appropriate interventions for treatment of hyperammonemia should be initiated, and such patients should undergo investigation for underlying urea cycle disorders <span class="Italics">[see Contraindications (<a href="#ID60">4</a>) and Warnings and Precautions (<a href="#ID76">5.6</a>, <a href="#ID86">5.10</a>)]</span>.</p>
<p>During the placebo controlled pediatric mania trial, one (1) in twenty (20) adolescents (5%) treated with valproate developed increased plasma ammonia levels compared to no (0) patients treated with placebo.</p>
<p>Asymptomatic elevations of ammonia are more common and when present, require close monitoring of plasma ammonia levels. If the elevation persists, discontinuation of valproate therapy should be considered.</p>

<a id="ID86"></a>
<h3>Hyperammonemia and Encephalopathy Associated with Concomitant Topiramate Use</h3>
<p class="First"><a id="ID87"></a>Concomitant administration of topiramate and valproate has been associated with hyperammonemia with or without encephalopathy in patients who have tolerated either drug alone. Clinical symptoms of hyperammonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting. Hypothermia can also be a manifestation of hyperammonemia <span class="Italics">[see Warnings and Precautions (<a href="#ID88">5.11</a>)]</span>. In most cases, symptoms and signs abated with discontinuation of either drug. This adverse reaction is not due to a pharmacokinetic interaction. Patients with inborn errors of metabolism or reduced hepatic mitochondrial activity may be at an increased risk for hyperammonemia with or without encephalopathy. Although not studied, an interaction of topiramate and valproate may exacerbate existing defects or unmask deficiencies in susceptible persons. In patients who develop unexplained lethargy, vomiting, or changes in mental status, hyperammonemic encephalopathy should be considered and an ammonia level should be measured <span class="Italics">[see Contraindications (<a href="#ID60">4</a>) and Warnings and Precautions (<a href="#ID76">5.6</a>, <a href="#ID84">5.9</a>)]</span>.</p>

<a id="ID88"></a>
<h3>Hypothermia</h3>
<p class="First"><a id="ID89"></a>Hypothermia, defined as an unintentional drop in body core temperature to &lt; 35&deg;C (95&deg;F), has been reported in association with valproate therapy both in conjunction with and in the absence of hyperammonemia. This adverse reaction can also occur in patients using concomitant topiramate with valproate after starting topiramate treatment or after increasing the daily dose of topiramate <span class="Italics">[see Drug Interactions (<a href="#ID136">7.3</a>)]</span>. Consideration should be given to stopping valproate in patients who develop hypothermia, which may be manifested by a variety of clinical abnormalities including lethargy, confusion, coma, and significant alterations in other major organ systems such as the cardiovascular and respiratory systems. Clinical management and assessment should include examination of blood ammonia levels.</p>

<a id="ID90"></a>
<h3>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions</h3>
<p class="First"><a id="ID91"></a>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan Hypersensitivity, has been reported in patients taking valproate. DRESS may be fatal or life- threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Valproate should be discontinued and not be resumed if an alternative etiology for the signs or symptoms cannot be established.</p>

<a id="ID92"></a>
<h3>Interaction with Carbapenem Antibiotics</h3>
<p class="First"><a id="ID93"></a>Carbapenem antibiotics (for example, ertapenem, imipenem, meropenem; this is not a complete list) may reduce serum valproate concentrations to subtherapeutic levels, resulting in loss of seizure control. Serum valproate concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or anticonvulsant therapy should be considered if serum valproate concentrations drop significantly or seizure control deteriorates <span class="Italics">[see Drug Interactions (<a href="#ID132">7.1</a>)]</span>.</p>

<a id="ID94"></a>
<h3>Somnolence in the Elderly</h3>
<p class="First"><a id="ID95"></a>In a double-blind, multicenter trial of valproate in elderly patients with dementia (mean age = 83 years), doses were increased by 125 mg/day to a target dose of 20 mg/kg/day. A significantly higher proportion of valproate patients had somnolence compared to placebo, and although not statistically significant, there was a higher proportion of patients with dehydration.</p>
<p>Discontinuations for somnolence were also significantly higher than with placebo. In some patients with somnolence (approximately one-half), there was associated reduced nutritional intake and weight loss. There was a trend for the patients who experienced these events to have a lower baseline albumin concentration, lower valproate clearance, and a higher BUN. In elderly patients, dosage should be increased more slowly and with regular monitoring for fluid and nutritional intake, dehydration, somnolence, and other adverse reactions. Dose reductions or discontinuation of valproate should be considered in patients with decreased food or fluid intake and in patients with excessive somnolence <span class="Italics">[see Dosage and Administration (<a href="#ID47">2.4</a>)]</span>.</p>

<a id="ID96"></a>
<h3>Monitoring: Drug Plasma Concentration</h3>
<p class="First"><a id="ID97"></a>Since valproate may interact with concurrently administered drugs which are capable of enzyme induction, periodic plasma concentration determinations of valproate and concomitant drugs are recommended during the early course of therapy <span class="Italics">[see Drug Interactions (<a href="#ID131">7</a>)]</span>.</p>

<a id="ID98"></a>
<h3>Effect on Ketone and Thyroid Function Tests</h3>
<p class="First"><a id="ID99"></a>Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test.</p>
<p>There have been reports of altered thyroid function tests associated with valproate. The clinical significance of these is unknown.</p>

<a id="ID100"></a>
<h3>Effect on HIV and CMV Viruses Replication</h3>
<p class="First"><a id="ID101"></a>There are <span class="Italics">in vitro</span> studies that suggest valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions. The clinical consequence, if any, is not known. Additionally, the relevance of these <span class="Italics">in vitro</span> findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. Nevertheless, these data should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.</p>

<a id="ID102"></a>
<h3>Medication Residue in the Stool</h3>
<p class="First"><a id="ID103"></a>There have been rare reports of medication residue in the stool. Some patients have had anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times. In some reports, medication residues have occurred in the context of diarrhea. It is recommended that plasma valproate levels be checked in patients who experience medication residue in the stool, and patients' clinical condition should be monitored. If clinically indicated, alternative treatment may be considered.</p>


<a id="ID106"></a><a id="s-34084-4"></a>
<h2>Adverse Reactions</h2>
<a id="ID107"></a>
<p class="First"><a id="ID108"></a>The following serious adverse reactions are described below and elsewhere in the labeling:</p>
<ul class="Disc">
<li>Hepatic failure <span class="Italics">[see Warnings and Precautions (<a href="#ID66">5.1</a>)]</span></li>
<li>Birth defects <span class="Italics">[see Warnings and Precautions (<a href="#ID68">5.2</a>)]</span></li>
<li>Decreased IQ following <span class="Italics">in utero</span> exposure <span class="Italics">[see Warnings and Precautions (<a href="#ID70">5.3</a>)]</span></li>
<li>Pancreatitis <span class="Italics">[see Warnings and Precautions (<a href="#ID74">5.5</a>)]</span></li>
<li>Hyperammonemic encephalopathy <span class="Italics">[see Warnings and Precautions (<a href="#ID76">5.6</a>, <a href="#ID84">5.9</a>, <a href="#ID86">5.10</a>)]</span></li>
<li>Suicidal behavior and ideation <span class="Italics">[see Warnings and Precautions (<a href="#ID78">5.7</a>)]</span></li>
<li>Bleeding and other hematopoietic disorders <span class="Italics">[see Warnings and Precautions (<a href="#ID82">5.8</a>)]</span></li>
<li>Hypothermia <span class="Italics">[see Warnings and Precautions (<a href="#ID88">5.11</a>)]</span></li>
<li>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan hypersensitivity reactions <span class="Italics">[see Warnings and Precautions (<a href="#ID90">5.12</a>)]</span></li>
<li>Somnolence in the elderly <span class="Italics">[see Warnings and Precautions (<a href="#ID94">5.14</a>)]</span></li>
</ul>
<p><a id="ID110"></a>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p>Information on pediatric adverse reactions is presented in section 8.</p>

<a id="ID111"></a>
<h3>Mania</h3>
<p class="First"><a id="ID112"></a>The incidence of treatment-emergent events has been ascertained based on combined data from two three week placebo-controlled clinical trials of Divalproex sodium extended-release tablets in the treatment of manic episodes associated with bipolar disorder.</p>
<p>Table 3 summarizes those adverse reactions reported for patients in these trials where the incidence rate in the Divalproex sodium extended-release tablet-treated group was greater than 5% and greater than the placebo incidence.</p>
<a id="ID113"></a>
<div class='responsive-table-wrap'><table class="Noautorules" style="width: 100%; ">
<caption>Table 3. Adverse Reactions Reported by &gt; 5% of Divalproex Sodium Extended-Release Tablets-Treated Patients During Placebo-Controlled Trials of Acute Mania<span class="Sup">1</span></caption>
<col style="width: 31%; " />
<col style="width: 50%; " />
<col style="width: 18%; " />
<tfoot>
<tr>
<td colspan="3" style="text-align: left; ">
<p class="First Footnote"><span class="Sup">1</span>The following adverse reactions/event occurred at an equal or greater incidence for placebo than for Divalproex sodium extended-release tablets: headache</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; "><span class="Bold">Adverse Event</span><br /></td>
<td class="Botrule Rrule Toprule" style="text-align: center; "><span class="Bold">Divalproex Sodium Extended-Release Tablets</span><br />
<span class="Bold">(n=338)</span><br />
<span class="Bold">%</span><br /></td>
<td class="Botrule Rrule Toprule" style="text-align: center; "><span class="Bold">Placebo</span><br />
<span class="Bold">(n=263)</span><br />
<span class="Bold">%</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Somnolence<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">26<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">14<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Dyspepsia<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">23<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">11<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Nausea<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">19<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">13<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Vomiting<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">13<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">5<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Diarrhea<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">12<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">8<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Dizziness<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">12<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">7<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Pain<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">11<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">10<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Abdominal Pain<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">10<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">5<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Accidental Injury<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">6<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">5<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Asthenia<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">6<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">5<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Pharyngitis<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">6<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">5<br /></td>
</tr>
</tbody>
</table></div>
<p><a id="ID114"></a>The following additional adverse reactions were reported by greater than 1% of the Divalproex sodium extended-release tablet-treated patients in controlled clinical trials:</p>
<p><span class="Bold"><span class="Italics">Body as a Whole:</span></span> Back Pain, Chills, Chills and Fever, Drug Level Increased, Flu Syndrome, Infection, Infection Fungal, Neck Rigidity.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular System:</span></span> Arrhythmia, Hypertension, Hypotension, Postural Hypotension.</p>
<p><span class="Bold"><span class="Italics">Digestive System:</span></span> Constipation, Dry Mouth, Dysphagia, Fecal Incontinence, Flatulence, Gastroenteritis, Glossitis, Gum Hemorrhage, Mouth Ulceration.</p>
<p><span class="Bold"><span class="Italics">Hemic and Lymphatic System:</span></span> Anemia, Bleeding Time Increased, Ecchymosis, Leucopenia.</p>
<p><span class="Bold"><span class="Italics">Metabolic and Nutritional Disorders:</span></span> Hypoproteinemia, Peripheral Edema.</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal System:</span></span> Arthrosis, Myalgia.</p>
<p><span class="Bold"><span class="Italics">Nervous System:</span></span> Abnormal Gait, Agitation, Catatonic Reaction, Dysarthria, Hallucinations, Hypertonia, Hypokinesia, Psychosis, Reflexes Increased, Sleep Disorder, Tardive Dyskinesia, Tremor.</p>
<p><span class="Bold"><span class="Italics">Respiratory System:</span></span> Hiccup, Rhinitis.</p>
<p><span class="Bold"><span class="Italics">Skin and Appendages:</span></span> Discoid Lupus Erythematosus, Erythema Nodosum, Furunculosis, Maculopapular Rash, Pruritus, Rash, Seborrhea, Sweating, Vesiculobullous Rash.</p>
<p><span class="Bold"><span class="Italics">Special Senses:</span></span> Conjunctivitis, Dry Eyes, Eye Disorder, Eye Pain, Photophobia, Taste Perversion.</p>
<p><span class="Bold"><span class="Italics">Urogenital System:</span></span> Cystitis, Urinary Tract Infection, Menstrual Disorder, Vaginitis.</p>

<a id="ID115"></a>
<h3>Epilepsy</h3>
<p class="First"><a id="ID116"></a>Based on a placebo-controlled trial of adjunctive therapy for treatment of complex partial seizures, Divalproex sodium delayed-release tablets was generally well tolerated with most adverse reactions rated as mild to moderate in severity. Intolerance was the primary reason for discontinuation in the Divalproex sodium delayed-release tablet-treated patients (6%), compared to 1% of placebo-treated patients.</p>
<p>Table 4 lists treatment-emergent adverse reactions which were reported by &ge; 5% of Divalproex sodium delayed-release tablet-treated patients and for which the incidence was greater than in the placebo group, in the placebo-controlled trial of adjunctive therapy for treatment of complex partial seizures. Since patients were also treated with other antiepilepsy drugs, it is not possible, in most cases, to determine whether the following adverse reactions can be ascribed to Divalproex sodium delayed-release tablets alone, or the combination of Divalproex sodium delayed-release tablets and other antiepilepsy drugs.</p>
<a id="ID117"></a>
<div class='responsive-table-wrap'><table class="Noautorules" style="width: 100%; ">
<caption>Table 4. Adverse Reactions Reported by &ge; 5% of Patients Treated with Valproate During Placebo-Controlled Trial of Adjunctive Therapy for Complex Partial Seizures</caption>
<col style="width: 33%; " />
<col style="width: 50%; " />
<col style="width: 15%; " />
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; "><span class="Bold">Body System/Event</span><br /></td>
<td class="Botrule Rrule Toprule" style="text-align: center; "><span class="Bold">Divalproex Sodium Delayed-Release Tablets</span><br />
<span class="Bold">(%)</span><br />
<span class="Bold">(N=77)</span><br /></td>
<td class="Botrule Rrule Toprule" style="text-align: center; "><span class="Bold">Placebo</span><br />
<span class="Bold">(%)</span><br />
<span class="Bold">(N=70)</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Body as a Whole</span><br /></td>
<td class="Botrule" style="text-align: center; "><br /></td>
<td class="Botrule Rrule" style="text-align: center; "><br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Headache<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">31<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">21<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Asthenia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">27<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">7<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Fever<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">6<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Gastrointestinal</span> <span class="Bold">System</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Nausea<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">48<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">14<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Vomiting<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">27<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">7<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Abdominal Pain<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">23<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">6<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Diarrhea<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">13<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">6<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Anorexia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">12<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">0<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Dyspepsia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">8<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Constipation<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">5<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Nervous</span> <span class="Bold">System</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Somnolence<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">27<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">11<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Tremor<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">25<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">6<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Dizziness<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">25<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">13<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Diplopia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">16<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">9<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Amblyopia/Blurred Vision<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">12<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">9<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Ataxia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">8<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Nystagmus<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">8<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Emotional Lability<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">6<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Thinking Abnormal<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">6<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">0<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Amnesia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">5<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Respiratory System</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Flu Syndrome<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">12<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">9<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Infection<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">12<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">6<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Bronchitis<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">5<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Rhinitis<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">5<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Other</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Alopecia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">6<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Weight Loss<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">6<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">0<br /></td>
</tr>
</tbody>
</table></div>
<p><a id="ID247"></a>Table 5 lists treatment-emergent adverse reactions which were reported by &ge; 5% of patients in the high dose valproate group, and for which the incidence was greater than in the low dose group, in a controlled trial of Divalproex sodium delayed-release tablets monotherapy treatment of complex partial seizures. Since patients were being titrated off another antiepilepsy drug during the first portion of the trial, it is not possible, in many cases, to determine whether the following adverse reactions can be ascribed to Divalproex sodium delayed-release tablets alone, or the combination of valproate and other antiepilepsy drugs.</p>
<a id="ID119"></a>
<div class='responsive-table-wrap'><table class="Noautorules" style="width: 100%; ">
<caption>Table 5. Adverse Reactions Reported by &ge; 5% of Patients in the High Dose Group in the Controlled Trial of Valproate Monotherapy for Complex Partial Seizures<span class="Sup">1</span></caption>
<col style="width: 48%; " />
<col style="width: 26%; " />
<col style="width: 24%; " />
<tfoot>
<tr>
<td colspan="3" style="text-align: left; ">
<p class="First Footnote"><span class="Sup">1</span>Headache was the only adverse event that occurred in &ge;5% of patients in the high dose group and at an equal or greater incidence in the low dose group.</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; "><span class="Bold">Body System/Event</span><br /></td>
<td class="Botrule Rrule Toprule" style="text-align: center; "><span class="Bold">High Dose</span><br />
<span class="Bold">(%)</span><br />
<span class="Bold">(n=131)</span><br /></td>
<td class="Botrule Rrule Toprule" style="text-align: center; "><span class="Bold">Low Dose</span><br />
<span class="Bold">(%)</span><br />
<span class="Bold">(n=134)</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Body as a Whole</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Asthenia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">21<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">10<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Digestive</span> <span class="Bold">System</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Nausea<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">34<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">26<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Diarrhea<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">23<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">19<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Vomiting<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">23<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">15<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Abdominal Pain<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">12<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">9<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Anorexia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">11<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Dyspepsia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">11<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">10<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Hemic/Lymphatic</span> <span class="Bold">System</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Thrombocytopenia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">24<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Ecchymosis<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">5<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Metabolic/Nutritional</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Weight Gain<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">9<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Peripheral Edema<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">8<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">3<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Nervous</span> <span class="Bold">System</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Tremor<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">57<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">19<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Somnolence<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">30<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">18<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Dizziness<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">18<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">13<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Insomnia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">15<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">9<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Nervousness<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">11<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">7<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Amnesia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">7<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Nystagmus<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">7<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Depression<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">5<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Respiratory</span> <span class="Bold">System</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Infection<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">20<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">13<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Pharyngitis<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">8<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">2<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Dyspnea<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">5<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Skin and Appendages</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Alopecia<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">24<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">13<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="text-align: left; "><span class="Bold">Special</span> <span class="Bold">Senses</span><br /></td>
<td class="Botrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Amblyopia/Blurred Vision<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">8<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Tinnitus<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">7<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1<br /></td>
</tr>
</tbody>
</table></div>
<p><a id="ID120"></a>The following additional adverse reactions were reported by greater than 1% but less than 5% of the 358 patients treated with valproate in the controlled trials of complex partial seizures:</p>
<p><span class="Bold"><span class="Italics">Body as a Whole:</span></span> Back pain, chest pain, malaise.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular System:</span></span> Tachycardia, hypertension, palpitation.</p>
<p><span class="Bold"><span class="Italics">Digestive System:</span></span> Increased appetite, flatulence, hematemesis, eructation, pancreatitis, periodontal abscess.</p>
<p><span class="Bold"><span class="Italics">Hemic and Lymphatic System</span>:</span><span class="Bold"> </span>Petechia.</p>
<p><span class="Bold"><span class="Italics">Metabolic and Nutritional Disorders:</span></span> SGOT increased, SGPT increased.</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal System:</span></span> Myalgia, twitching, arthralgia, leg cramps, myasthenia.</p>
<p><span class="Bold"><span class="Italics">Nervous System:</span></span> Anxiety, confusion, abnormal gait, paresthesia, hypertonia, incoordination, abnormal dreams, personality disorder.</p>
<p><span class="Bold"><span class="Italics">Respiratory System:</span></span> Sinusitis, cough increased, pneumonia, epistaxis.</p>
<p><span class="Bold"><span class="Italics">Skin and Appendages:</span></span> Rash, pruritus, dry skin.</p>
<p><span class="Bold"><span class="Italics">Special Senses:</span></span> Taste perversion, abnormal vision, deafness, otitis media.</p>
<p><span class="Bold"><span class="Italics">Urogenital System:</span></span> Urinary incontinence, vaginitis, dysmenorrhea, amenorrhea, urinary frequency.</p>

<a id="ID121"></a>
<h3>Migraine</h3>
<p class="First"><a id="ID122"></a>Based on two placebo-controlled clinical trials and their long term extension, valproate was generally well tolerated with most adverse reactions rated as mild to moderate in severity. Of the 202 patients exposed to valproate in the placebo-controlled trials, 17% discontinued for intolerance. This is compared to a rate of 5% for the 81 placebo patients. Including the long term extension study, the adverse reactions reported as the primary reason for discontinuation by &ge; 1% of 248 valproate-treated patients were alopecia (6%), nausea and/or vomiting (5%), weight gain (2%), tremor (2%), somnolence (1%), elevated SGOT and/or SGPT (1%), and depression (1%).</p>
<p>Table 6 includes those adverse reactions reported for patients in the placebo-controlled trial where the incidence rate in the Divalproex sodium extended-release tablet-treated group was greater than 5% and was greater than that for placebo patients.</p>
<a id="ID123"></a>
<div class='responsive-table-wrap'><table class="Noautorules" style="width: 100%; ">
<caption>Table 6. Adverse Reactions Reported by &gt;5% of Divalproex Sodium Extended-Release Tablet -Treated Patients During the Migraine Placebo-Controlled Trial with a Greater Incidence than Patients Taking Placebo<span class="Sup">1</span></caption>
<col style="width: 29%; " />
<col style="width: 49%; " />
<col style="width: 20%; " />
<tfoot>
<tr>
<td colspan="3" style="text-align: left; ">
<p class="First Footnote"><span class="Sup">1</span>The following adverse reactions occurred in greater than 5% of Divalproex sodium extended-release tablet-treated patients and at a greater incidence for placebo than for Divalproex sodium extended-release tablets: asthenia and flu syndrome.</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Body System Event</span><br /></td>
<td class="Botrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Divalproex Sodium Extended-Release Tablets</span><br />
<span class="Bold">(n=122)</span><br />
<span class="Bold">%</span><br /></td>
<td class="Botrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Placebo</span><br />
<span class="Bold">(n=115)</span><br />
<span class="Bold">%</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="vertical-align: top; text-align: left; "><span class="Bold">Gastrointestinal</span> <span class="Bold">System</span><br /></td>
<td class="Botrule" style="vertical-align: top; "></td>
<td class="Botrule Rrule" style="vertical-align: top; "></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Nausea<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">15<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">9<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Dyspepsia<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">7<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Diarrhea<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">7<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">3<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Vomiting<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">7<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">2<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Abdominal Pain<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">7<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">5<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="vertical-align: top; text-align: left; "><span class="Bold">Nervous</span> <span class="Bold">System</span><br /></td>
<td class="Botrule" style="vertical-align: top; "></td>
<td class="Botrule Rrule" style="vertical-align: top; "></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Somnolence<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">7<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">2<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="vertical-align: top; text-align: left; "><span class="Bold">Other</span><br /></td>
<td class="Botrule" style="vertical-align: top; "></td>
<td class="Botrule Rrule" style="vertical-align: top; "></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Infection<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">15<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">14<br /></td>
</tr>
</tbody>
</table></div>
<p><a id="ID124"></a>The following additional adverse reactions were reported by greater than 1% but not more than 5% of Divalproex sodium extended-release tablet-treated patients and with a greater incidence than placebo in the placebo- controlled clinical trial for migraine prophylaxis:</p>
<p><span class="Bold"><span class="Italics">Body as a Whole:</span></span> Accidental injury, viral infection.</p>
<p><span class="Bold"><span class="Italics">Digestive System:</span></span> Increased appetite, tooth disorder.</p>
<p><span class="Bold"><span class="Italics">Metabolic and Nutritional Disorders:</span></span> Edema, weight gain.</p>
<p><span class="Bold"><span class="Italics">Nervous System:</span> </span>Abnormal gait, dizziness, hypertonia, insomnia, nervousness, tremor, vertigo.</p>
<p><span class="Bold"><span class="Italics">Respiratory System:</span></span> Pharyngitis, rhinitis.</p>
<p><span class="Bold"><span class="Italics">Skin and Appendages:</span></span> Rash.</p>
<p><span class="Bold"><span class="Italics">Special Senses:</span></span> Tinnitus.</p>
<p>Table 7 includes those adverse reactions reported for patients in the placebo-controlled trials where the incidence rate in the valproate-treated group was greater than 5% and was greater than that for placebo patients.</p>
<a id="ID125"></a>
<div class='responsive-table-wrap'><table class="Noautorules" style="width: 100%; ">
<caption>Table 7. Adverse Reactions Reported by &gt; 5% of Valproate-Treated Patients During Migraine Placebo-Controlled Trials with a Greater Incidence than Patients Taking Placebo<span class="Sup">1</span></caption>
<col style="width: 32%; " />
<col style="width: 50%; " />
<col style="width: 16%; " />
<tfoot>
<tr>
<td colspan="3" style="text-align: left; ">
<p class="First Footnote"><span class="Sup">1</span>The following adverse reactions occurred in greater than 5% of Divalproex sodium delayed-release tablet-treated patients and at a greater incidence for placebo than for Divalproex sodium delayed-release tablets: flu syndrome and pharyngitis.</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Body System Reaction</span><br /></td>
<td class="Botrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Divalproex Sodium Delayed-Release Tablets</span><br />
<span class="Bold">(n=202)</span><br />
<span class="Bold">%</span><br /></td>
<td class="Botrule Rrule Toprule" style="vertical-align: top; text-align: center; "><span class="Bold">Placebo</span><br />
<span class="Bold">(n=81)</span><br />
<span class="Bold">%</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="vertical-align: top; text-align: left; "><span class="Bold">Gastrointestinal</span> <span class="Bold">System</span><br /></td>
<td class="Botrule" style="vertical-align: top; "></td>
<td class="Botrule Rrule" style="vertical-align: top; "></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Nausea<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">31<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">10<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Dyspepsia<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">13<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">9<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Diarrhea<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">12<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">7<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Vomiting<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">11<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Abdominal Pain<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">9<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Increased Appetite<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">6<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">4<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="vertical-align: top; text-align: left; "><span class="Bold">Nervous</span> <span class="Bold">System</span><br /></td>
<td class="Botrule" style="vertical-align: top; "></td>
<td class="Botrule Rrule" style="vertical-align: top; "></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Asthenia<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">20<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">9<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Somnolence<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">17<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">5<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Dizziness<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">12<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">6<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Tremor<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">9<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">0<br /></td>
</tr>
<tr>
<td class="Botrule Lrule" style="vertical-align: top; text-align: left; "><span class="Bold">Other</span><br /></td>
<td class="Botrule" style="vertical-align: top; "></td>
<td class="Botrule Rrule" style="vertical-align: top; "></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Weight Gain<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">8<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">2<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Back Pain<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">8<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">6<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="vertical-align: top; text-align: left; ">Alopecia<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">7<br /></td>
<td class="Botrule Rrule" style="vertical-align: top; text-align: center; ">1<br /></td>
</tr>
</tbody>
</table></div>
<p><a id="ID126"></a>The following additional adverse reactions were reported by greater than 1% but not more than 5% of the 202 valproate-treated patients in the controlled clinical trials:</p>
<p><span class="Bold"><span class="Italics">Body as a Whole:</span></span> Chest pain.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular System:</span></span> Vasodilatation.</p>
<p><span class="Bold"><span class="Italics">Digestive System:</span></span> Constipation, dry mouth, flatulence, and stomatitis.</p>
<p><span class="Bold"><span class="Italics">Hemic and Lymphatic System:</span></span><span class="Bold"> </span>Ecchymosis.</p>
<p><span class="Bold"><span class="Italics">Metabolic and Nutritional Disorders:</span></span> Peripheral edema.</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal System:</span></span> Leg cramps.</p>
<p><span class="Bold"><span class="Italics">Nervous System:</span></span> Abnormal dreams, confusion, paresthesia, speech disorder, and thinking abnormalities.</p>
<p><span class="Bold"><span class="Italics">Respiratory System:</span></span> Dyspnea, and sinusitis.</p>
<p><span class="Bold"><span class="Italics">Skin and Appendages:</span></span> Pruritus.</p>
<p><span class="Bold"><span class="Italics">Urogenital System:</span></span> Metrorrhagia.</p>

<a id="ID127"></a>
<h3>Postmarketing Experience</h3>
<p class="First"><a id="ID128"></a>The following adverse reactions have been identified during post approval use of Divalproex sodium delayed-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold"><span class="Italics">Dermatologic:</span></span> Hair texture changes, hair color changes, photosensitivity, erythema multiforme, toxic epidermal necrolysis, nail and nail bed disorders, and Stevens-Johnson syndrome.</p>
<p><span class="Bold"><span class="Italics">Psychiatric:</span></span> Emotional upset, psychosis, aggression, psychomotor hyperactivity, hostility, disturbance in attention, learning disorder, and behavioral deterioration.</p>
<p><span class="Bold"><span class="Italics">Neurologic:</span></span> Paradoxical convulsion, parkinsonism</p>
<p>There have been several reports of acute or subacute cognitive decline and behavioral changes (apathy or irritability) with cerebral pseudoatrophy on imaging associated with valproate therapy; both the cognitive/behavioral changes and cerebral pseudoatrophy reversed partially or fully after valproate discontinuation.</p>
<p>There have been reports of acute or subacute encephalopathy in the absence of elevated ammonia levels, elevated valproate levels, or neuroimaging changes. The encephalopathy reversed partially or fully after valproate discontinuation.</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal:</span></span> Fractures, decreased bone mineral density, osteopenia, osteoporosis, and weakness.</p>
<p><span class="Bold"><span class="Italics">Hematologic:</span></span> Relative lymphocytosis, macrocytosis, leukopenia, anemia including macrocytic with or without folate deficiency, bone marrow suppression, pancytopenia, aplastic anemia, agranulocytosis, and acute intermittent porphyria.</p>
<p><span class="Bold"><span class="Italics">Endocrine:</span></span> Irregular menses, secondary amenorrhea, hyperandrogenism, hirsutism, elevated testosterone level, breast enlargement, galactorrhea, parotid gland swelling, polycystic ovary disease, decreased carnitine concentrations, hyponatremia, hyperglycinemia, and inappropriate ADH secretion.</p>
<p>There have been rare reports of Fanconi's syndrome occurring chiefly in children.</p>
<p><span class="Bold"><span class="Italics">Metabolism and nutrition:</span></span> <span class="Italics">Weight gain</span></p>
<p><span class="Bold"><span class="Italics">Reproductive:</span></span> Aspermia, azoospermia, decreased sperm count, decreased spermatozoa motility, male infertility, and abnormal spermatozoa morphology.</p>
<p><span class="Bold"><span class="Italics">Genitourinary:</span></span> Enuresis and urinary tract infection.</p>
<p><span class="Bold"><span class="Italics">Special</span></span> <span class="Bold"><span class="Italics">Senses:</span></span> Hearing loss.</p>
<p><span class="Bold"><span class="Italics">Other:</span></span> Allergic reaction, anaphylaxis, developmental delay, bone pain, bradycardia, and cutaneous vasculitis.</p>


<a id="ID131"></a><a id="s-34073-7"></a>
<h2>Drug Interactions</h2>
<a id="ID132"></a>
<h3>Effects of Co-Administered Drugs on Valproate Clearance</h3>
<p class="First"><a id="ID133"></a>Drugs that affect the level of expression of hepatic enzymes, particularly those that elevate levels of glucuronosyltransferases (such as ritonavir), may increase the clearance of valproate. For example, phenytoin, carbamazepine, and phenobarbital (or primidone) can double the clearance of valproate. Thus, patients on monotherapy will generally have longer half-lives and higher concentrations than patients receiving polytherapy with antiepilepsy drugs.</p>
<p>In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation.</p>
<p>Because of these changes in valproate clearance, monitoring of valproate and concomitant drug concentrations should be increased whenever enzyme inducing drugs are introduced or withdrawn.</p>
<p>The following list provides information about the potential for an influence of several commonly prescribed medications on valproate pharmacokinetics. The list is not exhaustive nor could it be, since new interactions are continuously being reported.</p>
<p><span class="Bold"><span class="Italics">Drugs for which a potentially important interaction has been observed</span></span></p>
<p><span class="Bold"><span class="Italics">Aspirin:</span></span></p>
<p>A study involving the co-administration of aspirin at antipyretic doses (11 to 16 mg/kg) with valproate to pediatric patients (n=6) revealed a decrease in protein binding and an inhibition of metabolism of valproate. Valproate free fraction was increased 4-fold in the presence of aspirin compared to valproate alone. The &beta;-oxidation pathway consisting of 2-E-valproic acid, 3-OH- valproic acid, and 3-keto valproic acid was decreased from 25% of total metabolites excreted on valproate alone to 8.3% in the presence of aspirin. Whether or not the interaction observed in this study applies to adults is unknown, but caution should be observed if valproate and aspirin are to be co-administered.</p>
<p><span class="Bold"><span class="Italics">Carbapenem Antibiotics:</span></span></p>
<p>A clinically significant reduction in serum valproic acid concentration has been reported in patients receiving carbapenem antibiotics (for example, ertapenem, imipenem, meropenem; this is not a complete list) and may result in loss of seizure control. The mechanism of this interaction is not well understood. Serum valproic acid concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or anticonvulsant therapy should be considered if serum valproic acid concentrations drop significantly or seizure control deteriorates <span class="Italics">[see Warnings and Precautions (<a href="#ID92">5.13</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Estrogen-Containing Hormonal Contraceptives:</span></span></p>
<p>Estrogen-containing hormonal contraceptives may increase the clearance of valproate, which may result in decreased concentration of valproate and potentially increased seizure frequency. Prescribers should monitor serum valproate concentrations and clinical response when adding or discontinuing estrogen containing products.</p>
<p><span class="Bold"><span class="Italics">Felbamate:</span></span></p>
<p>A study involving the co-administration of 1,200 mg/day of felbamate with valproate to patients with epilepsy (n=10) revealed an increase in mean valproate peak concentration by 35% (from 86 to 115 mcg/mL) compared to valproate alone. Increasing the felbamate dose to 2,400 mg/day increased the mean valproate peak concentration to 133 mcg/mL (another 16% increase). A decrease in valproate dosage may be necessary when felbamate therapy is initiated.</p>
<p><span class="Bold"><span class="Italics">Rifampin:</span></span></p>
<p>A study involving the administration of a single dose of valproate (7 mg/kg) 36 hours after 5 nights of daily dosing with rifampin (600 mg) revealed a 40% increase in the oral clearance of valproate. Valproate dosage adjustment may be necessary when it is co-administered with rifampin.</p>
<p><span class="Bold"><span class="Italics">Drugs for which either no interaction or a likely clinically unimportant interaction has been observed</span></span></p>
<p><span class="Bold"><span class="Italics">Antacids:</span></span></p>
<p>A study involving the co-administration of valproate 500 mg with commonly administered antacids (Maalox, Trisogel, and Titralac - 160 mEq doses) did not reveal any effect on the extent of absorption of valproate.</p>
<p><span class="Bold"><span class="Italics">Chlorpromazine:</span></span></p>
<p>A study involving the administration of 100 to 300 mg/day of chlorpromazine to schizophrenic patients already receiving valproate (200 mg BID) revealed a 15% increase in trough plasma levels of valproate.</p>
<p><span class="Bold"><span class="Italics">Haloperidol:</span></span></p>
<p>A study involving the administration of 6 to 10 mg/day of haloperidol to schizophrenic patients already receiving valproate (200 mg BID) revealed no significant changes in valproate trough plasma levels.</p>
<p><span class="Bold"><span class="Italics">Cimetidine and Ranitidine:</span></span></p>
<p>Cimetidine and ranitidine do not affect the clearance of valproate.</p>

<a id="ID134"></a>
<h3>Effects of Valproate on Other Drugs</h3>
<p class="First"><a id="ID135"></a>Valproate has been found to be a weak inhibitor of some P450 isozymes, epoxide hydrase, and glucuronosyltransferases.</p>
<p>The following list provides information about the potential for an influence of valproate co- administration on the pharmacokinetics or pharmacodynamics of several commonly prescribed medications. The list is not exhaustive, since new interactions are continuously being reported.</p>
<p><span class="Bold"><span class="Italics">Drugs for which a potentially important valproate interaction has been observed</span></span></p>
<p><span class="Bold"><span class="Italics">Amitriptyline/Nortriptyline:</span></span></p>
<p>Administration of a single oral 50 mg dose of amitriptyline to 15 normal volunteers (10 males and 5 females) who received valproate (500 mg BID) resulted in a 21% decrease in plasma clearance of amitriptyline and a 34% decrease in the net clearance of nortriptyline. Rare postmarketing reports of concurrent use of valproate and amitriptyline resulting in an increased amitriptyline level have been received. Concurrent use of valproate and amitriptyline has rarely been associated with toxicity. Monitoring of amitriptyline levels should be considered for patients taking valproate concomitantly with amitriptyline. Consideration should be given to lowering the dose of amitriptyline/nortriptyline in the presence of valproate.</p>
<p><span class="Bold"><span class="Italics">Carbamazepine/carbamazepine-10,11-Epoxide:</span></span></p>
<p>Serum levels of carbamazepine (CBZ) decreased 17% while that of carbamazepine-10, 11- epoxide (CBZ-E) increased by 45% upon co-administration of valproate and CBZ to epileptic patients.</p>
<p><span class="Bold"><span class="Italics">Clonazepam:</span></span></p>
<p>The concomitant use of valproate and clonazepam may induce absence status in patients with a history of absence type seizures.</p>
<p><span class="Bold"><span class="Italics">Diazepam:</span></span></p>
<p>Valproate displaces diazepam from its plasma albumin binding sites and inhibits its metabolism. Co-administration of valproate (1,500 mg daily) increased the free fraction of diazepam (10 mg) by 90% in healthy volunteers (n=6). Plasma clearance and volume of distribution for free diazepam were reduced by 25% and 20%, respectively, in the presence of valproate. The elimination half-life of diazepam remained unchanged upon addition of valproate.</p>
<p><span class="Bold"><span class="Italics">Ethosuximide:</span></span></p>
<p>Valproate inhibits the metabolism of ethosuximide. Administration of a single ethosuximide dose of 500 mg with valproate (800 to 1,600 mg/day) to healthy volunteers (n=6) was accompanied by a 25% increase in elimination half-life of ethosuximide and a 15% decrease in its total clearance as compared to ethosuximide alone. Patients receiving valproate and ethosuximide, especially along with other anticonvulsants, should be monitored for alterations in serum concentrations of both drugs.</p>
<p><span class="Bold"><span class="Italics">Lamotrigine:</span></span></p>
<p>In a steady-state study involving 10 healthy volunteers, the elimination half-life of lamotrigine increased from 26 to 70 hours with valproate co-administration (a 165% increase). The dose of lamotrigine should be reduced when co-administered with valproate. Serious skin reactions (such as Stevens-Johnson syndrome and toxic epidermal necrolysis) have been reported with concomitant lamotrigine and valproate administration. See lamotrigine package insert for details on lamotrigine dosing with concomitant valproate administration.</p>
<p><span class="Bold"><span class="Italics">Phenobarbital:</span></span></p>
<p>Valproate was found to inhibit the metabolism of phenobarbital. Co-administration of valproate (250 mg BID for 14 days) with phenobarbital to normal subjects (n=6) resulted in a 50% increase in half-life and a 30% decrease in plasma clearance of phenobarbital (60 mg single-dose). The fraction of phenobarbital dose excreted unchanged increased by 50% in presence of valproate.</p>
<p>There is evidence for severe CNS depression, with or without significant elevations of barbiturate or valproate serum concentrations. All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. Serum barbiturate concentrations should be obtained, if possible, and the barbiturate dosage decreased, if appropriate. Primidone, which is metabolized to a barbiturate, may be involved in a similar interaction with valproate.</p>
<p><span class="Bold"><span class="Italics">Phenytoin:</span></span></p>
<p>Valproate displaces phenytoin from its plasma albumin binding sites and inhibits its hepatic metabolism. Co-administration of valproate (400 mg TID) with phenytoin (250 mg) in normal volunteers (n=7) was associated with a 60% increase in the free fraction of phenytoin. Total plasma clearance and apparent volume of distribution of phenytoin increased 30% in the presence of valproate. Both the clearance and apparent volume of distribution of free phenytoin were reduced by 25%.</p>
<p>In patients with epilepsy, there have been reports of breakthrough seizures occurring with the combination of valproate and phenytoin. The dosage of phenytoin should be adjusted as required by the clinical situation.</p>
<p><span class="Bold"><span class="Italics">Propofol:</span></span></p>
<p>The concomitant use of valproate and propofol may lead to increased blood levels of propofol. Reduce the dose of propofol when co-administering with valproate. Monitor patients closely for signs of increased sedation or cardiorespiratory depression.</p>
<p><span class="Bold"><span class="Italics">Rufinamide:</span></span></p>
<p>Based on a population pharmacokinetic analysis, rufinamide clearance was decreased by valproate. Rufinamide concentrations were increased by &lt;16% to 70%, dependent on concentration of valproate (with the larger increases being seen in pediatric patients at high doses or concentrations of valproate). Patients stabilized on rufinamide before being prescribed valproate should begin valproate therapy at a low dose, and titrate to a clinically effective dose <span class="Italics">[see Dosage and Administration (<a href="#ID249">2.6</a>)]</span>. Similarly, patients on valproate should begin at a rufinamide dose lower than 10 mg/kg per day (pediatric patients) or 400 mg per day (adults).</p>
<p><span class="Bold"><span class="Italics">Tolbutamide:</span></span></p>
<p>From <span class="Italics">in vitro</span> experiments, the unbound fraction of tolbutamide was increased from 20% to 50% when added to plasma samples taken from patients treated with valproate. The clinical relevance of this displacement is unknown.</p>
<p><span class="Bold"><span class="Italics">Warfarin:</span></span></p>
<p>In an <span class="Italics">in vitro</span> study, valproate increased the unbound fraction of warfarin by up to 32.6%. The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproate therapy is instituted in patients taking anticoagulants.</p>
<p><span class="Bold"><span class="Italics">Zidovudine:</span></span></p>
<p>In six patients who were seropositive for HIV, the clearance of zidovudine (100 mg q8h) was decreased by 38% after administration of valproate (250 or 500 mg q8h); the half-life of zidovudine was unaffected.</p>
<p><span class="Bold"><span class="Italics">Drugs for which either no interaction or a likely clinically unimportant interaction has been observed</span></span></p>
<p><span class="Bold"><span class="Italics">Acetaminophen:</span></span></p>
<p>Valproate had no effect on any of the pharmacokinetic parameters of acetaminophen when it was concurrently administered to three epileptic patients.</p>
<p><span class="Bold"><span class="Italics">Clozapine:</span></span></p>
<p>In psychotic patients (n=11), no interaction was observed when valproate was co-administered with clozapine.</p>
<p><span class="Bold"><span class="Italics">Lithium:</span></span></p>
<p>Co-administration of valproate (500 mg BID) and lithium carbonate (300 mg TID) to normal male volunteers (n=16) had no effect on the steady-state kinetics of lithium.</p>
<p><span class="Bold"><span class="Italics">Lorazepam:</span></span></p>
<p>Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n=9) was accompanied by a 17% decrease in the plasma clearance of lorazepam.</p>
<p><span class="Bold"><span class="Italics">Olanzapine:</span></span></p>
<p>No dose adjustment for olanzapine is necessary when olanzapine is administered concomitantly with valproate. Co-administration of valproate (500 mg BID) and olanzapine (5 mg) to healthy adults (n=10) caused 15% reduction in C<span class="Sub">max</span> and 35% reduction in AUC of olanzapine.</p>
<p><span class="Bold"><span class="Italics">Oral Contraceptive Steroids:</span></span></p>
<p>Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction.</p>

<a id="ID136"></a>
<h3>Topiramate</h3>
<p class="First"><a id="ID137"></a>Concomitant administration of valproate and topiramate has been associated with hyperammonemia with and without encephalopathy <span class="Italics">[see Contraindications (<a href="#ID60">4</a>) and Warnings and Precautions (<a href="#ID76">5.6</a>, <a href="#ID84">5.9</a>, <a href="#ID86">5.10</a>)]</span>. Concomitant administration of topiramate with valproate has also been associated with hypothermia in patients who have tolerated either drug alone. It may be prudent to examine blood ammonia levels in patients in whom the onset of hypothermia has been reported <span class="Italics">[see Warnings and Precautions (<a href="#ID84">5.9</a>, <a href="#ID88">5.11</a>)]</span>.</p>


<a id="ID140"></a><a id="s-43684-0"></a>
<h2>USE IN SPECIFIC POPULATIONS</h2>
<a id="ID141"></a>
<h3>Pregnancy</h3>
<p class="First"><a id="ID146"></a><span class="Bold"><span class="Italics">Pregnancy Exposure Registry</span></span></p>
<p>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), including Divalproex sodium during pregnancy. Encourage women who are taking Divalproex sodium during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling toll-free 1-888-233-2334 or visiting the website http://www.aedpregnancyregistry.org/. This must be done by the patient herself.</p>
<p><span class="Bold"><span class="Italics">Risk Summary</span></span></p>
<p>For use in prophylaxis of migraine headaches, valproate is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception <span class="Italics">[see Contraindications (<a href="#ID60">4</a>)]</span>.</p>
<p>For use in epilepsy or bipolar disorder, valproate should not be used to treat women who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable <span class="Italics">[see Boxed Warning and</span> <span class="Italics">Warnings and Precautions</span> <span class="Italics">(<a href="#ID68">5.2</a>, <a href="#ID70">5.3</a>)]</span>. Women with epilepsy who become pregnant while taking valproate should not discontinue valproate abruptly, as this can precipitate status epilepticus with resulting maternal and fetal hypoxia and threat to life.</p>
<p>Maternal valproate use during pregnancy for any indication increases the risk of congenital malformations, particularly neural tube defects including spina bifida, but also malformations involving other body systems (e.g., craniofacial defects including oral clefts, cardiovascular malformations, hypospadias, limb malformations). This risk is dose-dependent; however, a threshold dose below which no risk exists cannot be established. <span class="Italics">In utero</span> exposure to valproate may also result in hearing impairment or hearing loss. Valproate polytherapy with other AEDs has been associated with an increased frequency of congenital malformations compared with AED monotherapy. The risk of major structural abnormalities is greatest during the first trimester; however, other serious developmental effects can occur with valproate use throughout pregnancy. The rate of congenital malformations among babies born to epileptic mothers who used valproate during pregnancy has been shown to be about four times higher than the rate among babies born to epileptic mothers who used other anti-seizure monotherapies <span class="Italics">[see Warnings and Precautions (<a href="#ID68">5.2</a></span>) <span class="Italics">and Data (Human)]</span>.</p>
<p>Epidemiological studies have indicated that children exposed to valproate <span class="Italics">in utero</span> have lower IQ scores and a higher risk of neurodevelopmental disorders compared to children exposed to either another AED <span class="Italics">in utero</span> or to no AEDs <span class="Italics">in utero [see</span> <span class="Italics">Warnings and Precautions</span> <span class="Italics">(<a href="#ID70">5.3</a>) and Data (Human)]</span>.</p>
<p>An observational study has suggested that exposure to valproate products during pregnancy increases the risk of autism spectrum disorders <span class="Italics">[see</span> <span class="Italics">Data (Human</span><span class="Italics">)]</span>.</p>
<p>In animal studies, valproate administration during pregnancy resulted in fetal structural malformations similar to those seen in humans and neurobehavioral deficits in the offspring at clinically relevant doses <span class="Italics">[see Data (Animal)]</span>.</p>
<p>There have been reports of hypoglycemia in neonates and fatal cases of hepatic failure in infants following maternal use of valproate during pregnancy.</p>
<p>Pregnant women taking valproate may develop hepatic failure or clotting abnormalities including thrombocytopenia, hypofibrinogenemia, and/or decrease in other coagulation factors, which may result in hemorrhagic complications in the neonate including death <span class="Italics">[see</span> <span class="Italics">Warnings and Precautions</span> <span class="Italics">(<a href="#ID66">5.1</a>, <a href="#ID82">5.8</a>)]</span>.</p>
<p>Available prenatal diagnostic testing to detect neural tube and other defects should be offered to pregnant women using valproate.</p>
<p>Evidence suggests that folic acid supplementation prior to conception and during the first trimester of pregnancy decreases the risk for congenital neural tube defects in the general population. It is not known whether the risk of neural tube defects or decreased IQ in the offspring of women receiving valproate is reduced by folic acid supplementation. Dietary folic acid supplementation both prior to conception and during pregnancy should be routinely recommended for patients using valproate <span class="Italics">[see Warnings and Precautions</span> <span class="Italics">(<a href="#ID68">5.2</a>, <a href="#ID72">5.4</a>)].</span></p>
<p>All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</p>
<p><span class="Bold"><span class="Italics">Clinical Considerations</span></span></p>
<p><span class="Bold"><span class="Italics">Disease-associated maternal and/or embryo/fetal risk:</span></span></p>
<p>To prevent major seizures, women with epilepsy should not discontinue valproate abruptly, as this can precipitate status epilepticus with resulting maternal and fetal hypoxia and threat to life. Even minor seizures may pose some hazard to the developing embryo or fetus <span class="Italics">[see</span> <span class="Italics">Warnings and Precautions</span> <span class="Italics">(<a href="#ID72">5.4</a>)]</span>. However, discontinuation of the drug may be considered prior to and during pregnancy in individual cases if the seizure disorder severity and frequency do not pose a serious threat to the patient.</p>
<p><span class="Bold"><span class="Italics">Maternal adverse reactions</span></span></p>
<p>Pregnant women taking valproate may develop clotting abnormalities including thrombocytopenia, hypofibrinogenemia, and/or decrease in other coagulation factors, which may result in hemorrhagic complications in the neonate including death <span class="Italics">[see</span> <span class="Italics">Warnings and Precautions</span> <span class="Italics">(<a href="#ID82">5.8</a>)].</span> If valproate is used in pregnancy, the clotting parameters should be monitored carefully in the mother. If abnormal in the mother, then these parameters should also be monitored in the neonate.</p>
<p>Patients taking valproate may develop hepatic failure <span class="Italics">[see Boxed Warning</span> <span class="Italics">and Warnings and Precautions</span> <span class="Italics">(<a href="#ID66">5.1</a>)].</span> Fatal cases of hepatic failure in infants exposed to valproate <span class="Italics">in utero</span> have also been reported following maternal use of valproate during pregnancy.</p>
<p>Hypoglycemia has been reported in neonates whose mothers have taken valproate during pregnancy.</p>
<p><span class="Bold"><span class="Italics">Data</span></span></p>
<p><span class="Bold"><span class="Italics">Human:</span></span></p>
<p><span class="Italics">Neural</span> <span class="Italics">Tube Defects and Other Structural Abnormalities</span></p>
<p>There is an extensive body of evidence demonstrating that exposure to valproate <span class="Italics">in utero</span> increases the risk of neural tube defects and other structural abnormalities. Based on published data from the CDC's National Birth Defects Prevention Network, the risk of spina bifida in the general population is about 0.06 to 0.07% (6 to 7 in 10,000 births) compared to the risk following <span class="Italics">in utero</span> valproate exposure estimated to be approximately 1 to 2% (100 to 200 in 10,000 births).</p>
<p>The NAAED Pregnancy Registry has reported a major malformation rate of 9 to 11% in the offspring of women exposed to an average of 1,000 mg/day of valproate monotherapy during pregnancy. These data show an up to a five-fold increased risk for any major malformation following valproate exposure <span class="Italics">in utero</span> compared to the risk following exposure <span class="Italics">in utero</span> to other AEDs taken as monotherapy. The major congenital malformations included cases of neural tube defects, cardiovascular malformations, craniofacial defects (e.g., oral clefts, craniosynostosis), hypospadias, limb malformations (e.g., clubfoot, polydactyly), and other malformations of varying severity involving other body systems <span class="Italics">[see</span> <span class="Italics">Warnings and Precautions</span> <span class="Italics">(<a href="#ID68">5.2</a>)]</span>.</p>
<p><span class="Italics">Effect on IQ and neurodevelopmental effects</span></p>
<p>Published epidemiological studies have indicated that children exposed to valproate <span class="Italics">in utero</span> have lower IQ scores than children exposed to either another AED <span class="Italics">in utero</span> or to no AEDs <span class="Italics">in utero</span>. The largest of these studies<span class="Sup">1</span> is a prospective cohort study conducted in the United States and United Kingdom that found that children with prenatal exposure to valproate (n=62) had lower IQ scores at age 6 (97 [95% C.I. 94 to 101]) than children with prenatal exposure to the other anti-epileptic drug monotherapy treatments evaluated: lamotrigine (108 [95% C.I. 105 to 110]), carbamazepine (105 [95% C.I. 102 to 108]) and phenytoin (108 [95% C.I. 104 to 112]). It is not known when during pregnancy cognitive effects in valproate-exposed children occur. Because the women in this study were exposed to AEDs throughout pregnancy, whether the risk for decreased IQ was related to a particular time period during pregnancy could not be assessed. <span class="Italics">[see</span> <span class="Italics">Warnings and Precautions</span> <span class="Italics">(<a href="#ID70">5.3</a>)]</span>.</p>
<p>Although the available studies have methodological limitations, the weight of the evidence supports a causal association between valproate exposure <span class="Italics">in utero</span> and subsequent adverse effects on neurodevelopment, including increases in autism spectrum disorders and attention deficit/hyperactivity disorder (ADHD). An observational study has suggested that exposure to valproate products during pregnancy increases the risk of autism spectrum disorders. In this study, children born to mothers who had used valproate products during pregnancy had 2.9 times the risk (95% confidence interval [CI]: 1.7 to 4.9) of developing autism spectrum disorders compared to children born to mothers not exposed to valproate products during pregnancy. The absolute risks for autism spectrum disorders were 4.4% (95% CI: 2.6% to 7.5%) in valproate-exposed children and 1.5% (95% CI: 1.5% to 1.6%) in children not exposed to valproate products. Another observational study found that children who were exposed to valproate in utero had an increased risk of ADHD (adjusted HR 1.48; 95% CI, 1.09 to 2.00) compared with the unexposed children. Because these studies were observational in nature, conclusions regarding a causal association between <span class="Italics">in utero</span> valproate exposure and an increased risk of autism spectrum disorder and ADHD cannot be considered definitive.</p>
<p><span class="Italics">Other</span></p>
<p>There are published case reports of fatal hepatic failure in offspring of women who used valproate during pregnancy.</p>
<p><span class="Bold"><span class="Italics">Animal:</span></span></p>
<p>In developmental toxicity studies conducted in mice, rats, rabbits, and monkeys, increased rates of fetal structural abnormalities, intrauterine growth retardation, and embryo-fetal death occurred following administration of valproate to pregnant animals during organogenesis at clinically relevant doses (calculated on a body surface area [mg/m<span class="Sup">2</span>] basis). Valproate induced malformations of multiple organ systems, including skeletal, cardiac, and urogenital defects. In mice, in addition to other malformations, fetal neural tube defects have been reported following valproate administration during critical periods of organogenesis, and the teratogenic response correlated with peak maternal drug levels. Behavioral abnormalities (including cognitive, locomotor, and social interaction deficits) and brain histopathological changes have also been reported in mice and rat offspring exposed prenatally to clinically relevant doses of valproate.</p>

<a id="ID254"></a>
<h3>Lactation</h3>
<p class="First"><a id="ID255"></a><span class="Bold"><span class="Italics">Risk Summary</span></span></p>
<p>Valproate is excreted in human milk. Data in the published literature describe the presence of valproate in human milk (range: 0.4 mcg/mL to 3.9 mcg/mL), corresponding to 1% to 10% of maternal serum levels. Valproate serum concentrations collected from breastfed infants aged 3 days postnatal to 12 weeks following delivery ranged from 0.7 mcg/mL to 4 mcg/mL, which were 1% to 6% of maternal serum valproate levels. A published study in children up to six years of age did not report adverse developmental or cognitive effects following exposure to valproate via breast milk <span class="Italics">[see Data (Human)]</span>.</p>
<p>There are no data to assess the effects of Divalproex sodium on milk production or excretion.</p>
<p><span class="Bold"><span class="Italics">Clinical Considerations</span></span></p>
<p>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Divalproex sodium and any potential adverse effects on the breastfed infant from Divalproex sodium or from the underlying maternal condition.</p>
<p>Monitor the breastfed infant for signs of liver damage including jaundice and unusual bruising or bleeding. There have been reports of hepatic failure and clotting abnormalities in offspring of women who used valproate during pregnancy <span class="Italics">[see Use in Specific Populations (<a href="#ID141">8.1</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Data</span></span></p>
<p><span class="Bold"><span class="Italics">Human:</span></span></p>
<p>In a published study, breast milk and maternal blood samples were obtained from 11 epilepsy patients taking valproate at doses ranging from 300 mg/day to 2,400 mg/day on postnatal days 3 to 6. In 4 patients who were taking valproate only, breast milk contained an average valproate concentration of 1.8 mcg/mL (range: 1.1 mcg/mL to 2.2 mcg/mL), which corresponded to 4.8% of the maternal plasma concentration (range: 2.7% to 7.4%). Across all patients (7 of whom were taking other AEDs concomitantly), similar results were obtained for breast milk concentration (1.8 mcg/mL, range: 0.4 mcg/mL to 3.9 mcg/mL) and maternal plasma ratio (5.1%, range: 1.3% to 9.6%).</p>
<p>A published study of 6 breastfeeding mother-infant pairs measured serum valproate levels during maternal treatment for bipolar disorder (750 mg/day or 1,000 mg/day). None of the mothers received valproate during pregnancy, and infants were aged from 4 weeks to 19 weeks at the time of evaluation. Infant serum levels ranged from 0.7 mcg/mL to 1.5 mcg/mL. With maternal serum valproate levels near or within the therapeutic range, infant exposure was 0.9% to 2.3% of maternal levels. Similarly, in 2 published case reports with maternal doses of 500 mg/day or 750 mg/day during breastfeeding of infants aged 3 months and 1 month, infant exposure was 1.5% and 6% that of the mother, respectively.</p>
<p>A prospective observational multicenter study evaluated the long-term neurodevelopmental effects of AED use on children. Pregnant women receiving monotherapy for epilepsy were enrolled with assessments of their children at ages 3 years and 6 years. Mothers continued AED therapy during the breastfeeding period. Adjusted IQs measured at 3 years for breastfed and non-breastfed children were 93 (n=11) and 90 (n=24), respectively. At 6 years, the scores for breastfed and non-breastfed children were 106 (n=11) and 94 (n=25), respectively (p=0.04). For other cognitive domains evaluated at 6 years, no adverse cognitive effects of continued exposure to an AED (including valproate) via breast milk were observed.</p>

<a id="ID147"></a>
<h3>Females and Males of Reproductive Potential</h3>
<p class="First"><a id="ID148"></a><span class="Bold"><span class="Italics">Contraception</span></span></p>
<p>Women of childbearing potential should use effective contraception while taking valproate <span class="Italics">[see BOXED WARNING, WARNINGS AND PRECAUTIONS (<a href="#ID72">5.4</a>), DRUG INTERACTIONS (<a href="#ID131">7</a>), AND USE IN SPECIFIC POPULATIONS (<a href="#ID141">8.1</a>)]</span>. This is especially important when valproate use is considered for a condition not usually associated with permanent injury or death such as prophylaxis of migraine headaches <span class="Italics">[see CONTRAINDICATIONS (<a href="#ID60">4</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Infertility</span></span></p>
<p>There have been reports of male infertility coincident with valproate therapy <span class="Italics">[see ADVERSE REACTIONS (<a href="#ID106">6.4</a>)]</span>. In animal studies, oral administration of valproate at clinically relevant doses resulted in adverse reproductive effects in males <span class="Italics">[see NONCLINICAL TOXICOLOGY (<a href="#ID175">13.1</a>)]</span>.</p>

<a id="ID149"></a>
<h3>Pediatric Use</h3>
<p class="First"><a id="ID150"></a>Experience has indicated that pediatric patients under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those with the aforementioned conditions <span class="Italics">[see <a href="#ID19">Boxed Warning</a> and Warnings and Precautions (<a href="#ID66">5.1</a>)]</span>. When Divalproex sodium extended-release tablets are used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. Above the age of 2 years, experience in epilepsy has indicated that the incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.</p>
<p>Younger children, especially those receiving enzyme inducing drugs, will require larger maintenance doses to attain targeted total and unbound valproate concentrations. Pediatric patients (i.e., between 3 months and 10 years) have 50% higher clearances expressed on weight (i.e., mL/min/kg) than do adults. Over the age of 10 years, children have pharmacokinetic parameters that approximate those of adults.</p>
<p>The variability in free fraction limits the clinical usefulness of monitoring total serum valproic acid concentrations. Interpretation of valproic acid concentrations in children should include consideration of factors that affect hepatic metabolism and protein binding.</p>
<p><span class="Bold"><span class="Italics">Pediatric Clinical Trials</span></span></p>
<p>Divalproex sodium delayed-release tablets were studied in seven pediatric clinical trials.</p>
<p>Two of the pediatric studies were double-blinded placebo-controlled trials to evaluate the efficacy of Divalproex sodium extended-release tablets for the indications of mania (150 patients aged 10 to 17 years, 76 of whom were on Divalproex sodium extended-release tablets) and migraine (304 patients aged 12 to 17 years, 231 of whom were on Divalproex sodium extended-release tablets). Efficacy was not established for either the treatment of migraine or the treatment of mania. The most common drug-related adverse reactions (reported &gt;5% and twice the rate of placebo) reported in the controlled pediatric mania study were nausea, upper abdominal pain, somnolence, increased ammonia, gastritis and rash.</p>
<p>The remaining five trials were long term safety studies. Two six-month pediatric studies were conducted to evaluate the long-term safety of Divalproex sodium extended-release tablets for the indication of mania (292 patients aged 10 to 17 years). Two twelve-month pediatric studies were conducted to evaluate the long-term safety of Divalproex sodium extended-release tablets for the indication of migraine (353 patients aged 12 to 17 years). One twelve-month study was conducted to evaluate the safety of Divalproex sodium delayed-release capsules in the indication of partial seizures (169 patients aged 3 to 10 years).</p>
<p>In these seven clinical trials, the safety and tolerability of Divalproex sodium delayed-release tablets in pediatric patients were shown to be comparable to those in adults <span class="Italics">[see Adverse Reactions (<a href="#ID106">6</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Juvenile Animal Toxicology</span></span></p>
<p>In studies of valproate in immature animals, toxic effects not observed in adult animals included retinal dysplasia in rats treated during the neonatal period (from postnatal day 4) and nephrotoxicity in rats treated during the neonatal and juvenile (from postnatal day 14) periods. The no-effect dose for these findings was less than the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis.</p>

<a id="ID151"></a>
<h3>Geriatric Use</h3>
<p class="First"><a id="ID152"></a>No patients above the age of 65 years were enrolled in double-blind prospective clinical trials of mania associated with bipolar illness. In a case review study of 583 patients, 72 patients (12%) were greater than 65 years of age. A higher percentage of patients above 65 years of age reported accidental injury, infection, pain, somnolence, and tremor. Discontinuation of valproate was occasionally associated with the latter two events. It is not clear whether these events indicate additional risk or whether they result from preexisting medical illness and concomitant medication use among these patients.</p>
<p>A study of elderly patients with dementia revealed drug related somnolence and discontinuation for somnolence <span class="Italics">[see Warnings and Precautions (<a href="#ID94">5.14</a>)]</span>. The starting dose should be reduced in these patients, and dosage reductions or discontinuation should be considered in patients with excessive somnolence <span class="Italics">[see Dosage and Administration (<a href="#ID51">2.5</a>)]</span>.</p>
<p>There is insufficient information available to discern the safety and effectiveness of valproate for the prophylaxis of migraines in patients over 65.</p>
<p>The capacity of elderly patients (age range: 68 to 89 years) to eliminate valproate has been shown to be reduced compared to younger adults (age range: 22 to 26 years) <span class="Italics">[see Clinical Pharmacology (<a href="#ID170">12.3</a>)]</span>.</p>

<a id="ID153"></a>
<h3>Effect of Disease</h3>
<p class="First"><a id="ID154"></a><span class="Bold"><span class="Italics">Liver Disease</span></span></p>
<p>Liver disease impairs the capacity to eliminate valproate. <span class="Italics">[(See <a href="#ID19">Boxed Warning</a>, Contraindications (<a href="#ID60">4</a>), Warnings and Precautions (<a href="#ID65">5.1</a>), and Clinical Pharmacology (<a href="#ID170">12.3</a>)]</span>.</p>


<a id="ID157"></a><a id="s-34088-5"></a>
<h2>Overdosage</h2>
<a id="ID158"></a>
<p class="First"><a id="ID159"></a>Overdosage with valproate may result in somnolence, heart block, deep coma, and hypernatremia. Fatalities have been reported; however patients have recovered from valproate levels as high as 2,120 mcg/mL.</p>
<p>In overdose situations, the fraction of drug not bound to protein is high and hemodialysis or tandem hemodialysis plus hemoperfusion may result in significant removal of drug. The benefit of gastric lavage or emesis will vary with the time since ingestion. General supportive measures should be applied with particular attention to the maintenance of adequate urinary output.</p>
<p>Naloxone has been reported to reverse the CNS depressant effects of valproate overdosage. Because naloxone could theoretically also reverse the antiepileptic effects of valproate, it should be used with caution in patients with epilepsy.</p>


<a id="ID160"></a><a id="s-34089-3"></a>
<h2>Divalproex Description</h2>
<a id="ID161"></a>
<p class="First"><a id="ID162"></a>Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure:</p>
<div class="Figure"><img data-lazy-load data-src='https://www.drugs.com/pro/images/1f081c74-9f73-4ed9-9157-8d73d586a409/d95f9b1b-f1e4-4ae4-a215-7317fb1ca565-01.jpg' src='/img/pixel.gif' alt="" />
<p class="MultiMediaCaption">Image 1</p>
</div>
<p><a id="ID164"></a>Divalproex sodium occurs as a white to off white powder.</p>
<p>Divalproex sodium extended-release 250 mg and 500 mg tablets are for oral administration. Divalproex sodium extended-release tablets, USP contain Divalproex sodium in a once-a-day extended-release formulation equivalent to 250 mg and 500 mg of valproic acid.</p>
<p><span class="Bold"><span class="Italics">Inactive Ingredients</span></span></p>
<p>Divalproex Sodium Extended-Release Tablets USP, 250 mg and 500 mg: ethyl acrylate and methyl methacrylate copolymer dispersion, ethyl cellulose, hypromellose, iron oxide black (ferrosoferric oxide), lactose monohydrate, magnesium stearate, microcrystalline cellulose, propylene glycol, polyethylene glycol, polyvinyl alcohol, shellac, silicon dioxide, talc, and titanium dioxide.</p>
<p>In addition, 500 mg tablets contain iron oxide red and iron oxide yellow.</p>
<p>Divalproex sodium extended-release tablets USP meet USP Dissolution Test 11.</p>


<a id="ID165"></a><a id="s-34090-1"></a>
<h2>Divalproex - Clinical Pharmacology</h2>
<a id="ID166"></a>
<h3>Mechanism of Action</h3>
<p class="First"><a id="ID167"></a>Divalproex sodium dissociates to the valproate ion in the gastrointestinal tract. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in epilepsy is related to increased brain concentrations of gamma-aminobutyric acid (GABA).</p>

<a id="ID168"></a>
<h3>Pharmacodynamics</h3>
<p class="First"><a id="ID169"></a>The relationship between plasma concentration and clinical response is not well documented. One contributing factor is the nonlinear, concentration dependent protein binding of valproate which affects the clearance of the drug. Thus, monitoring of total serum valproate may not provide a reliable index of the bioactive valproate species.</p>
<p>For example, because the plasma protein binding of valproate is concentration dependent, the free fraction increases from approximately 10% at 40 mcg/mL to 18.5% at 130 mcg/mL. Higher than expected free fractions occur in the elderly, in hyperlipidemic patients, and in patients with hepatic and renal diseases.</p>
<p><span class="Bold"><span class="Italics">Epilepsy</span></span></p>
<p>The therapeutic range in epilepsy is commonly considered to be 50 to 100 mcg/mL of total valproate, although some patients may be controlled with lower or higher plasma concentrations.</p>
<p><span class="Bold"><span class="Italics">Mania</span></span></p>
<p>In placebo-controlled clinical trials of acute mania, patients were dosed to clinical response with trough plasma concentrations between 85 and 125 mcg/mL <span class="Italics">[see Dosage and Administration (<a href="#ID41">2.1</a>)]</span>.</p>

<a id="ID170"></a>
<h3>Pharmacokinetics</h3>
<p class="First"><a id="ID171"></a><span class="Bold"><span class="Italics">Absorption/Bioavailability</span></span></p>
<p>The absolute bioavailability of Divalproex sodium extended-release tablets administered as a single dose after a meal was approximately 90% relative to intravenous infusion.</p>
<p>When given in equal total daily doses, the bioavailability of Divalproex sodium extended-release tablets is less than that of Divalproex sodium delayed-release tablets. In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, Divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of Divalproex sodium delayed-release tablets given BID, TID, or QID. The median time to maximum plasma valproate concentrations (C<span class="Sub">max</span>) after Divalproex sodium extended-release tablets administration ranged from 4 to 17 hours. After multiple once-daily dosing of Divalproex sodium extended-release tablets, the peak-to-trough fluctuation in plasma valproate concentrations was 10 to 20% lower than that of regular Divalproex sodium delayed-release tablets given BID, TID, or QID.</p>
<p><span class="Bold"><span class="Italics">Conversion from Divalproex Sodium Delayed-Release Tablets to Divalproex Sodium Extended-Release Tablets</span></span></p>
<p>When Divalproex sodium extended-release tablets are given in doses 8 to 20% higher than the total daily dose of Divalproex sodium delayed-release tablets, the two formulations are bioequivalent. In two randomized, crossover studies, multiple daily doses of Divalproex sodium delayed-release tablets were compared to 8 to 20% higher once-daily doses of Divalproex sodium extended-release tablets. In these two studies, Divalproex sodium extended-release tablets and Divalproex sodium delayed-release tablets regimens were equivalent with respect to area under the curve (AUC; a measure of the extent of bioavailability). Additionally, valproate C<span class="Sub">max</span> was lower, and C<span class="Sub">min</span> was either higher or not different, for Divalproex sodium extended-release tablets relative to Divalproex sodium delayed-release tablets regimens (see Table 8).</p>
<a id="ID172"></a>
<div class='responsive-table-wrap'><table class="Noautorules" style="width: 100%; ">
<caption>Table 8. Bioavailability of Divalproex Sodium Extended-Release Tablets Relative to Divalproex Sodium Delayed-Release Tablets When Divalproex Sodium Extended-Release Tablets Dose is 8 to 20% Higher</caption>
<col style="width: 29%; " />
<col style="width: 46%; " />
<col style="width: 8%; " />
<col style="width: 7%; " />
<col style="width: 7%; " />
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; "><span class="Bold">Study</span> <span class="Bold">Population</span><br /></td>
<td class="Botrule Rrule Toprule" style="text-align: center; "><span class="Bold">Regimens</span><br /></td>
<td class="Botrule Rrule Toprule" colspan="3" style="text-align: center; "><span class="Bold">Relative Bioavailability</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" style="text-align: center; ">Divalproex sodium extended-release tablets vs. Divalproex sodium delayed-release tablets<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">AUC<span class="Sub">24</span><br /></td>
<td class="Botrule Rrule" style="text-align: center; ">C<span class="Sub">max</span><br /></td>
<td class="Botrule Rrule" style="text-align: center; ">C<span class="Sub">min</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Healthy Volunteers<br />
(N=35)<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1,000 and 1,500 mg Divalproex sodium extended-release tablets vs. 875 and 1,250 mg Divalproex sodium delayed-release tablets<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1.059<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">0.882<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1.173<br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" style="text-align: left; ">Patients with epilepsy on concomitant enzyme- inducing antiepilepsy drugs<br />
(N = 64)<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1,000 to 5,000 mg Divalproex sodium extended-release tablets vs. 875 to 4,250 mg Divalproex sodium delayed-release tablets<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1.008<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">0.899<br /></td>
<td class="Botrule Rrule" style="text-align: center; ">1.022<br /></td>
</tr>
</tbody>
</table></div>
<p><a id="ID173"></a>Concomitant antiepilepsy drugs (topiramate, phenobarbital, carbamazepine, phenytoin, and lamotrigine were evaluated) that induce the cytochrome P450 isozyme system did not significantly alter valproate bioavailability when converting between Divalproex sodium delayed-release tablets and Divalproex sodium extended-release tablets.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p><span class="Bold"><span class="Italics">Protein Binding:</span></span></p>
<p>The plasma protein binding of valproate is concentration dependent and the free fraction increases from approximately 10% at 40 mcg/mL to 18.5% at 130 mcg/mL. Protein binding of valproate is reduced in the elderly, in patients with chronic hepatic diseases, in patients with renal impairment, and in the presence of other drugs (e.g., aspirin). Conversely, valproate may displace certain protein-bound drugs (e.g., phenytoin, carbamazepine, warfarin, and tolbutamide) <span class="Italics">[see DRUG INTERACTIONS (<a href="#ID134">7.2</a>)</span> for more detailed information on the pharmacokinetic interactions of valproate with other drugs<span class="Italics">]</span>.</p>
<p><span class="Bold"><span class="Italics">CNS Distribution:</span></span></p>
<p>Valproate concentrations in cerebrospinal fluid (CSF) approximate unbound concentrations in plasma (about 10% of total concentration).</p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>Valproate is metabolized almost entirely by the liver. In adult patients on monotherapy, 30 to 50% of an administered dose appears in urine as a glucuronide conjugate. Mitochondrial &beta;-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose. Usually, less than 15 to 20% of the dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose is excreted unchanged in urine.</p>
<p>The relationship between dose and total valproate concentration is nonlinear; concentration does not increase proportionally with the dose, but rather, increases to a lesser extent due to saturable plasma protein binding. The kinetics of unbound drug are linear.</p>
<p><span class="Bold"><span class="Italics">Elimination</span></span></p>
<p>Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m<span class="Sup">2</span> and 11 L/1.73 m<span class="Sup">2</span>, respectively. Mean plasma clearance and volume of distribution for free valproate are 4.6 L/hr/1.73 m<span class="Sup">2</span>and 92 L/1.73 m<span class="Sup">2</span>. Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.</p>
<p>The estimates cited apply primarily to patients who are not taking drugs that affect hepatic metabolizing enzyme systems. For example, patients taking enzyme-inducing antiepileptic drugs (carbamazepine, phenytoin, and phenobarbital) will clear valproate more rapidly. Because of these changes in valproate clearance, monitoring of antiepileptic concentrations should be intensified whenever concomitant antiepileptics are introduced or withdrawn.</p>
<p><span class="Bold"><span class="Italics">Special Populations</span></span></p>
<p><span class="Bold"><span class="Italics">Effect of Age:</span></span></p>
<p><span class="Italics">Pediatric</span></p>
<p>The valproate pharmacokinetic profile following administration of Divalproex sodium extended-release tablets were characterized in a multiple-dose, non-fasting, open label, multi-center study in children and adolescents. Divalproex sodium extended-release tablets once daily doses ranged from 250 to 1,750 mg. Once daily administration of Divalproex sodium extended-release tablets in pediatric patients (10 to 17 years) produced plasma VPA concentration-time profiles similar to those that have been observed in adults.</p>
<p><span class="Italics">Elderly</span></p>
<p>The capacity of elderly patients (age range: 68 to 89 years) to eliminate valproate has been shown to be reduced compared to younger adults (age range: 22 to 26 years). Intrinsic clearance is reduced by 39%; the free fraction is increased by 44%. Accordingly, the initial dosage should be reduced in the elderly <span class="Italics">[see DOSAGE AND ADMINISTRATION (<a href="#ID47">2.4</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Effect of Sex:</span></span></p>
<p>There are no differences in the body surface area adjusted unbound clearance between males and females (4.8&plusmn;0.17 and 4.7&plusmn;0.07 L/hr per 1.73 m<span class="Sup">2</span>, respectively).</p>
<p><span class="Bold"><span class="Italics">Effect of Race:</span></span></p>
<p>The effects of race on the kinetics of valproate have not been studied.</p>
<p><span class="Bold"><span class="Italics">Effect of Disease:</span></span></p>
<p><span class="Italics">Liver Disease</span></p>
<p>Liver disease impairs the capacity to eliminate valproate. In one study, the clearance of free valproate was decreased by 50% in 7 patients with cirrhosis and by 16% in 4 patients with acute hepatitis, compared with 6 healthy subjects. In that study, the half-life of valproate was increased from 12 to 18 hours. Liver disease is also associated with decreased albumin concentrations and larger unbound fractions (2 to 2.6 fold increase) of valproate. Accordingly, monitoring of total concentrations may be misleading since free concentrations may be substantially elevated in patients with hepatic disease whereas total concentrations may appear to be normal <span class="Italics">[see BOXED WARNING, CONTRAINDICATIONS (<a href="#ID60">4</a>), and WARNINGS AND PRECAUTIONS (<a href="#ID66">5.1</a>)]</span>.</p>
<p><span class="Italics">Renal Disease</span></p>
<p>A slight reduction (27%) in the unbound clearance of valproate has been reported in patients with renal failure (creatinine clearance &lt;10 mL/minute); however, hemodialysis typically reduces valproate concentrations by about 20%. Therefore, no dosage adjustment appears to be necessary in patients with renal failure. Protein binding in these patients is substantially reduced; thus, monitoring total concentrations may be misleading.</p>


<a id="ID174"></a><a id="s-43680-8"></a>
<h2>Nonclinical Toxicology</h2>
<a id="ID175"></a>
<h3>Carcinogenesis, Mutagenesis, Impairment of Fertility</h3>
<p class="First"><a id="ID176"></a><span class="Bold"><span class="Italics">Carcinogenesis</span></span></p>
<p>Valproate was administered orally to rats and mice at doses of 80 and 170 mg/kg/day (less than the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) for two years. The primary findings were an increase in the incidence of subcutaneous fibrosarcomas in high-dose male rats receiving valproate and a dose-related trend for benign pulmonary adenomas in male mice receiving valproate.</p>
<p><span class="Bold"><span class="Italics">Mutagenesis</span></span></p>
<p>Valproate was not mutagenic in an <span class="Italics">in vitro</span> bacterial assay (Ames test), did not produce dominant lethal effects in mice, and did not increase chromosome aberration frequency in an <span class="Italics">in vivo</span> cytogenetic study in rats. Increased frequencies of sister chromatid exchange (SCE) have been reported in a study of epileptic children taking valproate, this association was not observed in another study conducted in adults.</p>
<p><span class="Bold"><span class="Italics">Impairment</span></span> <span class="Bold"><span class="Italics">of Fertility</span></span></p>
<p>In chronic toxicity studies in juvenile and adult rats and dogs, administration of valproate resulted in testicular atrophy and reduced spermatogenesis at oral doses of 400 mg/kg/day or greater in rats (approximately equal to or greater than the maximum recommended human dose (MRHD) on a mg/m<span class="Sup">2</span> basis) and 150 mg/kg/day or greater in dogs (approximately equal to or greater than the MRHD on a mg/m<span class="Sup">2</span> basis). Fertility studies in rats have shown no effect on fertility at oral doses of valproate up to 350 mg/kg/day (approximately equal to the MRHD on a mg/m<span class="Sup">2</span> basis) for 60 days.</p>


<a id="ID177"></a><a id="s-34092-7"></a>
<h2>Clinical Studies</h2>
<a id="ID178"></a>
<h3>Mania</h3>
<p class="First"><a id="ID179"></a>The effectiveness of Divalproex sodium extended-release tablets for the treatment of acute mania is based in part on studies establishing the effectiveness of Divalproex sodium delayed-release tablets for this indication. Divalproex sodium extended-release tablet's effectiveness was confirmed in one randomized, double-blind, placebo-controlled, parallel group, 3-week, multicenter study. The study was designed to evaluate the safety and efficacy of Divalproex sodium extended-release tablets in the treatment of bipolar I disorder, manic or mixed type, in adults. Adult male and female patients who had a current DSM-IV TR primary diagnosis of bipolar I disorder, manic or mixed type, and who were hospitalized for acute mania, were enrolled into this study. Divalproex sodium extended-release tablets were initiated at a dose of 25 mg/kg/day given once daily, increased by 500 mg/day on Day 3, then adjusted to achieve plasma valproate concentrations in the range of 85 to 125 mcg/mL. Mean daily Divalproex sodium extended-release tablet doses for observed cases were 2,362 mg (range: 500 to 4,000), 2,874 mg (range: 1,500 to 4,500), 2,993 mg (range: 1,500 to 4,500), 3,181 mg (range: 1,500 to 5,000), and 3,353 mg (range: 1,500 to 5,500) at Days 1, 5, 10, 15, and 21, respectively. Mean valproate concentrations were 96.5 mcg/mL, 102.1 mcg/mL, 98.5 mcg/mL, 89.5 mcg/mL at Days 5, 10, 15 and 21, respectively. Patients were assessed on the Mania Rating Scale (MRS; score ranges from 0 to 52).</p>
<p>Divalproex sodium extended-release tablets were significantly more effective than placebo in reduction of the MRS total score.</p>

<a id="ID180"></a>
<h3>Epilepsy</h3>
<p class="First"><a id="ID181"></a>The efficacy of valproate in reducing the incidence of complex partial seizures (CPS) that occur in isolation or in association with other seizure types was established in two controlled trials.</p>
<p>In one, multi-clinic, placebo controlled study employing an add-on design, (adjunctive therapy) 144 patients who continued to suffer eight or more CPS per 8 weeks during an 8 week period of monotherapy with doses of either carbamazepine or phenytoin sufficient to assure plasma concentrations within the "therapeutic range" were randomized to receive, in addition to their original antiepilepsy drug (AED), either Divalproex sodium delayed-release tablets or placebo. Randomized patients were to be followed for a total of 16 weeks. The following table presents the findings.</p>
<a id="ID182"></a>
<div class='responsive-table-wrap'><table style="width: 100%; ">
<caption>Table 9. Adjunctive Therapy Study Median Incidence of CPS per 8 Weeks</caption>
<col style="width: 25%; " />
<col style="width: 25%; " />
<col style="width: 24%; " />
<col style="width: 26%; " />
<tfoot>
<tr>
<td colspan="4" style="text-align: left; ">
<dl class="Footnote">
<dt><a href="#footnote-reference-2" id="footnote-2">*</a></dt>
<dd>Reduction from baseline statistically significantly greater for valproate than placebo at p &le; 0.05 level.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; "><span class="Bold">Add</span><span class="Bold">-</span><span class="Bold">on </span><span class="Bold">Treatment</span><br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; "><span class="Bold">Number </span><span class="Bold">of </span><span class="Bold">Patients</span><br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; "><span class="Bold">Baseline </span><span class="Bold">Incidence</span> <span class="Bold"><br /></span></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; "><span class="Bold">Experimental </span><span class="Bold">Incidence</span> <span class="Bold"><br /></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" style="text-align: left; vertical-align: middle; ">Divalproex sodium delayed-release tablets<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">75<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">16.0<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">8.9<a href="#footnote-2" class="Sup" id="footnote-reference-2">*</a><br /></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" style="text-align: left; vertical-align: middle; ">Placebo<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">69<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">14.5<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">11.5<br /></td>
</tr>
</tbody>
</table></div>
<p><a id="ID183"></a>Figure 1 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial seizure rates was at least as great as that indicated on the Y axis in the adjunctive therapy study. A positive percent reduction indicates an improvement (i.e., a decrease in seizure frequency), while a negative percent reduction indicates worsening. Thus, in a display of this type, the curve for an effective treatment is shifted to the left of the curve for placebo. This figure shows that the proportion of patients achieving any particular level of improvement was consistently higher for valproate than for placebo. For example, 45% of patients treated with valproate had a &ge; 50% reduction in complex partial seizure rate compared to 23% of patients treated with placebo.</p>
<p><span class="Bold">Figure 1</span></p>
<div class="Figure"><img data-lazy-load data-src='https://www.drugs.com/pro/images/1f081c74-9f73-4ed9-9157-8d73d586a409/d95f9b1b-f1e4-4ae4-a215-7317fb1ca565-02.jpg' src='/img/pixel.gif' alt="" />
<p class="MultiMediaCaption">Image 2</p>
</div>
<p><a id="ID185"></a>The second study assessed the capacity of valproate to reduce the incidence of CPS when administered as the sole AED. The study compared the incidence of CPS among patients randomized to either a high or low dose treatment arm. Patients qualified for entry into the randomized comparison phase of this study only if 1) they continued to experience 2 or more CPS per 4 weeks during an 8 to 12 week long period of monotherapy with adequate doses of an AED (i.e., phenytoin, carbamazepine, phenobarbital, or primidone) and 2) they made a successful transition over a two week interval to valproate. Patients entering the randomized phase were then brought to their assigned target dose, gradually tapered off their concomitant AED and followed for an interval as long as 22 weeks. Less than 50% of the patients randomized, however, completed the study. In patients converted to Divalproex sodium delayed-release tablets monotherapy, the mean total valproate concentrations during monotherapy were 71 and 123 mcg/mL in the low dose and high dose groups, respectively.</p>
<p>The following table presents the findings for all patients randomized who had at least one post- randomization assessment.</p>
<a id="ID186"></a>
<div class='responsive-table-wrap'><table style="width: 101%; ">
<caption>Table 10. Monotherapy Study Median Incidence of CPS per 8 Weeks</caption>
<col style="width: 23%; " />
<col style="width: 23%; " />
<col style="width: 22%; " />
<col style="width: 33%; " />
<tfoot>
<tr class="First Last">
<td colspan="4" style="text-align: left; ">
<p class="First Footnote"><span class="Sup">*</span>Reduction from baseline statistically significantly greater for high dose than low dose at p &le; 0.05 level.<br /></p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; "><span class="Bold">Treatment</span><br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; "><span class="Bold">Number </span><span class="Bold">of </span><span class="Bold">Patients</span><br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; "><span class="Bold">Baseline </span><span class="Bold">Incidence</span><br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; "><span class="Bold">Randomized </span><span class="Bold">Phase </span><span class="Bold">Incidence</span><br /></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" style="text-align: left; vertical-align: middle; ">High dose Valproate<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">131<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">13.2<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">10.7<span class="Sup">*</span><br /></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" style="text-align: left; vertical-align: middle; ">Low dose Valproate<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">134<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">14.2<br /></td>
<td class="Botrule Lrule Rrule Toprule" style="text-align: center; vertical-align: middle; ">13.8<br /></td>
</tr>
</tbody>
</table></div>
<p><a id="ID187"></a>Figure 2 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial seizure rates was at least as great as that indicated on the Y axis in the monotherapy study. A positive percent reduction indicates an improvement (i.e., a decrease in seizure frequency), while a negative percent reduction indicates worsening. Thus, in a display of this type, the curve for a more effective treatment is shifted to the left of the curve for a less effective treatment. This figure shows that the proportion of patients achieving any particular level of reduction was consistently higher for high dose valproate than for low dose valproate.</p>
<p>For example, when switching from carbamazepine, phenytoin, phenobarbital or primidone monotherapy to high dose valproate monotherapy, 63% of patients experienced no change or a reduction in complex partial seizure rates compared to 54% of patients receiving low dose valproate.</p>
<p><span class="Bold">Figure 2</span></p>
<div class="Figure"><img data-lazy-load data-src='https://www.drugs.com/pro/images/1f081c74-9f73-4ed9-9157-8d73d586a409/d95f9b1b-f1e4-4ae4-a215-7317fb1ca565-03.jpg' src='/img/pixel.gif' alt="" />
<p class="MultiMediaCaption">Image 3</p>
</div>
<p><a id="ID189"></a>Information on pediatric studies is presented in section 8.</p>

<a id="ID190"></a>
<h3>Migraine</h3>
<p class="First"><a id="ID191"></a>The results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial demonstrated the effectiveness of Divalproex sodium extended-release tablets in the prophylactic treatment of migraine headache. This trial recruited patients with a history of migraine headaches with or without aura occurring on average twice or more a month for the preceding three months. Patients with cluster or chronic daily headaches were excluded. Women of childbearing potential were allowed in the trial if they were deemed to be practicing an effective method of contraception.</p>
<p>Patients who experienced &ge; 2 migraine headaches in the 4-week baseline period were randomized in a 1:1 ratio to Divalproex sodium extended-release tablets or placebo and treated for 12 weeks. Patients initiated treatment on 500 mg once daily for one week, and were then increased to 1,000 mg once daily with an option to permanently decrease the dose back to 500 mg once daily during the second week of treatment if intolerance occurred. Ninety-eight of 114 Divalproex sodium extended-release tablet-treated patients (86%) and 100 of 110 placebo-treated patients (91%) treated at least two weeks maintained the 1,000 mg once daily dose for the duration of their treatment periods. Treatment outcome was assessed on the basis of reduction in 4-week migraine headache rate in the treatment period compared to the baseline period.</p>
<p>Patients (50 male, 187 female) ranging in age from 16 to 69 were treated with Divalproex sodium extended-release tablets (N=122) or placebo (N=115). Four patients were below the age of 18 and 3 were above the age of 65. Two hundred and two patients (101 in each treatment group) completed the treatment period. The mean reduction in 4-week migraine headache rate was 1.2 from a baseline mean of 4.4 in the Divalproex sodium extended-release tablets group, versus 0.6 from a baseline mean of 4.2 in the placebo group. The treatment difference was statistically significant (see Figure 3).</p>
<p><span class="Bold">Figure 3 Mean Reduction In 4-Week Migraine Headache Rates</span></p>
<div class="Figure"><img data-lazy-load data-src='https://www.drugs.com/pro/images/1f081c74-9f73-4ed9-9157-8d73d586a409/d95f9b1b-f1e4-4ae4-a215-7317fb1ca565-04.jpg' src='/img/pixel.gif' alt="" />
<p class="MultiMediaCaption">Image 4</p>
</div>


<a id="ID193"></a><a id="s-34093-5"></a>
<h2>REFERENCES</h2>
<a id="ID194"></a>
<ol>
<li>Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology 2013; 12 (3):244-252.</li>
</ol>


<a id="ID196"></a><a id="s-34069-5"></a>
<h2>How Supplied/Storage and Handling</h2>
<p class="First"><a id="ID198"></a>Divalproex sodium extended-release tablets USP, 250 mg are available as white, oval shaped, film coated tablets, imprinted "L088" on one side and plain on the other side. Each Divalproex sodium extended-release tablet contains Divalproex sodium equivalent to 250 mg of valproic acid in the following package sizes:</p>
<p>Bottle of 30                 (NDC 68180-260-06)</p>
<p>Bottle of 100               (NDC 68180-260-01)</p>
<p>Bottle of 500               (NDC 68180-260-02)</p>
<p>Divalproex sodium extended-release tablets USP, 500 mg are available as grey colored, oval shaped, film coated tablets, imprinted "L089" on one side and plain on the other side. Each Divalproex sodium extended-release tablet contains Divalproex sodium equivalent to 500 mg of valproic acid in the following packaging sizes:</p>
<p>Bottle of 30                 (NDC 68180-261-06)</p>
<p>Bottle of 100               (NDC 68180-261-01)</p>
<p>Bottle of 500               (NDC 68180-261-02)</p>
<p><span class="Bold"><span class="Italics">Recommended Storage</span></span></p>
<p>Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg; to 30&deg;C (59&deg; to 86&deg;F). [See USP Controlled Room Temperature].</p>

<a id="ID199"></a><a id="s-34076-0"></a>
<h2>Patient Counseling Information</h2>
<a id="ID200"></a>
<p class="First"><a id="ID201"></a>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</p>
<p><span class="Bold"><span class="Italics">Hepatotoxicity</span></span></p>
<p>Warn patients and guardians that nausea, vomiting, abdominal pain, anorexia, diarrhea, asthenia, and/or jaundice can be symptoms of hepatotoxicity and, therefore, require further medical evaluation promptly <span class="Italics">[see Warnings and Precautions (<a href="#ID66">5.1</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Pancreatitis</span></span></p>
<p>Warn patients and guardians that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis and, therefore, require further medical evaluation promptly <span class="Italics">[see Warnings and Precautions (<a href="#ID74">5.5</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Birth</span></span> <span class="Bold"><span class="Italics">Defects and Decreased IQ</span></span></p>
<p>Inform pregnant women and women of childbearing potential (including girls beginning the onset of puberty) that use of valproate during pregnancy increases the risk of birth defects, decreased IQ, and neurodevelopmental disorders in children who were exposed <span class="Italics">in utero</span>. Advise women to use effective contraception while taking valproate. When appropriate, counsel these patients about alternative therapeutic options. This is particularly important when valproate use is considered for a condition not usually associated with permanent injury or death such as prophylaxis of migraine headache <span class="Italics">[see Contraindications (<a href="#ID60">4</a>)]</span>. Advise patients to read the Medication Guide, which appears as the last section of the labeling <span class="Italics">[see Warnings and Precautions (<a href="#ID68">5.2</a>, <a href="#ID70">5.3</a>, <a href="#ID72">5.4</a>) and Use in Specific Populations (<a href="#ID141">8.1</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Pregnancy Registry</span></span></p>
<p>Advise women of childbearing potential to discuss pregnancy planning with their doctor and to contact their doctor immediately if they think they are pregnant.</p>
<p>Encourage women who are taking Divalproex sodium extended-release tablets to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334 or visit the website, http://www.aedpregnancyregistry.org/ <span class="Italics">[see Use in Specific Populations (<a href="#ID141">8.1</a>)].</span></p>
<p><span class="Bold"><span class="Italics">Suicidal Thinking and Behavior</span></span></p>
<p>Counsel patients, their caregivers, and families that AEDs, including Divalproex sodium extended-release tablets, may increase the risk of suicidal thoughts and behavior and to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Instruct patients, caregivers, and families to report behaviors of concern immediately to the healthcare providers <span class="Italics">[see Warnings and Precautions (<a href="#ID78">5.7</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Hyperammonemia</span></span></p>
<p>Inform patients of the signs and symptoms associated with hyperammonemic encephalopathy and to notify the prescriber if any of these symptoms occur <span class="Italics">[see Warnings and Precautions (<a href="#ID84">5.9</a>, <a href="#ID86">5.10</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">CNS Depression</span></span></p>
<p>Since valproate products may produce CNS depression, especially when combined with another CNS depressant (e.g., alcohol), advise patients not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.</p>
<p><span class="Bold"><span class="Italics">Multiorgan Hypersensitivity Reactions</span></span></p>
<p>Instruct patients that a fever associated with other organ system involvement (rash, lymphadenopathy, etc.) may be drug-related and should be reported to the physician immediately <span class="Italics">[see Warnings and Precautions (<a href="#ID90">5.12</a>)]</span>.</p>
<p><span class="Bold"><span class="Italics">Medication Residue in the Stool</span></span></p>
<p>Instruct patients to notify their healthcare provider if they notice a medication residue in the stool <span class="Italics">[see Warnings and Precautions (<a href="#ID102">5.18</a>)]</span>.</p>
<p>Distributed by:</p>
<p><span class="Bold">Lupin Pharmaceuticals, Inc.</span></p>
<p>Baltimore, Maryland 21202</p>
<p>United States</p>
<p>Manufactured by:</p>
<p><span class="Bold">Lupin Limited</span></p>
<p>Nagpur 441108</p>
<p>India</p>
<p>December 15, 2020                                                                             ID#: 265515</p>


<a id="ID202"></a><a id="s-42231-1"></a>
<a id="ID203"></a>
<p class="First"><a id="ID204"></a><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">Divalproex SODIUM EXTENDED-RELEASE TABLETS</span></p>
<p><span class="Bold">(dye val' proe ex soe' dee um)</span></p>
<p>Read this Medication Guide before you start taking Divalproex sodium extended-release tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about Divalproex sodium extended-release tablets?</span></p>
<p><span class="Bold">Do not stop taking Divalproex sodium extended-release tablets without first talking to your healthcare provider.</span></p>
<p>Stopping Divalproex sodium extended-release tablets suddenly can cause serious problems.</p>
<p><span class="Bold">Divalproex sodium extended-release tablets can cause serious side effects, including:</span></p>
<p><span class="Bold">1. Serious liver damage that can cause death, especially in children younger than 2 years old.</span> The risk of getting this serious liver damage is more likely to happen within the first 6 months of treatment.</p>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following symptoms:</span></p>
<ul class="Disc">
<li>nausea or vomiting that does not go away</li>
<li>loss of appetite</li>
<li>pain on the right side of your stomach (abdomen)</li>
<li>dark urine</li>
<li>swelling of your face</li>
<li>yellowing of your skin or the whites of your eyes</li>
</ul>
<p><a id="ID206"></a>In some cases, liver damage may continue despite stopping the drug.</p>
<p><span class="Bold">2. Divalproex sodium extended-release tablets may harm your unborn baby.</span></p>
<ul class="Disc">
<li>If you take Divalproex sodium extended-release tablets during pregnancy for any medical condition, your baby is at risk for serious birth defects that affect the brain and spinal cord and are called spina bifida or neural tube defects. These defects occur in 1 to 2 out of every 100 babies born to mothers who use this medicine during pregnancy. These defects can begin in the first month, even before you know you are pregnant. Other birth defects that affect the structures of the heart, head, arms, legs, and the opening where the urine comes out (urethra) on the bottom of the penis can also happen. Decreased hearing or hearing loss can also happen.</li>
<li>Birth defects may occur even in children born to women who are not taking any medicines and do not have other risk factors.</li>
<li>Taking folic acid supplements before getting pregnant and during early pregnancy can lower the chance of having a baby with a neural tube defect.</li>
<li>If you take Divalproex sodium extended-release tablets during pregnancy for any medical condition, your child is at risk for having lower IQ and may be at risk for developing autism or attention deficit/hyperactivity disorder.</li>
<li>There may be other medicines to treat your condition that have a lower chance of causing birth defects, decreased IQ, or other disorders in your child.</li>
<li>Women who are pregnant must not take Divalproex sodium extended-release tablets to prevent migraine headaches.</li>
<li><span class="Bold">All women of childbearing age (including girls from the start of puberty) should talk to their healthcare provider about using other possible treatments instead of Divalproex sodium extended-release tablets. If the decision is made to use Divalproex sodium extended-release tablets, you should use effective birth control (contraception).</span></li>
<li>Tell your healthcare provider right away if you become pregnant while taking Divalproex sodium extended-release tablets. You and your healthcare provider should decide if you will continue to take Divalproex sodium extended-release tablets while you are pregnant.</li>
<li><span class="Bold">Pregnancy Registry:</span> If you become pregnant while taking Divalproex sodium extended-release tablets, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling toll-free 1-888-233-2334 or by visiting the website, http://www.aedpregnancyregistry.org/. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.</li>
</ul>
<p><a id="ID208"></a><span class="Bold">3. Inflammation of your pancreas that can cause death.</span></p>
<p><span class="Bold">Call your healthcare provider right away if you have any of these symptoms:</span></p>
<ul class="Disc">
<li>severe stomach pain that you may also feel in your back</li>
<li>nausea or vomiting that does not go away</li>
</ul>
<p><a id="ID210"></a><span class="Bold">4. Like other antiepileptic drugs, Divalproex sodium extended-release tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.</span></p>
<p><span class="Bold">Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:</span></p>
<ul class="Disc">
<li>thoughts about suicide or dying</li>
<li>attempts to commit suicide</li>
<li>new or worse depression</li>
<li>new or worse anxiety</li>
<li>feeling agitated or restless</li>
<li>panic attacks</li>
<li>trouble sleeping (insomnia)</li>
<li>new or worse irritability</li>
<li>acting aggressive, being angry, or violent</li>
<li>acting on dangerous impulses</li>
<li>an extreme increase in activity and talking (mania)</li>
<li>other unusual changes in behavior or mood</li>
</ul>
<p><a id="ID212"></a><span class="Bold">How can I watch for early symptoms of suicidal thoughts and actions?</span></p>
<ul class="Disc">
<li>Pay attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings.</li>
<li>Keep all follow-up visits with your healthcare provider as scheduled.</li>
</ul>
<p><a id="ID214"></a>Call your healthcare provider between visits as needed, especially if you are worried about symptoms.</p>
<p><span class="Bold">Do not stop Divalproex sodium extended-release tablets without first talking to a healthcare provider.</span> Stopping Divalproex sodium extended-release tablets suddenly can cause serious problems. Stopping a seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).</p>
<p>Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.</p>
<p><span class="Bold">What are Divalproex sodium extended-release tablets?</span></p>
<p>Divalproex sodium come in different dosage forms with different usages.</p>
<p><span class="Italics">Divalproex Sodium Extended-Release Tablets</span> are prescription medicines used:</p>
<ul class="Disc">
<li>to treat manic episodes associated with bipolar disorder</li>
<li>alone or with other medicines to treat:
<ul class="Square">
<li>complex partial seizures in adults and children 10 years of age and older</li>
<li>simple and complex absence seizures, with or without other seizure types</li>
</ul>
</li>
<li>to prevent migraine headaches</li>
</ul>
<p><a id="ID216"></a><span class="Bold">Who should not take Divalproex sodium extended-release tablets?</span></p>
<p>Do not take Divalproex sodium extended-release tablets if you:</p>
<ul class="Disc">
<li>have liver problems</li>
<li>have or think you have a genetic liver problem caused by a mitochondrial disorder (e.g. Alpers-Huttenlocher syndrome)</li>
<li>are allergic to Divalproex sodium, valproic acid, sodium valproate, or any of the ingredients in Divalproex sodium extended-release tablets. See the end of this leaflet for a complete list of ingredients in Divalproex sodium extended-release tablets.</li>
<li>have a genetic problem called urea cycle disorder</li>
<li>are taking it to prevent migraine headaches and are either pregnant or may become pregnant because you are not using effective birth control(contraception)</li>
</ul>
<p><a id="ID218"></a><span class="Bold">What should I tell my healthcare provider before taking Divalproex sodium extended-release tablets?</span></p>
<p>Before you take Divalproex sodium extended-release tablets, tell your healthcare provider if you:</p>
<ul class="Disc">
<li>have a genetic liver problem caused by a mitochondrial disorder (e.g. Alpers-Huttenlocher syndrome)</li>
<li>drink alcohol</li>
<li>are pregnant or breastfeeding. Divalproex sodium can pass into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Divalproex sodium extended-release tablets.</li>
<li>have or have had depression, mood problems, or suicidal thoughts or behavior</li>
<li>have any other medical conditions</li>
</ul>
<p><a id="ID220"></a><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, herbal supplements and medicines that you take for a short period of time.</p>
<p>Taking Divalproex sodium extended-release tablets with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.</p>
<p>Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist each time you get a new medicine.</p>
<p><span class="Bold">How should I take Divalproex sodium extended-release tablets?</span></p>
<ul class="Disc">
<li>Take Divalproex sodium extended-release tablets exactly as your healthcare provider tells you. Your healthcare provider will tell you how much Divalproex sodium extended-release tablets to take and when to take it.</li>
<li>Your healthcare provider may change your dose.</li>
<li>Do not change your dose of Divalproex sodium extended-release tablets without talking to your healthcare provider.</li>
<li><span class="Bold">Do not stop taking Divalproex sodium extended-release tablets without first talking to your healthcare provider.</span> Stopping Divalproex sodium extended-release tablets suddenly can cause serious problems.</li>
<li>Swallow Divalproex sodium extended-release tablets whole. Do not crush or chew Divalproex sodium extended-release tablets. Tell your healthcare provider if you cannot swallow Divalproex sodium extended-release tablets whole. You may need a different medicine.</li>
<li>If you take too much Divalproex sodium extended-release tablets, call your healthcare provider or local Poison Control Center right away.</li>
</ul>
<p><a id="ID222"></a><span class="Bold">What should I avoid while taking Divalproex sodium extended-release tablets?</span></p>
<ul class="Disc">
<li>Divalproex sodium extended-release tablets can cause drowsiness and dizziness. Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking Divalproex sodium extended-release tablets, until you talk with your doctor. Taking Divalproex sodium extended-release tablets with alcohol or drugs that cause sleepiness or dizziness may make your sleepiness or dizziness worse.</li>
<li>Do not drive a car or operate dangerous machinery until you know how Divalproex sodium extended-release tablets affects you. Divalproex sodium extended-release tablets can slow your thinking and motor skills.</li>
</ul>
<p><a id="ID224"></a><span class="Bold">What are the possible side effects of Divalproex sodium extended-release tablets?</span></p>
<ul class="Disc">
<li>See <span class="Bold">"What is the most important information I should know about Divalproex sodium extended-release tablets?"</span></li>
</ul>
<p><a id="ID226"></a>Divalproex sodium extended-release tablets can cause serious side effects including:</p>
<ul class="Disc">
<li><span class="Bold">Bleeding problems:</span> red or purple spots on your skin, bruising, pain and swelling into your joints due to bleeding or bleeding from your mouth or nose.</li>
<li><span class="Bold">High ammonia levels in your blood:</span> feeling tired, vomiting, changes in mental status.</li>
<li><span class="Bold">Low body temperature (hypothermia):</span> drop in your body temperature to less than 95&deg;F, feeling tired, confusion, coma.</li>
<li><span class="Bold">Allergic (hypersensitivity) reactions:</span> fever, skin rash, hives, sores in your mouth, blistering and peeling of your skin, swelling of your lymph nodes, swelling of your face, eyes, lips, tongue, or throat, trouble swallowing or breathing.</li>
<li><span class="Bold">Drowsiness or sleepiness in the elderly.</span> This extreme drowsiness may cause you to eat or drink less than you normally would. Tell your doctor if you are not able to eat or drink as you normally do. Your doctor may start you at a lower dose of Divalproex sodium extended-release tablets.</li>
</ul>
<p><a id="ID228"></a><span class="Bold">Call your healthcare provider right away, if you have any of the symptoms listed above. The common side effects of Divalproex sodium extended-release tablets include:</span></p>
<ul class="Disc">
<li>nausea</li>
<li>headache</li>
<li>sleepiness</li>
<li>vomiting</li>
<li>weakness</li>
<li>tremor</li>
<li>dizziness</li>
<li>stomach pain</li>
<li>blurry vision</li>
<li>double vision</li>
<li>diarrhea</li>
<li>increased appetite</li>
<li>weight gain</li>
<li>hair loss</li>
<li>loss of appetite</li>
<li>problems with walking or coordination</li>
</ul>
<p><a id="ID230"></a>These are not all of the possible side effects of <span class="Bold">Divalproex sodium extended-release tablets</span>. For more information, ask your healthcare provider or pharmacist.</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or Lupin Pharmaceuticals, Inc. at 1-800-399-2561.</span></p>
<p><span class="Bold">How should I store Divalproex sodium extended-release tablets?</span></p>
<ul class="Disc">
<li>Store Divalproex sodium extended-release tablets between 59&deg;F to 86&deg;F (15&deg;C to 30&deg;C).</li>
</ul>
<p><a id="ID232"></a><span class="Bold">Keep Divalproex sodium extended-release tablets and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of Divalproex sodium extended-release tablets</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Divalproex sodium extended-release tablets for a condition for which it was not prescribed. Do not give Divalproex sodium extended-release tablets to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about Divalproex sodium extended-release tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about Divalproex sodium extended-release tablets that is written for health professionals.</p>
<p>For more information, go to www.lupinpharmaceuticals.com or call 1-800-399-2561.</p>
<p><span class="Bold">What are the ingredients in Divalproex sodium extended-release tablets?</span></p>
<p>Active ingredient: Divalproex sodium</p>
<p>Inactive ingredients:</p>
<p>&bull; <span class="Bold">Divalproex Sodium Extended-Release Tablets:</span> ethyl acrylate and methyl methacrylate copolymer dispersion, ethyl cellulose, hypromellose, iron oxide black (ferrosoferric oxide), lactose monohydrate, magnesium stearate, microcrystalline cellulose, propylene glycol, polyethylene glycol, polyvinyl alcohol, shellac, silicon dioxide, talc, and titanium dioxide. In addition, 500 mg tablets also contain iron oxide red and iron oxide yellow</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Distributed by:</p>
<p><span class="Bold">Lupin Pharmaceuticals, Inc.</span></p>
<p>Baltimore, Maryland 21202</p>
<p>United States</p>
<p>Manufactured by:</p>
<p><span class="Bold">Lupin Limited</span></p>
<p>Nagpur 441108</p>
<p>India</p>
<p>December 15, 2020                                                                             ID#: 265516</p>


<a id="ID233"></a>
<h2>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h2>
<p class="First"><a id="ID234"></a>NDC 68180-260-06</p>
<p>Bottle of 30 Tablets</p>
<p>Once-Daily Dosing</p>
<p>Divalproex Sodium Extended-release Tablets, USP</p>
<p>250 mg Valproic Acid Activity</p>
<p>Rx only</p>
<p>Dispense with Medication Guide provided separately to each patient.</p>
<div class="Figure"><img data-lazy-load data-src='https://www.drugs.com/pro/images/1f081c74-9f73-4ed9-9157-8d73d586a409/d95f9b1b-f1e4-4ae4-a215-7317fb1ca565-05.jpg' src='/img/pixel.gif' alt="" />
<p class="MultiMediaCaption">Image 5</p>
</div>
<p><a id="ID236"></a>NDC 68180-261-06</p>
<p>Bottle of 30 Tablets</p>
<p>Once-Daily Dosing</p>
<p>Divalproex Sodium Extended-release Tablets, USP</p>
<p>500 mg Valproic Acid Activity</p>
<p>Rx only</p>
<p>Dispense with Medication Guide provided separately to each patient.</p>
<div class="Figure"><img data-lazy-load data-src='https://www.drugs.com/pro/images/1f081c74-9f73-4ed9-9157-8d73d586a409/d95f9b1b-f1e4-4ae4-a215-7317fb1ca565-06.jpg' src='/img/pixel.gif' alt="" />
<p class="MultiMediaCaption">Image 6</p>
</div>


<div class="DataElementsTables">
<div class='responsive-table-wrap'><table class="contentTablePetite" style="width: 100%; ">
<tbody>
<tr>
<td class="contentTableTitle"><strong>Divalproex SODIUM </strong><br />
<span class="contentTableReg">Divalproex sodium tablet, extended release</span></td>
</tr>
<tr>
<td>
<div class='responsive-table-wrap'><table class="formTablePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingTitle">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68180-260</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" style="width: 30%; ">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" style="width: 30%; ">DEA Schedule</td>
<td class="formItem">    </td>
</tr>
</table></div>
</td>
</tr>
<tr>
<td>
<div class='responsive-table-wrap'><table class="formTablePetite" style="width: 100%; ">
<tr>
<td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td>
</tr>
<tr>
<td class="formTitle">Ingredient Name</td>
<td class="formTitle">Basis of Strength</td>
<td class="formTitle">Strength</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Divalproex SODIUM</strong> (VALPROIC ACID)</td>
<td class="formItem">VALPROIC ACID</td>
<td class="formItem">250 mg</td>
</tr>
</table></div>
</td>
</tr>
<tr>
<td>
<div class='responsive-table-wrap'><table class="formTablePetite" style="width: 100%; ">
<tr>
<td colspan="2" class="formHeadingTitle">Inactive Ingredients</td>
</tr>
<tr>
<td class="formTitle">Ingredient Name</td>
<td class="formTitle">Strength</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER (2:1; 750000 MW)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSE (7 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (100000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL, UNSPECIFIED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></div>
</td>
</tr>
<tr>
<td>
<div class='responsive-table-wrap'><table class="formTablePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingTitle">Product Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">L088</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></div>
</td>
</tr>
<tr>
<td>
<div class='responsive-table-wrap'><table class="formTablePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingTitle">Packaging</td>
</tr>
<tr>
<td class="formTitle" style="width: 1px; ">#</td>
<td class="formTitle">Item Code</td>
<td class="formTitle">Package Description</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>1</strong></td>
<td class="formItem">NDC:68180-260-06</td>
<td class="formItem">30 TABLET, EXTENDED RELEASE in 1 BOTTLE</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>2</strong></td>
<td class="formItem">NDC:68180-260-02</td>
<td class="formItem">500 TABLET, EXTENDED RELEASE in 1 BOTTLE</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>3</strong></td>
<td class="formItem">NDC:68180-260-01</td>
<td class="formItem">100 TABLET, EXTENDED RELEASE in 1 BOTTLE</td>
</tr>
</table></div>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<div class='responsive-table-wrap'><table class="formTableMorePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<td class="formTitle">Marketing Category</td>
<td class="formTitle">Application Number or Monograph Citation</td>
<td class="formTitle">Marketing Start Date</td>
<td class="formTitle">Marketing End Date</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA209286</td>
<td class="formItem">09/18/2020</td>
<td class="formItem"></td>
</tr>
</table></div>
</td>
</tr>
</tbody>
</table></div>
<div class='responsive-table-wrap'><table class="contentTablePetite" style="width: 100%; ">
<tbody>
<tr>
<td class="contentTableTitle"><strong>Divalproex SODIUM </strong><br />
<span class="contentTableReg">Divalproex sodium tablet, extended release</span></td>
</tr>
<tr>
<td>
<div class='responsive-table-wrap'><table class="formTablePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingTitle">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68180-261</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" style="width: 30%; ">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" style="width: 30%; ">DEA Schedule</td>
<td class="formItem">    </td>
</tr>
</table></div>
</td>
</tr>
<tr>
<td>
<div class='responsive-table-wrap'><table class="formTablePetite" style="width: 100%; ">
<tr>
<td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td>
</tr>
<tr>
<td class="formTitle">Ingredient Name</td>
<td class="formTitle">Basis of Strength</td>
<td class="formTitle">Strength</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Divalproex SODIUM</strong> (VALPROIC ACID)</td>
<td class="formItem">VALPROIC ACID</td>
<td class="formItem">500 </td>
</tr>
</table></div>
</td>
</tr>
<tr>
<td>
<div class='responsive-table-wrap'><table class="formTablePetite" style="width: 100%; ">
<tr>
<td colspan="2" class="formHeadingTitle">Inactive Ingredients</td>
</tr>
<tr>
<td class="formTitle">Ingredient Name</td>
<td class="formTitle">Strength</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER (2:1; 750000 MW)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSE (7 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (100000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL, UNSPECIFIED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></div>
</td>
</tr>
<tr>
<td>
<div class='responsive-table-wrap'><table class="formTablePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingTitle">Product Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GRAY</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">L089</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></div>
</td>
</tr>
<tr>
<td>
<div class='responsive-table-wrap'><table class="formTablePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingTitle">Packaging</td>
</tr>
<tr>
<td class="formTitle" style="width: 1px; ">#</td>
<td class="formTitle">Item Code</td>
<td class="formTitle">Package Description</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>1</strong></td>
<td class="formItem">NDC:68180-261-01</td>
<td class="formItem">100 TABLET, EXTENDED RELEASE in 1 BOTTLE</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>2</strong></td>
<td class="formItem">NDC:68180-261-06</td>
<td class="formItem">30 TABLET, EXTENDED RELEASE in 1 BOTTLE</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>3</strong></td>
<td class="formItem">NDC:68180-261-02</td>
<td class="formItem">500 TABLET, EXTENDED RELEASE in 1 BOTTLE</td>
</tr>
</table></div>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<div class='responsive-table-wrap'><table class="formTableMorePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<td class="formTitle">Marketing Category</td>
<td class="formTitle">Application Number or Monograph Citation</td>
<td class="formTitle">Marketing Start Date</td>
<td class="formTitle">Marketing End Date</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA209286</td>
<td class="formItem">09/18/2020</td>
<td class="formItem"></td>
</tr>
</table></div>
</td>
</tr>
</tbody>
</table></div>
<div class='responsive-table-wrap'><table class="formTableMorePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Labeler - </span>Lupin Pharmaceuticals, Inc. (089153071)</td>
</tr>
</table></div>
<div class='responsive-table-wrap'><table class="formTableMorePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Registrant - </span>LUPIN LIMITED (675923163)</td>
</tr>
</table></div>
<div class='responsive-table-wrap'><table class="formTableMorePetite" style="width: 100%; ">
<tr>
<td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td>
</tr>
<tr>
<td class="formTitle">Name</td>
<td class="formTitle">Address</td>
<td class="formTitle">ID/FEI</td>
<td class="formTitle">Operations</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">LUPIN LIMITED</td>
<td class="formItem"></td>
<td class="formItem">650759348</td>
<td class="formItem">MANUFACTURE(68180-260, 68180-261), PACK(68180-260, 68180-261)</td>
</tr>
</table></div>
</div>

 
<div class="DistributorName">Lupin Pharmaceuticals, Inc.</div>
<div id='moreResources' class='more-resources'>
<h2>More about divalproex sodium</h2>
<ul class='more-resources-list more-resources-list-general'>
<li><a href='/sfx/divalproex-sodium-side-effects.html'>Side Effects</a></li>
<li><a href='/pregnancy/divalproex-sodium.html'>During Pregnancy</a> or 
<a href='/breastfeeding/divalproex.html'>Breastfeeding</a></li>
<li><a href='/dosage/divalproex-sodium.html' data-action='drug-dosage-disambiguation' data-ddc_id='918' data-brand_id='0'>Dosage Information</a></li>
<li><a href='/tips/divalproex-sodium-patient-tips'>Patient Tips</a></li>
<li><a href='/divalproex-sodium-images.html'>Drug Images</a></li>
<li><a href='/drug-interactions/divalproex-sodium.html'>Drug Interactions</a></li>
<li><a href='/price-guide/divalproex-sodium'>Pricing &amp; Coupons</a></li>
<li><a href='/mtm_esp/divalproex-sodium.html'>En Espa&ntilde;ol</a></li>
<li><a href='/comments/divalproex-sodium/'>424 Reviews</a></li>
<li><a href='/drug-class/fatty-acid-derivative-anticonvulsants.html'>Drug class: fatty acid derivative anticonvulsants</a></li>
</ul>
<h3>Consumer resources</h3>
<ul class='more-resources-list more-resources-list-consumer'>
<li><a href='/mtm/divalproex-sodium.html'>Patient Information</a></li>
<li data-more-config-id='list-data-resources-consumer'><a href='#' class='more-resources-more-toggle' data-more-toggle rel='nofollow'>... +3 more</a></li>
</ul>
<h3>Professional resources</h3>
<ul class='more-resources-list more-resources-list-professional'>
<li><a href='/pro/divalproex-capsules.html'>Prescribing Information</a></li>
<li><a href='/pro/divalproex-delayed-release.html'>Divalproex Delayed Release <span>(FDA)</span></a></li>
<li><a href='/pro/divalproex-delayed-release-tablets.html'>Divalproex Delayed Release Tablets <span>(FDA)</span></a></li>
<li><a href='/pro/divalproex-extended-release.html'>Divalproex Extended Release <span>(FDA)</span></a></li>
<li><a href='/pro/divalproex-sprinkle.html'>Divalproex Sprinkle <span>(FDA)</span></a></li>
</ul>
<dl class='more-resources-other-brands more-resources-other-brands-professional'><dt>Other brands</dt><dd><a href='/pro/depakote.html'>Depakote</a>, <a href='/pro/depakote-er.html'>Depakote ER</a>, <a href='/pro/depakote-capsules.html'>Depakote Sprinkles</a></dd></dl>
<h3>Related treatment guides</h3>
<ul class='more-resources-list more-resources-list-conditions'>
<li><a href='/cg/bipolar-disorder.html' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='918' data-brand_name_id='0' data-condition_id='105'>Bipolar Disorder</a></li>
<li><a href='/health-guide/borderline-personality-disorder.html' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='918' data-brand_name_id='0' data-condition_id='10061'>Borderline Personality Disorder</a></li>
<li><a href='/condition/cyclothymic-disorder.html' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='918' data-brand_name_id='0' data-condition_id='10296'>Cyclothymic Disorder</a></li>
<li><a href='/health-guide/epilepsy.html' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='918' data-brand_name_id='0' data-condition_id='931'>Epilepsy</a></li>
<li data-more-config-id='list-data-resources-conditions'><a href='#' class='more-resources-more-toggle' data-more-toggle rel='nofollow'>... +3 more</a></li>
</ul>
</div>
<p class='ddc-disclaimer-link'><a href='/support/disclaimer-pro.html'>Medical Disclaimer</a></p>

</div>
<!-- google_ad_section_end -->

</div>


<div id='sidebar' class='ddc-clearfix'>
<div class='ddc-status-info'>
	<h3 class='ddc-status-info-title'>Drug Status</h3>
	<div class="ddc-box">
		<div class="ddc-accordion" role="presentation">

			
		<div class='ddc-accordion-section'>
			<div class='ddc-accordion-header ddc-mg-0'  data-static='true'>
				<h4 class='ddc-accordion-heading'>Availability
					<span class='ddc-accordion-summary ddc-display-block ddc-mg-0'>Prescription only</span>
					<span class='ddc-status-icon drugInfoRx1'>Rx</span>
					</h4>
			</div>
			
		</div>
		
		<div class='ddc-accordion-section'>
			<div class='ddc-accordion-header ddc-mg-0'  data-static='true'>
				<h4 class='ddc-accordion-heading'><a href='/pregnancy/divalproex-sodium.html'>Pregnancy &amp; Lactation
					<span class='ddc-accordion-summary ddc-display-block ddc-mg-0'>Risk data available</span>
					<span class='ddc-status-icon drugInfoPregMultiple'><svg class='ddc-icon ddc-icon-pregnancy' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M10.62 7.03c.38-1.4 2.43-2.17 3.3-1.27.2.2.33.5.48.98l.11.36.12.42.06.23.29 1.13.09.34.02.08c.08.17.48.42 1.19.69l.98.34.26.1.3.14a2.7 2.7 0 011.42 2.99c-.2 1.2-.9 2.25-2.24 3.68a8.56 8.56 0 01-5.62 2.44c-2.35.17-4.48-1.02-5.23-2.63a5.89 5.89 0 01-.24-.6l-.11-.35-.12-.42-.26-.94-.09-.32-.08-.27-.08-.2-.07-.16a.57.57 0 00-.08-.14H5l-.1.01-.15.02-.62.13c-.35.06-.56.07-.83 0-.87-.18-1.3-.67-1.5-1.45a2.28 2.28 0 011-2.36l.16-.1.1-.06.18-.1.22-.1.24-.11.45-.18.36-.14.93-.34c1.67-.6 2.7-.28 3.44.85a3 3 0 01.51 1.27l.07.46.04.18c.07.33.37.5.8.5.2 0 .77-.24 1.14-.44l.07-.05-.1-.15-.17-.27-.07-.12a1 1 0 01-.06-.19l-.02-.08-.24-.9-.1-.48c-.06-.26-.1-.5-.14-.74-.08-.59-.1-1.1-.02-1.54zm2.24-.14h-.02c-.09 0-.19.03-.28.07-.28.1-.46.29-.5.47-.04.26-.03.63.03 1.07.05.3.11.63.2.98l.27 1.05c0-.01 0-.01 0 0l.17.23.17.26c.08.14.14.26.19.4a1 1 0 01-.17 1.01c-.42.5-1.88 1.2-2.62 1.2-1.06 0-2.03-.56-2.27-1.7a8.8 8.8 0 01-.08-.41l-.07-.43-.02-.1a1.6 1.6 0 00-.23-.44c-.36-.54-.65-.63-1.69-.26l-.66.24-.66.25-.37.15-.2.08-.16.09-.14.08-.2.12c-.2.14-.34.51-.3.69.08.27.1.3.36.36h.16l.08-.02.54-.1c.78-.15 1.26-.1 1.73.4.26.28.43.63.62 1.26l.12.41.31 1.16.1.33.1.28.04.13.1.22c.48 1.03 2.02 1.9 3.76 1.77a7.08 7.08 0 004.63-1.97c1.15-1.23 1.72-2.1 1.86-2.92.12-.68-.12-1.13-.64-1.4a.6.6 0 00-.04-.03l-.16-.06-.35-.13-.8-.28-.24-.1c-.96-.37-1.55-.78-1.82-1.43l-.03-.07-.05-.17-.06-.22-.44-1.7-.1-.35-.1-.27-.07-.2zM19 3.25a3.25 3.25 0 110 6.5 3.25 3.25 0 010-6.5zm0 1.5a1.75 1.75 0 100 3.5 1.75 1.75 0 000-3.5z' /></svg></span>
					</a></h4>
			</div>
			
		</div>
		
		<div class='ddc-accordion-section'>
			<div class='ddc-accordion-header ddc-mg-0' aria-expanded='false' id='accordion-heading-2' role='button' tabindex='0' aria-controls='accordion-content-2' data-type='csa' data-box-info-module='drug' data-id='N' data-ddc_id='0' data-brand_name_id='0'>
				<h4 class='ddc-accordion-heading'>CSA Schedule*
					<span class='ddc-accordion-summary ddc-display-block ddc-mg-0'>Not a controlled drug</span>
					<span class='ddc-status-icon drugInfoCSAN'>N/A</span>
					<svg class='ddc-icon ddc-icon-accordion-expand' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z' /></svg></h4>
			</div>
			
<div class='ddc-status-info-content ddc-accordion-content ddc-text-wordbreak' id='accordion-content-2' aria-labelledby='accordion-heading-2'>
	<div class='ddc-text-color-secondary ddc-text-size-small' aria-live='polite'>
	  <p>Loading...</p>
	</div>
</div>
		</div>
		
		<div class='ddc-accordion-section'>
			<div class='ddc-accordion-header ddc-mg-0' aria-expanded='false' id='accordion-heading-3' role='button' tabindex='0' aria-controls='accordion-content-3' data-type='approval' data-box-info-module='drug' data-id='/pro/divalproex.html' data-ddc_id='918' data-brand_name_id='0'>
				<h4 class='ddc-accordion-heading'>Approval History
					<span class='ddc-accordion-summary ddc-display-block ddc-mg-0'>Drug history at FDA</span>
					<span class='ddc-status-icon drugInfoDateCal'><svg class='ddc-icon ddc-icon-history' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M8.75 2.25v1h6.5v-1h1.5v1H19c.92 0 1.67.7 1.74 1.6l.01.15v14c0 .97-.78 1.75-1.75 1.75H5c-.97 0-1.75-.78-1.75-1.75V5c0-.97.78-1.75 1.75-1.75h2.25v-1h1.5zm10.5 6.5H4.75V19c0 .12.08.22.2.24l.05.01h14c.14 0 .25-.11.25-.25V8.75zm-12-4H5a.25.25 0 00-.25.25v2.25h14.5V5a.25.25 0 00-.2-.24L19 4.75h-2.25v1h-1.5v-1h-6.5v1h-1.5v-1z' /></svg></span>
					<svg class='ddc-icon ddc-icon-accordion-expand' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z' /></svg></h4>
			</div>
			
<div class='ddc-status-info-content ddc-accordion-content ddc-text-wordbreak' id='accordion-content-3' aria-labelledby='accordion-heading-3'>
	<div class='ddc-text-color-secondary ddc-text-size-small' aria-live='polite'>
	  <p>Loading...</p>
	</div>
</div>
		</div>
				</div>
	</div>
</div>
	<div class="sideBox sideBoxRelatedDrugs">
	<div class="sideBoxHead">
		<div class="sideBoxTitle">Related Drugs</div>
	</div>
	<div class="sideBoxContent">
<p><a href="/gabapentin.html">gabapentin</a>, <a href="/clonazepam.html">clonazepam</a>, <a href="/propranolol.html">propranolol</a>, <a href="/mtm/quetiapine.html">quetiapine</a>, <a href="/atenolol.html">atenolol</a>, <a href="/mtm/lamotrigine.html">lamotrigine</a>, <a href="/abilify.html">Abilify</a>, <a href="/lyrica.html">Lyrica</a>, <a href="/mtm/topiramate.html">topiramate</a>, <a href="/seroquel.html">Seroquel</a></p>	</div>
</div>
<div class='sideBox sideBoxUserReviews'>
	<div class='sideBoxContent ddc-clearfix'>
		<div class='sideBoxTitle'>User Reviews &amp; Ratings</div>
		<div class='ddc-rating-summary'>

<div><b>6.5</b><span class='ddc-text-color-secondary'> / 10</span></div>
<div class='ddc-rating-bar'><span style='width: 64.7%;'></span></div>
<em><a href='/comments/divalproex-sodium/'>424 Reviews</a></em>
		</div>
	</div>
</div>
<div class="sideBox sideBoxDrugImage">
	<div class="sideBoxHead">
		<div class="sideBoxTitle">Images</div>
	</div>
	<div class="sideBoxContent">
		<div id='drug-imprint-primary' class="drugImage">
			<div class="drugImageHolder">
				<a href="/imprints/u-s-180-13103.html" title="View larger image">
					<img alt="Pill Imprint U-S 180 (Divalproex Sodium Delayed-Release 125 mg)" src='/img/pixel.gif' width='300' height='225' data-lazy-load data-src='https://www.drugs.com/images/pills/nlm/002450180.jpg'>
					<noscript><img alt="Pill Imprint U-S 180 (Divalproex Sodium Delayed-Release 125 mg)" src='https://www.drugs.com/images/pills/nlm/002450180.jpg'></noscript>
				</a>
			</div>
			<div class="drugImageText">
				Divalproex sodium systemic 125 mg (U-S 180)			</div>
		</div>

		<nav class='drugImageNav' aria-label="Browse pill images">
<a href='#' role='button' data-drug-imprint-image data-url='/imprints/u-s-180-13103.html' data-label='Divalproex sodium systemic 125 mg (U-S 180)'><img alt='Divalproex sodium systemic 125 mg (U-S 180)' src='/img/pixel.gif' width='100' height='75' data-lazy-load data-src='https://www.drugs.com/images/pills/nlm/002450180.jpg'></a>
<a href='#' role='button' data-drug-imprint-image data-url='/imprints/u-s-181-13104.html' data-label='Divalproex sodium systemic 250 mg (U-S 181)'><img alt='Divalproex sodium systemic 250 mg (U-S 181)' src='/img/pixel.gif' width='100' height='75' data-lazy-load data-src='https://www.drugs.com/images/pills/nlm/002450181.jpg'></a>
<a class='more' href='/divalproex-sodium-images.html' role='button'>View all images</a>
		</nav>
	</div>
</div>
	<div id='sideBoxStackedAdWrap-1' class='sideBoxStackedAdWrap'>
		<div id='sideBoxStackedAd-1' class='sideBox sideBoxFixedAd300 sideBoxStackedAd'>
			<div id='drugs-drugs-2' class='display-ad display-ad-300x600'>
<script>
var ehs_ad_called = ++ehs_ad_called || 1;
</script>
</div>
<script src='//ads.ehealthcaresolutions.com/a/?adid=drugs-drugs-2&slotid=2&url=www.drugs.com%2Fpro%2Fdivalproex.html&size=300x250,300x600&vpos=t&hpos=r&site=ehs.pro.drugs.drugs&drg=divalproex_sodium&drc=fatty_acid_derivative_anticonvulsants&dra=1' defer></script>
		</div>
	</div>
	</div>

</div>
</main>

<footer id='footer' class='footer ddc-clearfix'>
	<section class="footer-feature">
		<div class="container">
			<div class="promo-content" data-lazy-load data-background-image='/img/apps/promo-uberapp.png'>
				<h2 class='ddc-mgt-0 ddc-text-weight-bold'>Drugs.com <span>Mobile Apps</span></h2>
				<p>The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.</p>
				<a href="/apps/" class="ddc-btn" onclick="ga('send', { hitType: 'event', eventCategory: 'App Promo', eventAction: 'Footer', eventLabel: 'Explore Apps' });">Explore Apps</a>
			</div>
		</div>
	</section>

	<div class="container">
		<div class="footer-sections">
			<div class='footer-logomark' data-lazy-load data-background-image='/img/logo/drugscom-logo.png'></div>

			<div class="footer-content-links">
				<section class="footer-section">
					<h2 class='ddc-mgt-0'>Support</h2>
					<ul class='ddc-list-unstyled ddc-mg-0'>
						<li><a href='/support/'>Help Center</a></li>
						<li><a href='/sitemap.html'>Sitemap</a></li>
						<li><a href="/support/contact.html">Contact Us</a></li>
					</ul>
				</section>

				<section class="footer-section">
					<h2 class='ddc-mgt-0'>About</h2>
					<ul class='ddc-list-unstyled ddc-mg-0'>
						<li><a href="/support/about.html">About Drugs.com</a></li>
						<li><a href="/support/advertising.html">Advertising Policy</a></li>
						<li><a href="/support/citations.html">Attribution &amp; Citations</a></li>
					</ul>
				</section>

				<section class="footer-section ddc-mg-0">
					<h2 class='ddc-mgt-0'>Terms &amp; Privacy</h2>
					<ul class='ddc-list-unstyled ddc-mg-0'>
						<li><a href='/support/editorial_policy.html'>Editorial Policy</a></li>
						<li><a href='/support/privacy.html'>Privacy Policy</a>
						</li>
						<li><a href='/support/terms.html'>Terms of Use</a></li>
					</ul>
				</section>

				<div class="footer-section footer-social">
					<ul class="footer-social-list ddc-list-inline ddc-mgt-0 ddc-mgb-1">
						<li>
							<a href="https://www.facebook.com/Drugscom" target='_blank' rel='noopener' class="ddc-share-icon ddc-share-icon-facebook">
								<span class='ddc-share-icon-label'>Follow Drugs.com on Facebook</span> <svg class='ddc-icon ddc-icon-facebook' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M14 6.54c-2.06 0-3.4 1.25-3.4 3.52v2H8.3v2.61h2.3V21A9.04 9.04 0 013 12.05C3 7.05 7.03 3 12 3s9 4.05 9 9.05c0 4.53-3.3 8.27-7.6 8.95v-6.33h2.1l.4-2.62h-2.5v-1.7c0-.7.35-1.4 1.47-1.4h1.14V6.7s-1.03-.17-2.02-.17z' /></svg>							</a>
						</li>
						<li>
							<a href="https://twitter.com/drugscom" target='_blank' rel='noopener' class="ddc-share-icon ddc-share-icon-twitter">
								<span class='ddc-share-icon-label'>Follow Drugs.com on Twitter</span> <svg class='ddc-icon ddc-icon-twitter' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M8.66 19.63a10.44 10.44 0 0010.5-10.5v-.5A7.7 7.7 0 0021 6.74c-.67.3-1.39.5-2.12.58a3.73 3.73 0 001.64-2.04c-.72.43-1.52.74-2.34.9a3.7 3.7 0 00-6.3 3.36 10.46 10.46 0 01-7.61-3.85 3.69 3.69 0 001.14 4.9 3.66 3.66 0 01-1.63-.45v.04a3.7 3.7 0 002.9 3.64 3.7 3.7 0 01-1.63.06 3.69 3.69 0 003.42 2.53 7.4 7.4 0 01-4.6 1.64 8 8 0 01-.87-.07 10.45 10.45 0 005.66 1.63' /></svg>							</a>
						</li>
						<li>
							<a href="https://www.pinterest.com/drugscom/" target='_blank' rel='noopener' class="ddc-share-icon ddc-share-icon-pinterest">
								<span class='ddc-share-icon-label'>Follow Drugs.com on Pinterest</span> <svg class='ddc-icon ddc-icon-pinterest' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M11.97 3a9 9 0 00-3.29 17.36 8.48 8.48 0 010-2.57l1.06-4.5c-.16-.41-.25-.85-.24-1.29 0-1.25.73-2.19 1.63-2.19a1.14 1.14 0 011.14 1.29c0 .77-.49 1.93-.75 3a1.28 1.28 0 001.35 1.62c1.6 0 2.83-1.69 2.83-4.12a3.55 3.55 0 00-3.77-3.66 3.92 3.92 0 00-4.08 3.9c0 .74.22 1.46.65 2.06.06.07.09.16.06.25l-.25 1.03c-.02.12-.13.2-.3.12-1.13-.53-1.83-2.17-1.83-3.5 0-2.83 2.07-5.44 5.96-5.44 3.13 0 5.57 2.23 5.57 5.2 0 3.1-1.93 5.6-4.69 5.6-.82.02-1.6-.36-2.07-1.03l-.56 2.14a9.98 9.98 0 01-1.12 2.36c.87.25 1.79.38 2.7.37A9.02 9.02 0 0021 12c0-4.97-4.04-9-9.03-9' /></svg>							</a>
						</li>
						<li>
							<a href="https://www.youtube.com/user/drugscom" target='_blank' rel='noopener' class="ddc-share-icon ddc-share-icon-youtube">
								<span class='ddc-share-icon-label'>Follow Drugs.com on YouTube</span> <svg class='ddc-icon ddc-icon-youtube' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M12.25 5c.57 0 2.05.01 3.58.07l.5.01c1.45.06 2.85.16 3.48.32.86.22 1.54.86 1.77 1.68.38 1.33.42 3.96.42 4.5v.18c0 .53-.04 3.16-.42 4.5-.23.81-.9 1.46-1.77 1.68-1.33.34-6.12.39-7.46.4h-.71c-1.33-.01-6.12-.06-7.45-.4a2.45 2.45 0 01-1.77-1.69A22.62 22.62 0 012 11.76v-.19c0-.53.04-3.16.42-4.49.23-.82.9-1.46 1.77-1.68.63-.16 2.03-.26 3.47-.32l.51-.01C9.7 5 11.18 5 11.75 5zm-2.3 3.85v5.63l5.23-2.81-5.23-2.82z' /></svg>							</a>
						</li>
						<li>
							<a href="/newsletters/" title='Drugs.com RSS Feeds' class="ddc-share-icon">
								<span class='ddc-share-icon-label'>Subscribe to our Newsletters</span> <svg class='ddc-icon ddc-icon-email' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M20 4.25c.92 0 1.67.7 1.74 1.6l.01.15v12c0 .92-.7 1.67-1.6 1.74l-.15.01H4c-.92 0-1.67-.7-1.74-1.6L2.25 18V6c0-.92.7-1.67 1.6-1.74L4 4.25h16zm-.17 1.77a.75.75 0 00-1.06-.1L12 11.52l-6.77-5.6-.1-.06a.75.75 0 00-.86 1.22l7.25 6 .1.07c.27.15.61.13.86-.07l7.25-6L19.8 7a.75.75 0 00.02-.98z' /></svg>							</a>
						</li>
					</ul>
					<p class='ddc-mgb-1'><a href="/newsletters/">Subscribe</a> to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates.</p>
				</div>
			</div>

		</div>

		<div class='footer-description'>
			<p><strong>Drugs.com</strong> provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 July 2021), Cerner Multum&trade; (updated 1 July 2021), ASHP (updated 30 June 2021) and others.</p>
		</div>

		<div class='footer-info ddc-clearfix'>

			<div class='footPrivacy'>
				<ul class="site-privacy ddc-list-unstyled ddc-mg-0">
					<li class="privacy-logo logo-truste ddc-clearfix">
						<a href='//privacy.truste.com/privacy-seal/validation?rid=d18cba4a-afc4-4863-af81-8262bb120271' target='_blank' rel='noopener'>
							<img data-lazy-load data-src='//privacy-policy.truste.com/privacy-seal/seal?rid=d18cba4a-afc4-4863-af81-8262bb120271' src='/img/pixel.gif' width='142' height='45' alt='TRUSTe'>
						</a>
					</li>
					<li class="privacy-logo logo-adchoices ddc-clearfix">
						<a href="/support/privacy/advertising.html">
							<img data-lazy-load data-src='/img/logo/vendor/adchoices-logomark.png' src='/img/pixel.gif' width='40' height='42' alt='AdChoices'>
							<span>
								<b>Ad Choices</b>
							</span>
						</a>
					</li>
					<li class="privacy-logo logo-honcode ddc-clearfix">
						<img data-lazy-load data-src='/img/logo/vendor/honcode-2020.png' src='/img/pixel.gif' width='43' height='60' alt='HonCode'>
						<span>We comply with the HONcode standard for trustworthy health information. <a class='ddc-text-nowrap' href='//www.hon.ch/HONcode/Conduct.html?HONConduct756274' target='_blank' rel='noopener nofollow'>Verify here</a></span>
					</li>
					<li class="site-info">
						<span>Copyright &copy; 2000-2021 Drugs.com. <span class='ddc-display-block'>All rights reserved.</span></span>
					</li>
				</ul>
			</div>
		</div>
	</div>
</footer>
<div class='ddc-social-share'></div>


<!-- Global JS var for configuration data/settings -->
<script>SITECONFIG = {"agent":{"isMobile":false},"user":{"userid":0,"modal":{"login":"/api/user/modal/login/"},"consent":{"skip":true,"api":{"url":"/api/user/"}}},"page":{"section":"pro","subsection":"","doc":"content","delayedCss":["/bundle/css/component/component.share.min.9d6804aa.css","/bundle/css/component/component.toast.min.c049fb21.css"],"delayedScripts":[],"image":{"lazyLoad":{"selector":"[data-lazy-load]","screens":1,"delay":2000}},"mailTo":{"delay":5000,"location":"/support/email-mailto.html"}},"form":{"recaptcha":{"sitekey":"6Ld-iSYTAAAAAOO0VTEwVl71HtvrFoSlPSibGr4g","callback":"DDC_RECAPTCHA_CALLBACK"}},"dwLog":{"a":918,"b":"null","c":"105,10061,10296,931,10225,40,730","d":"100,102,107,108,112","e":"327","f":18348,"h":0,"i":"default","k":"105,931,40,730","l":"","m":"","n":"","o":"","p":0,"q":"drugs/pro"},"drugs":[{"ddc_id":918,"brand_name_id":0,"mtm_id":"d03833","generic_name":"divalproex sodium systemic","name":"divalproex sodium"}],"options":{"recordSelection":false,"classifyLists":{"wrapper":"#content","countHtmlItems":false,"numItems":{"short":10,"medium":25,"long":50},"charLimit":{"paragraph":30,"content":350}}},"subscribe":null,"dictionary":[],"share":{"sticky":{"target":".ddc-social-share"},"types":[{"title":"Facebook","label":"Share on Facebook","cssClass":"ddc-share-icon ddc-share-icon-facebook","labelClass":"ddc-share-icon-label","icon":"<svg class='ddc-icon ddc-icon-facebook' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M14 6.54c-2.06 0-3.4 1.25-3.4 3.52v2H8.3v2.61h2.3V21A9.04 9.04 0 013 12.05C3 7.05 7.03 3 12 3s9 4.05 9 9.05c0 4.53-3.3 8.27-7.6 8.95v-6.33h2.1l.4-2.62h-2.5v-1.7c0-.7.35-1.4 1.47-1.4h1.14V6.7s-1.03-.17-2.02-.17z' /></svg>","shareUrl":"https://www.facebook.com/sharer/sharer.php?u=SHAREURL","width":600,"height":500},{"title":"Twitter","label":"Share on Twitter","cssClass":"ddc-share-icon ddc-share-icon-twitter","labelClass":"ddc-share-icon-label","icon":"<svg class='ddc-icon ddc-icon-twitter' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M8.66 19.63a10.44 10.44 0 0010.5-10.5v-.5A7.7 7.7 0 0021 6.74c-.67.3-1.39.5-2.12.58a3.73 3.73 0 001.64-2.04c-.72.43-1.52.74-2.34.9a3.7 3.7 0 00-6.3 3.36 10.46 10.46 0 01-7.61-3.85 3.69 3.69 0 001.14 4.9 3.66 3.66 0 01-1.63-.45v.04a3.7 3.7 0 002.9 3.64 3.7 3.7 0 01-1.63.06 3.69 3.69 0 003.42 2.53 7.4 7.4 0 01-4.6 1.64 8 8 0 01-.87-.07 10.45 10.45 0 005.66 1.63' /></svg>","shareUrl":"https://twitter.com/intent/tweet?text=SHARETITLE&url=SHAREURL","width":600,"height":420},{"title":"Email","label":"Email to a friend","cssClass":"ddc-share-icon ddc-share-icon-email","labelClass":"ddc-share-icon-label","icon":"<svg class='ddc-icon ddc-icon-email' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M20 4.25c.92 0 1.67.7 1.74 1.6l.01.15v12c0 .92-.7 1.67-1.6 1.74l-.15.01H4c-.92 0-1.67-.7-1.74-1.6L2.25 18V6c0-.92.7-1.67 1.6-1.74L4 4.25h16zm-.17 1.77a.75.75 0 00-1.06-.1L12 11.52l-6.77-5.6-.1-.06a.75.75 0 00-.86 1.22l7.25 6 .1.07c.27.15.61.13.86-.07l7.25-6L19.8 7a.75.75 0 00.02-.98z' /></svg>","mailUrl":"mailto:?body=https%3A%2F%2Fwww.drugs.com%2Fpro%2Fdivalproex.html","width":600,"height":420}],"mednotes":{"apiUrl":"/mednotes/api/modal","saveButton":"data-modal-mednotes-save"}},"ads":{"section":"drugs/pro","ugc":false,"display":{"mobile":false,"logUrl":"/api/logger/ads/","units":[]},"injection":{"placeholder":[{"selector":"[data-ad-placeholder=TAP_NATIVE_AD]","ad":{"type":"TapNative","format":"fluid","buffer":0,"lazy":0.75},"buffer":{"before":800,"after":1000}}],"lazy":0.75,"maximum":{"ads":10,"tags":1000},"container":"#content","start":[".nav-tabs","h2","h1"],"stop":[".footer-feature","#sidebar"],"last":{"buffer":500},"insert":["section","h2","h3","h4","h5","p","ol","ul","table",".ddc-legend",".nav-tabs",".nav-tabs-group",".responsive-table-wrap"],"blacklist":["form","ol","ul","dl","table",".blackboxWarning",".column-split",".ddc-accordion",".ddc-box",".ddc-card",".ddc-card-group",".ddc-form-inline",".ddc-expand-read-more",".ddc-grid",".ddc-legend",".ddc-media",".ddc-navtree",".ddc-notification",".ddc-paging",".ddc-toc",".ddc-widget-calculator",".injection-ignore-inside",".nav-tabs",".nav-tabs-group",".paging-list-wrap",".responsive-table-wrap",".snippet",".ddc-official-answer"],"list":[{"type":"EHS","width":300,"height":250,"buffer":-1,"viewportPercent":75,"lazy":0.75,"data":{"size":"300x250","vpos":"b","hpos":"r","site":"ehs.pro.drugs.drugs","iprof":"md","ims1":"n23","ims2":"p29","ims3":"p38","drg":["divalproex_sodium"],"drc":["fatty_acid_derivative_anticonvulsants"],"dra":1}}]}},"nativeApp":{"version":0,"appSrc":"","memoryWarning":{"log":0,"ads":1}},"fixable":{"items":[{"targetSelector":".topbanner-wrap","delay":2500,"leaderboard":true},{"containerSelector":"#contentWrap","targetSelector":"#sideBoxStackedAd-1","delay":2500,"maximizeStickyHeight":true}]},"toc":[],"interaction":{"isDeferredSave":false,"url":"/interaction/list/","param":{"drugList":"drug_list","listId":"interaction_list_id"}},"identityLink":{"api":{"url":"/api/user/"},"cookie":{"link":"pbjs_identitylink","data":"pbjs_identitydata"}},"toast":{"show":{"wait":3000,"scroll":250},"url":"/aptiom.html","content":"<span>Learn about a treatment option for <span>Epilepsy</span></span>","classList":["ddc-toast-alert"],"cookie":{"name":"ts_slider","expires":30},"ga":{"category":"TreatmentSeeker","action":"Aptiom - Epilepsy","label":"FullBarBottom"},"gtm":{"data":{"event":"footer_toast","category":"Priority Drug Target","campaign":"Briviact","content":"Learn about a treatment option for Epilepsy","drug_id":"3499-16370","drug_name":"Aptiom"}}},"moreResources":{"list-data-resources-consumer":"<li><a onclick='window.location=\"/cons/divalproex-sodium.html\";return false;' href='#'>Divalproex sodium <span>(Advanced Reading)</span></a></li> <li><a onclick='window.location=\"/cdi/divalproex-sprinkle-capsules.html\";return false;' href='#'>Divalproex Sprinkle Capsules</a></li> <li><a onclick='window.location=\"/cdi/divalproex-long-acting-tablets.html\";return false;' href='#'>Divalproex Long-Acting Tablets</a></li>","list-data-resources-conditions":"<li><a onclick='window.location=\"/condition/hyperekplexia.html\";return false;' href='#' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='918' data-brand_name_id='0' data-condition_id='10225'>Hyperekplexia</a></li> <li><a onclick='window.location=\"/condition/mania.html\";return false;' href='#' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='918' data-brand_name_id='0' data-condition_id='40'>Mania</a></li> <li><a onclick='window.location=\"/condition/migraine-prophylaxis.html\";return false;' href='#' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='918' data-brand_name_id='0' data-condition_id='730'>Migraine Prevention</a></li>"}};</script>

<script src='//www.google-analytics.com/analytics.js' defer></script>
<script>
(function(i,r){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();})(window,'ga');
ga('create', 'UA-78451-2', 'auto', {'siteSpeedSampleRate': 30, 'useAmpClientId': true});
ga('require', 'linkid', 'linkid.js');
ga('require', 'displayfeatures');
ga('set', 'anonymizeIp', true);
ga('set', {"dimension46":"no","dimension47":"no","dimension79":"Aptiom - Epilepsy","dimension82":"Yes","dimension1":"918-0","dimension26":";105;10061;10296;931;10225;40;730;","dimension25":";4249;2950;1812;1826;4094;","dimension11":"No","dimension43":"index\/follow","contentGroup1":"Drug","contentGroup2":"FDA Monographs","dimension24":"FDA Monographs","dimension16":"HCP","dimension17":"English","contentGroup3":"Very Long Page","dimension15":"No","dimension18":"Web","dimension59":"Yes"});
ga('send', 'pageview', {});
</script>
<script>
window.dataLayer = window.dataLayer || [];
window.dataLayer.push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
window.dataLayer.push({"event":"pageview","drug_name":"divalproex sodium","drug_id":"918-0","ddc_id":"918","condition_ids":";105;10061;10296;931;10225;40;730;","zone_ids":";4249;2950;1812;1826;4094;","user_signed_in":"No","user_ilink":"No","page_index_status":"index/follow","page_orphan":"No","page_traffic_op":"No","content_type":"Drug","content_section":"FDA Monographs","content_sub_section":"FDA Monographs","content_audience":"HCP","content_language":"English","content_size":"Very Long Page","content_ugc":"No","app_source":"Web","ads_pro":"Yes","ads_pdt_enabled":"Yes","ads_pdt_label":"Aptiom - Epilepsy"});

</script>
<script src='//www.googletagmanager.com/gtm.js?id=GTM-MZ4MM39' defer></script>

<script>
var AD_Z = 'drugs/pro';
var AD_T = "_('ugc','0')_('c1',['4249','2950','1812','1826','4094'])_('d','918')_('b','0')_('c2',['105','10061','10296','931','10225','40','730'])_('dc',['327'])_('mi','1')_('rx','1')_('c2o',['105','931','40','730'])";
var AD_PT = "_('ppro', ['md','n23','p29','p38'])";
</script>
<script src='/bundle/js/polyfill.min.b17ad879.js' defer></script>
<script src='/bundle/js/launch-base.min.100d9649.js' defer></script>
<script src='/bundle/js/module-subscribe.min.305e1074.js' defer></script>

<script>
var _comscore = _comscore || [];
_comscore.push({c1: '2', c2: '9355535'});
</script>
<script src='//sb.scorecardresearch.com/beacon.js' defer></script>
<noscript><img src='https://sb.scorecardresearch.com/p?c1=2&amp;c2=9355535&amp;cv=2.0&amp;cj=1' alt=''></noscript>
<div id='drugs-drugs-3' class='display-ad display-ad-inter'>
<script>
var ehs_ad_called = ++ehs_ad_called || 1;
</script>
</div>
<script src='//ads.ehealthcaresolutions.com/a/?adid=drugs-drugs-3&slotid=3&url=www.drugs.com%2Fpro%2Fdivalproex.html&size=inter&vpos=t&hpos=r&site=ehs.pro.drugs.drugs&iprof=md&ims1=n23&ims2=p29&ims3=p38&drg=divalproex_sodium&drc=fatty_acid_derivative_anticonvulsants&dra=1' defer></script>
<script>
(function(){/*
 Copyright The Closure Library Authors.
 SPDX-License-Identifier: Apache-2.0
*/
'use strict';var g=function(a){var b=0;return function(){return b<a.length?{done:!1,value:a[b++]}:{done:!0}}},l=this||self,m=/^[\w+/_-]+[=]{0,2}$/,p=null,q=function(){},r=function(a){var b=typeof a;if("object"==b)if(a){if(a instanceof Array)return"array";if(a instanceof Object)return b;var c=Object.prototype.toString.call(a);if("[object Window]"==c)return"object";if("[object Array]"==c||"number"==typeof a.length&&"undefined"!=typeof a.splice&&"undefined"!=typeof a.propertyIsEnumerable&&!a.propertyIsEnumerable("splice"))return"array";
if("[object Function]"==c||"undefined"!=typeof a.call&&"undefined"!=typeof a.propertyIsEnumerable&&!a.propertyIsEnumerable("call"))return"function"}else return"null";else if("function"==b&&"undefined"==typeof a.call)return"object";return b},u=function(a,b){function c(){}c.prototype=b.prototype;a.prototype=new c;a.prototype.constructor=a};var v=function(a,b){Object.defineProperty(l,a,{configurable:!1,get:function(){return b},set:q})};var y=function(a,b){this.b=a===w&&b||"";this.a=x},x={},w={};var aa=function(a,b){a.src=b instanceof y&&b.constructor===y&&b.a===x?b.b:"type_error:TrustedResourceUrl";if(null===p)b:{b=l.document;if((b=b.querySelector&&b.querySelector("script[nonce]"))&&(b=b.nonce||b.getAttribute("nonce"))&&m.test(b)){p=b;break b}p=""}b=p;b&&a.setAttribute("nonce",b)};var z=function(){return Math.floor(2147483648*Math.random()).toString(36)+Math.abs(Math.floor(2147483648*Math.random())^+new Date).toString(36)};var A=function(a,b){b=String(b);"application/xhtml+xml"===a.contentType&&(b=b.toLowerCase());return a.createElement(b)},B=function(a){this.a=a||l.document||document};B.prototype.appendChild=function(a,b){a.appendChild(b)};var C=function(a,b,c,d,e,f){try{var k=a.a,h=A(a.a,"SCRIPT");h.async=!0;aa(h,b);k.head.appendChild(h);h.addEventListener("load",function(){e();d&&k.head.removeChild(h)});h.addEventListener("error",function(){0<c?C(a,b,c-1,d,e,f):(d&&k.head.removeChild(h),f())})}catch(n){f()}};var ba=l.atob("aHR0cHM6Ly93d3cuZ3N0YXRpYy5jb20vaW1hZ2VzL2ljb25zL21hdGVyaWFsL3N5c3RlbS8xeC93YXJuaW5nX2FtYmVyXzI0ZHAucG5n"),ca=l.atob("WW91IGFyZSBzZWVpbmcgdGhpcyBtZXNzYWdlIGJlY2F1c2UgYWQgb3Igc2NyaXB0IGJsb2NraW5nIHNvZnR3YXJlIGlzIGludGVyZmVyaW5nIHdpdGggdGhpcyBwYWdlLg=="),da=l.atob("RGlzYWJsZSBhbnkgYWQgb3Igc2NyaXB0IGJsb2NraW5nIHNvZnR3YXJlLCB0aGVuIHJlbG9hZCB0aGlzIHBhZ2Uu"),ea=function(a,b,c){this.b=a;this.f=new B(this.b);this.a=null;this.c=[];this.g=!1;this.i=b;this.h=c},F=function(a){if(a.b.body&&!a.g){var b=
function(){D(a);l.setTimeout(function(){return E(a,3)},50)};C(a.f,a.i,2,!0,function(){l[a.h]||b()},b);a.g=!0}},D=function(a){for(var b=G(1,5),c=0;c<b;c++){var d=H(a);a.b.body.appendChild(d);a.c.push(d)}b=H(a);b.style.bottom="0";b.style.left="0";b.style.position="fixed";b.style.width=G(100,110).toString()+"%";b.style.zIndex=G(2147483544,2147483644).toString();b.style["background-color"]=I(249,259,242,252,219,229);b.style["box-shadow"]="0 0 12px #888";b.style.color=I(0,10,0,10,0,10);b.style.display=
"flex";b.style["justify-content"]="center";b.style["font-family"]="Roboto, Arial";c=H(a);c.style.width=G(80,85).toString()+"%";c.style.maxWidth=G(750,775).toString()+"px";c.style.margin="24px";c.style.display="flex";c.style["align-items"]="flex-start";c.style["justify-content"]="center";d=A(a.f.a,"IMG");d.className=z();d.src=ba;d.style.height="24px";d.style.width="24px";d.style["padding-right"]="16px";var e=H(a),f=H(a);f.style["font-weight"]="bold";f.textContent=ca;var k=H(a);k.textContent=da;J(a,
e,f);J(a,e,k);J(a,c,d);J(a,c,e);J(a,b,c);a.a=b;a.b.body.appendChild(a.a);b=G(1,5);for(c=0;c<b;c++)d=H(a),a.b.body.appendChild(d),a.c.push(d)},J=function(a,b,c){for(var d=G(1,5),e=0;e<d;e++){var f=H(a);b.appendChild(f)}b.appendChild(c);c=G(1,5);for(d=0;d<c;d++)e=H(a),b.appendChild(e)},G=function(a,b){return Math.floor(a+Math.random()*(b-a))},I=function(a,b,c,d,e,f){return"rgb("+G(Math.max(a,0),Math.min(b,255)).toString()+","+G(Math.max(c,0),Math.min(d,255)).toString()+","+G(Math.max(e,0),Math.min(f,
255)).toString()+")"},H=function(a){a=A(a.f.a,"DIV");a.className=z();return a},E=function(a,b){0>=b||null!=a.a&&0!=a.a.offsetHeight&&0!=a.a.offsetWidth||(fa(a),D(a),l.setTimeout(function(){return E(a,b-1)},50))},fa=function(a){var b=a.c;var c="undefined"!=typeof Symbol&&Symbol.iterator&&b[Symbol.iterator];b=c?c.call(b):{next:g(b)};for(c=b.next();!c.done;c=b.next())(c=c.value)&&c.parentNode&&c.parentNode.removeChild(c);a.c=[];(b=a.a)&&b.parentNode&&b.parentNode.removeChild(b);a.a=null};var ia=function(a,b,c,d,e){var f=ha(c),k=function(n){n.appendChild(f);l.setTimeout(function(){f?(0!==f.offsetHeight&&0!==f.offsetWidth?b():a(),f.parentNode&&f.parentNode.removeChild(f)):a()},d)},h=function(n){document.body?k(document.body):0<n?l.setTimeout(function(){h(n-1)},e):b()};h(3)},ha=function(a){var b=document.createElement("div");b.className=a;b.style.width="1px";b.style.height="1px";b.style.position="absolute";b.style.left="-10000px";b.style.top="-10000px";b.style.zIndex="-10000";return b};var K={},L=null;var M=function(){},N="function"==typeof Uint8Array,O=function(a,b){a.b=null;b||(b=[]);a.j=void 0;a.f=-1;a.a=b;a:{if(b=a.a.length){--b;var c=a.a[b];if(!(null===c||"object"!=typeof c||Array.isArray(c)||N&&c instanceof Uint8Array)){a.g=b-a.f;a.c=c;break a}}a.g=Number.MAX_VALUE}a.i={}},P=[],Q=function(a,b){if(b<a.g){b+=a.f;var c=a.a[b];return c===P?a.a[b]=[]:c}if(a.c)return c=a.c[b],c===P?a.c[b]=[]:c},R=function(a,b,c){a.b||(a.b={});if(!a.b[c]){var d=Q(a,c);d&&(a.b[c]=new b(d))}return a.b[c]};
M.prototype.h=N?function(){var a=Uint8Array.prototype.toJSON;Uint8Array.prototype.toJSON=function(){var b;void 0===b&&(b=0);if(!L){L={};for(var c="ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789".split(""),d=["+/=","+/","-_=","-_.","-_"],e=0;5>e;e++){var f=c.concat(d[e].split(""));K[e]=f;for(var k=0;k<f.length;k++){var h=f[k];void 0===L[h]&&(L[h]=k)}}}b=K[b];c=[];for(d=0;d<this.length;d+=3){var n=this[d],t=(e=d+1<this.length)?this[d+1]:0;h=(f=d+2<this.length)?this[d+2]:0;k=n>>2;n=(n&
3)<<4|t>>4;t=(t&15)<<2|h>>6;h&=63;f||(h=64,e||(t=64));c.push(b[k],b[n],b[t]||"",b[h]||"")}return c.join("")};try{return JSON.stringify(this.a&&this.a,S)}finally{Uint8Array.prototype.toJSON=a}}:function(){return JSON.stringify(this.a&&this.a,S)};var S=function(a,b){return"number"!==typeof b||!isNaN(b)&&Infinity!==b&&-Infinity!==b?b:String(b)};M.prototype.toString=function(){return this.a.toString()};var T=function(a){O(this,a)};u(T,M);var U=function(a){O(this,a)};u(U,M);var ja=function(a,b){this.c=new B(a);var c=R(b,T,5);c=new y(w,Q(c,4)||"");this.b=new ea(a,c,Q(b,4));this.a=b},ka=function(a,b,c,d){b=new T(b?JSON.parse(b):null);b=new y(w,Q(b,4)||"");C(a.c,b,3,!1,c,function(){ia(function(){F(a.b);d(!1)},function(){d(!0)},Q(a.a,2),Q(a.a,3),Q(a.a,1))})};var la=function(a,b){V(a,"internal_api_load_with_sb",function(c,d,e){ka(b,c,d,e)});V(a,"internal_api_sb",function(){F(b.b)})},V=function(a,b,c){a=l.btoa(a+b);v(a,c)},W=function(a,b,c){for(var d=[],e=2;e<arguments.length;++e)d[e-2]=arguments[e];e=l.btoa(a+b);e=l[e];if("function"==r(e))e.apply(null,d);else throw Error("API not exported.");};var X=function(a){O(this,a)};u(X,M);var Y=function(a){this.h=window;this.a=a;this.b=Q(this.a,1);this.f=R(this.a,T,2);this.g=R(this.a,U,3);this.c=!1};Y.prototype.start=function(){ma();var a=new ja(this.h.document,this.g);la(this.b,a);na(this)};
var ma=function(){var a=function(){if(!l.frames.googlefcPresent)if(document.body){var b=document.createElement("iframe");b.style.display="none";b.style.width="0px";b.style.height="0px";b.style.border="none";b.style.zIndex="-1000";b.style.left="-1000px";b.style.top="-1000px";b.name="googlefcPresent";document.body.appendChild(b)}else l.setTimeout(a,5)};a()},na=function(a){var b=Date.now();W(a.b,"internal_api_load_with_sb",a.f.h(),function(){var c;var d=a.b,e=l[l.btoa(d+"loader_js")];if(e){e=l.atob(e);
e=parseInt(e,10);d=l.btoa(d+"loader_js").split(".");var f=l;d[0]in f||"undefined"==typeof f.execScript||f.execScript("var "+d[0]);for(;d.length&&(c=d.shift());)d.length?f[c]&&f[c]!==Object.prototype[c]?f=f[c]:f=f[c]={}:f[c]=null;c=Math.abs(b-e);c=1728E5>c?0:c}else c=-1;0!=c&&(W(a.b,"internal_api_sb"),Z(a,Q(a.a,6)))},function(c){Z(a,c?Q(a.a,4):Q(a.a,5))})},Z=function(a,b){a.c||(a.c=!0,a=new l.XMLHttpRequest,a.open("GET",b,!0),a.send())};(function(a,b){l[a]=function(c){for(var d=[],e=0;e<arguments.length;++e)d[e-0]=arguments[e];l[a]=q;b.apply(null,d)}})("__d3lUW8vwsKlB__",function(a){"function"==typeof window.atob&&(a=window.atob(a),a=new X(a?JSON.parse(a):null),(new Y(a)).start())});}).call(this);

window.__d3lUW8vwsKlB__("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");
</script>
</body>
</html>
